U.S. patent application number 13/121062 was filed with the patent office on 2011-08-25 for novel fused aminodihydrothiazine derivative.
This patent application is currently assigned to EISAI R&D MANAGEMENT CO., LTD.. Invention is credited to Tasuku Ishida, Yoichi Kita, Takafumi Motoki, Yuichi Suzuki, Mamoru Takaishi, Kunitoshi Takeda.
Application Number | 20110207723 13/121062 |
Document ID | / |
Family ID | 42073450 |
Filed Date | 2011-08-25 |
United States Patent
Application |
20110207723 |
Kind Code |
A1 |
Motoki; Takafumi ; et
al. |
August 25, 2011 |
NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE
Abstract
A compound represented by the general formula (I): ##STR00001##
a pharmaceutically acceptable salt thereof, or a solvate of the
compound or salt has an A.beta. production inhibitory activity or
BACE 1 inhibitory activity, and is thus useful as an agent for
treating neurodegenerative diseases caused by A.beta. as typified
by Alzheimer's disease. In the formula, ring A represents a
C.sub.6-14 aryl group or the like; L represents --NR.sup.1CO--
(wherein R.sup.L represents a hydrogen atom or the like) or the
like; ring B represents a C.sub.6-14 aryl group or the like; X
represents a C.sub.1-3 alkylene group or the like; Y represents a
C.sub.1-3 alkylene group or the like; Z represents an oxygen atom
or the like; R.sup.1 and R.sup.2 each independently represents a
hydrogen atom or the like; and R.sup.3, R.sup.4, R.sup.5 and
R.sup.6 each independently represents a hydrogen atom, a halogen
atom or the like.
Inventors: |
Motoki; Takafumi; (Tsukuba,
JP) ; Takeda; Kunitoshi; (Tsukuba, JP) ; Kita;
Yoichi; (Tsukuba, JP) ; Takaishi; Mamoru;
(Tsukuba, JP) ; Suzuki; Yuichi; (Tsukuba, JP)
; Ishida; Tasuku; (Tsukuba, JP) |
Assignee: |
EISAI R&D MANAGEMENT CO.,
LTD.
Tokyo
JP
|
Family ID: |
42073450 |
Appl. No.: |
13/121062 |
Filed: |
September 28, 2009 |
PCT Filed: |
September 28, 2009 |
PCT NO: |
PCT/JP2009/066728 |
371 Date: |
March 25, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61101359 |
Sep 30, 2008 |
|
|
|
61170179 |
Apr 17, 2009 |
|
|
|
61226365 |
Jul 17, 2009 |
|
|
|
Current U.S.
Class: |
514/222.8 ;
435/184; 544/48 |
Current CPC
Class: |
C07D 513/04 20130101;
A61P 25/00 20180101; A61P 43/00 20180101; A61P 25/28 20180101 |
Class at
Publication: |
514/222.8 ;
544/48; 435/184 |
International
Class: |
A61K 31/542 20060101
A61K031/542; C07D 513/04 20060101 C07D513/04; C12N 9/99 20060101
C12N009/99; A61P 25/28 20060101 A61P025/28 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 30, 2008 |
JP |
2008-252062 |
Apr 17, 2009 |
JP |
2009-100457 |
Jul 17, 2009 |
JP |
2009-168490 |
Claims
1. A compound represented by the formula (I): ##STR00146## or a
pharmaceutically acceptable salt thereof, or a solvate thereof,
wherein Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., L is a single bond, an
oxygen atom, --NR.sup.LCO-- (wherein R.sup.L is a hydrogen atom or
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), an --NR.sup.LCO--C.sub.1-6 alkyl
group (wherein R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha.), --NR.sup.LSO.sub.2-- (wherein R.sup.L is a hydrogen
atom or a C.sub.1-6 alkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha.), a C.sub.1-6 alkylene
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.2-6 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-6
alkynylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha., Ring B is a C.sub.3-8 cycloalkyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 aryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha., X is a single bond or a C.sub.1-3
alkylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha., Y is a C.sub.1-3 alkylene group which
may have 1 to 3 substituents selected from Substituent Group
.alpha. or a C.sub.2-3 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha., Z is an
oxygen atom, a sulfur atom, a sulfoxide, a sulfone or --NR.sup.M--
(wherein R.sup.M is a hydrogen atom, a C.sub.1-6 alkyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 cycloalkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylcarbonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.1-6 alkylsulfonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
arylsulfonyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.6-14 aryl group which may have 1
to 3 substituents selected from Substituent Group .alpha. or a 5-
to 10-membered heterocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha.), R.sup.1 and
R.sup.2 are each independently a hydrogen atom, a C.sub.1-6 alkyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkylcarbonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a
C.sub.6-14 arylcarbonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.1-6 alkylsulfonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.6-14 arylsulfonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.3-8
carbocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are
independently a hydrogen atom, a halogen atom, a hydroxy group, a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkoxy group which may
have 1 to 3 substituents selected from Substituent Group .alpha., a
3- to 10-membered carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., or R.sup.4 and R.sup.6
together may form a ring represented by the formula (II):
##STR00147## wherein Y, Z, R.sup.5 and R.sup.3 are the same as
defined above and Q is an oxygen atom, a methylene group or an
ethylene group [Substituent Group .alpha.: a hydrogen atom, a
halogen atom, a hydroxy group, a nitro group, a C.sub.1-6 alkylthio
group, a C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group,
a C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-6 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .beta., Substituent Group .beta.: a
halogen atom, a cyano group, a hydroxy group and a C.sub.1-6 alkoxy
group (wherein the alkoxy group may be substituted with a phenyl
group which may be substituted with 1 to 3 substituents selected
from a hydrogen atom, a halogen atom, a hydroxy group and a nitro
group)].
2. A compound represented by the formula (I): ##STR00148## or a
pharmaceutically acceptable salt thereof, or a solvate thereof,
wherein Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., L is a single bond, an
oxygen atom, --NR.sup.LCO-- (wherein R.sup.L is a hydrogen atom or
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), --NR.sup.LSO.sub.2-- (wherein
R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.),
a C.sub.1-6 alkylene group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.2-6 alkenylene
group which may have 1 to 3 substituents selected from Substituent
Group .alpha. or a C.sub.2-6 alkynylene group which may have 1 to 3
substituents selected from Substituent Group .alpha., Ring B is a
C.sub.3-8 cycloalkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 aryl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha., X is a
single bond or a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha., Y is a
C.sub.1-3 alkylene group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a C.sub.2-3 alkenylene
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., Z is an oxygen atom, a sulfur atom, a sulfoxide, a
sulfone or --NR.sup.M-- (wherein R.sup.M is a hydrogen atom, a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.3-8 cycloalkyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.1-6 alkylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
arylcarbonyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkylsulfonyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylsulfonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
aryl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.), R.sup.1 and R.sup.2 are each independently a hydrogen
atom, a C.sub.1-6 alkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., and R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are independently a hydrogen atom, a halogen
atom, a hydroxy group, a C.sub.1-6 alkyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.1-6
alkoxy group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a 3- to 10-membered carbocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha., or
R.sup.4 and R.sup.6 together may form a ring represented by the
formula (II): ##STR00149## wherein Y, Z, R.sup.5 and R.sup.3 are
the same as defined above and Q is an oxygen atom, a methylene
group or an ethylene group [Substituent Group .alpha.: a hydrogen
atom, a halogen atom, a hydroxy group, a nitro group, a C.sub.1-6
alkylthio group, a C.sub.6-14 aryl group, a C.sub.6-14
aryloxycarbonyl group, a C.sub.6-14 arylcarbonyl group, a cyano
group, a C.sub.3-8 cycloalkoxy group, a C.sub.3-8 cycloalkyl group,
a C.sub.3-8 cycloalkylthio group, a sulfonylamino group (wherein
the sulfonylamino group may be substituted with 1 to 2 C.sub.1-6
alkyl groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group p, a carbamoyl group which may be substituted
with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy group which
may have 1 to 3 substituents selected from Substituent Group
.beta., a C.sub.1-6 alkyl group which may have 1 to 3 substituents
selected from Substituent Group .beta. and a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .beta., Substituent Group .beta.: a halogen atom,
a cyano group, a hydroxy group and a C.sub.1-6 alkoxy group].
3. A compound represented by the formula (I): ##STR00150## or a
pharmaceutically acceptable salt thereof, or a solvate thereof,
wherein Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., L is a single bond, an
oxygen atom, --NR.sup.LCO-- (wherein R.sup.L is a hydrogen atom or
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), --NR.sup.LSO.sub.2-- (wherein
R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.),
a C.sub.1-6 alkylene group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.2-6 alkenylene
group which may have 1 to 3 substituents selected from Substituent
Group .alpha. or a C.sub.2-6 alkynylene group which may have 1 to 3
substituents selected from Substituent Group .alpha., Ring B is a
C.sub.3-8 cycloalkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 aryl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha., X is a
single bond or a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha., Y is a
C.sub.1-3 alkylene group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a C.sub.2-3 alkenylene
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., Z is an oxygen atom, a sulfur atom, a sulfoxide, a
sulfone or --NR.sup.M-- (wherein R.sup.M is a hydrogen atom, a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.3-8 cycloalkyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.1-6 alkylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
arylcarbonyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkylsulfonyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylsulfonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
aryl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.), R.sup.1 and R.sup.2 are each independently a hydrogen
atom, a C.sub.1-6 alkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., and L R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 are independently a hydrogen atom, a halogen
atom, a hydroxy group, a C.sub.1-6 alkyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.1-6
alkoxy group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a 3- to 10-membered carbocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha.
[Substituent Group .alpha.: a hydrogen atom, a halogen atom, a
hydroxy group, a nitro group, a C.sub.1-6 alkylthio group, a
C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group, a
C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-6 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group p, Substituent Group .beta.: a
halogen atom, a cyano group, a hydroxy group and a C.sub.1-6 alkoxy
group].
4. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein X is a methylene
group which may have 1 to 2 substituents selected from Substituent
Group .alpha..
5. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein Z is an oxygen atom
and Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha..
6. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein Z is an oxygen atom
and Y is a C.sub.2-3 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha..
7. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein Z is a sulfur atom or
a sulfone and Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha..
8. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein L is --NR.sup.LCO--
(wherein R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.).
9. The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to claim 1, wherein the substituents
selected from Substituent Group .alpha. is a hydrogen atom, a
halogen atom, a C.sub.1-6 alkoxy group which may have 1 to 3
substituents selected from Substituent Group .beta. or a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .beta..
10. A compound or a pharmaceutically acceptable salt thereof, or a
solvate thereof, wherein the compound is selected from the
following compounds: 1)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide, 2)
N-[3-((8S*,8aR*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide, 3)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide,
4)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-trifluoromethoxyphenyl]-5-cyanopyridine-2-carboxamide,
5) N-[3-((8
S*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-trifluoromethoxyphenyl]-5-chloropyridine-2-carboxamide,
6)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
7)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
8)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxam-
ide, 9)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-c-
arboxamide, 10)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamid-
e, 11)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-
-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carbo-
xamide, 12)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-ca-
rboxamide, 13)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamid-
e, 14)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-
-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-
-2-carboxamide, 15)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-c-
arboxamide, 16)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
17)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide,
18)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
19)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxamide-
, 20)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-
-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carbox-
amide, 21)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-car-
boxamide, 22)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide-
, 23)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-t-
hia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
24)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
25)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carb-
oxamide, 26)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
27)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
28)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, 29)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa--
3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-c-
arboxamide, 30)
N-[3-((4aS*,5R*,8aS*)-2-amino-5-methoxy-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
31)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
32)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de, 33)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro-7-o-
xa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carbox-
amide, 34)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro--
7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carb-
oxamide, 35)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxami-
de, 36)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydr-
o-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyr-
azine-2-carboxamide, 37)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxam-
ide, 38)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahyd-
ro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyridine-2-carboxam-
ide, 39)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahyd-
ro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyra-
zine-2-carboxamide, 40)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyrimidine-4-carboxamide,
41)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2--
carboxamide, 42)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-
-carboxamide, 43)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2--
carboxamide, 44)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
45)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamid-
e, 46)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-
-carboxamide, 47)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxa-
mide, 48)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7--
oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-
-2-carboxamide, 49)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide, 50)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide, 51)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide, 52)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide, 53)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxamide, 54)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dibromopyridine-2-carboxamide, 55)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxamide,
56)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethylpyridine-2-carboxamide,
57)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide,
58)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide,
59)
(.+-.)-(4aR*,6R*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-tri-
fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamin-
e, 60)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-fluorom-
ethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
61)
(.+-.)-(4aR*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, 62)
(.+-.)-(4aR*,8aS*)-8a-(2-fluoro-5-pyrimidin-5-ylphenyl)-4,4a,5,6,8,8a-hex-
ahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, 63)
(.+-.)-(4aR*,8aS*)-8a-[5-(5-chloropyridin-3-yl)-2-fluorophenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, 64)
N-[5-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)thiophen-3-yl]-5-cyanopyridine-2-carboxamide, 65)
(.+-.)-(4aR*,8aR*)-8a-[4-(2-fluoropyridin-3-yl)-thiophen-2-yl]-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, 66)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-benzyloxymeth-
yl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
67)
(.+-.)-N-[7-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azana-
phthalen-8a-yl)-2,2-difluorobenzo[1,3]dioxol-5-yl]-5-cyanopyridine-2-carbo-
xamide, 68)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-(2-methoxyethoxy)-pyrazine-2-carboxamide,
69)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-2-methylthiazole-4-carboxamide, 70)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-2,5-dimethylfuran-3-carboxamide,
71)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-4-methyl-[1,2,3]thiadiazole-5-carbox-
amide, 72)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-ox-
a-3-thia-1-azanaphthalen-8a-yl)-4
fluorophenyl]-3-piperidin-1-ylpropionamide and 73) N-[3-((4
aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaph-
thalen-8a-yl)-4-fluorophenyl]-2-methyl oxazole-4-carboxamide, or a
pharmaceutically acceptable salt thereof, or a solvate thereof.
11. A pharmaceutical composition comprising the compound or
pharmaceutically acceptable salt thereof, or solvate thereof
according to claim 1 as an active ingredient.
12. A method of claim 11 for inhibiting production of
amyloid-.beta. protein, comprising administering an effective
amount of the pharmaceutical composition according to claim 11.
13. A method of claim 11 for inhibiting beta-site amyloid-.beta.
precursor protein cleaving enzyme 1 (BACE1), comprising
administering an effective amount of the pharmaceutical composition
according to claim 11.
14. A method of treating a neurodegenerative disease, comprising
administering an effective amount of the pharmaceutical composition
according to claim 11.
15. The method according to claim 14, wherein the neurodegenerative
disease is Alzheimer-type dementia or Down's syndrome.
Description
TECHNICAL FIELD
[0001] The present invention relates to a fused
aminodihydrothiazine derivative and pharmaceutical use thereof.
More particularly, the present invention relates to a fused
aminodihydrothiazine derivative which has an amyloid-.beta.
(hereinafter referred to as A.beta.) protein production inhibitory
effect or a beta-site amyloid-.beta. precursor protein cleavage
enzyme 1 (hereinafter referred to as BACE1 or beta-secretase)
inhibitory effect and is effective for treating a neurodegenerative
disease caused by A.beta. protein, in particular, Alzheimer-type
dementia, Down's syndrome or the like, and to a pharmaceutical
composition comprising the fused aminodihydrothiazine derivative as
an active ingredient.
BACKGROUND ART
[0002] Alzheimer's disease is a disease characterized by
degeneration and loss of neurons as well as formation of senile
plaques and neurofibrillary tangles. Currently, Alzheimer-type
dementia is treated only with symptomatic treatment using a symptom
improving agent typified by an acetylcholinesterase inhibitor, and
a fundamental remedy to inhibit progression of the disease has not
yet been developed. It is necessary to develop a method for
controlling the cause of the onset of pathology in order to create
a fundamental remedy for Alzheimer-type dementia.
[0003] It is assumed that A.beta.-proteins as metabolites of
amyloid precursor proteins (hereinafter referred to as APP) are
highly involved in degeneration and loss of neurons and onset of
symptoms of dementia (see Non-Patent Documents 3 and 4, for
example). A.beta.-proteins have, as main components, A.beta.40
consisting of 40 amino acids and A.beta.42 with two amino acids
added at the C-terminal. The A.beta.40 and A.beta.42 are known to
have high aggregability (see Non-Patent Document 5, for example)
and to be main components of senile plaques (see Non-Patent
Documents 5, 6 and 7, for example). Further, it is known that the
A.beta.40 and A.beta.42 are increased by mutation in APP and
presenilin genes which is observed in familial Alzheimer's disease
(see Non-Patent Documents 8, 9 and 10, for example). Accordingly, a
compound that reduces production of A.beta.40 and A.beta.42 is
expected as a progression inhibitor or prophylactic agent for
Alzheimer-type dementia.
[0004] A.beta. is produced by cleaving APP by beta-secretase
(BACE1) and subsequently by gamma-secretase. For this reason,
attempts have been made to create gamma-secretase and
beta-secretase inhibitors in order to inhibit A.beta. production.
Already known beta-secretase inhibitors are reported in Patent
Documents 1 to 15 and Non-Patent Documents 1 and 2 shown below and
the like. In particular, Patent Documents 1, 14 and 15 describes an
aminodihydrothiazine derivative and a compound having BACE1
inhibitory activity.
PRIOR ART DOCUMENTS
Patent Documents
[0005] [Patent Document 1] WO 2007/049532 [0006] [Patent Document
2] U.S. Pat. No. 3,235,551 [0007] [Patent Document 3] U.S. Pat. No.
3,227,713 [0008] [Patent Document 4] JP-A-09-067355 [0009] [Patent
Document 5] WO 01/087293 [0010] [Patent Document 6] WO 04/014843
[0011] [Patent Document 7] JP-A-2004-149429 [0012] [Patent Document
8] WO 02/96897 [0013] [Patent Document 9] WO 04/043916 [0014]
[Patent Document 10] WO 2005/058311 [0015] [Patent Document 11] WO
2005/097767 [0016] [Patent Document 12] WO 2006/041404 [0017]
[Patent Document 13] WO 2006/041405 [0018] [Patent Document 14] WO
2008/133273 [0019] [Patent Document 15] WO 2008/133274
Non-Patent Documents
[0019] [0020] [Non-Patent Document 1] Journal of Heterocyclic
Chemistry, Vol. 14, p. 717-723 (1977) [0021] [Non-Patent Document
2] Journal of Organic Chemistry, Vol. 33, p. 3126-3132 (1968)
[0022] [Non-Patent Document 3] Klein W L, and seven others,
Alzheimer's disease-affected brain: Presence of oligomeric A.beta.
ligands (ADDLs) suggests a molecular basis for reversible memory
loss, Proceedings of National Academy of Science USA 2003, Sep. 2;
100 (18), p. 10417-10422. [0023] [Non-Patent Document 4] Nitsch R
M, and sixteen others, Antibodies against .beta.-amyloid slow
cognitive decline in Alzheimer's disease, Neuron, 2003, May 22; 38,
p. 547-554. [0024] [Non-Patent Document 5] Jarrett J T, and two
others, The carboxy terminus of the .beta. amyloid protein is
critical for the seeding of amyloid formation: Implications for the
pathogenesis of Alzheimers' disease, Biochemistry, 1993, 32 (18),
p. 4693-4697. [0025] [Non-Patent Document 6] Glenner G G and one
other, Alzheimer's disease: initial report of the purification and
characterization of a novel cerebrovascular amyloid protein,
Biochemical and biophysical research communications, 1984, May 16,
120 (3), p. 885-890. [0026] [Non-Patent Document 7] Masters C L,
and five others, Amyloid plaque core protein in Alzheimer disease
and Down syndrome, Proceedings of National Academy of Science USA,
1985, Jun. 82 (12), p. 4245-4249. [0027] [Non-Patent Document 8]
Gouras G K, and eleven others, Intraneuronal A.beta.42 accumulation
in human brain, American Journal of Pathology, 2000, January, 156
(1), p. 15-20, [0028] [Non-Patent Document 9] Scheuner D, and 20
others, Secreted amyloid 3-protein similar to that in the senile
plaques of Alzheimer's disease is increased in vivo by the
presenilin 1 and 2 and APP mutations linked to familial Alzheimer's
disease, Nature Medicine, 1996, Aug. 2 (8), p, 864-870. [0029]
[Non-Patent Document 10] Forman M S, and four others, Differential
effects of the swedish mutant amyloid precursor protein on
.beta.-amyloid accumulation and secretion in neurons and
normeuronal cells, The Journal of Biological Chemistry, 1997, Dec.
19, 272 (51), p. 32247-32253.
SUMMARY OF THE INVENTION
Problem to be Solved by the Invention
[0030] An object of the present invention is to provide a fused
aminodihydrothiazine compound which differs from an
aminodihydrothiazine derivative and a compound having BACE1
inhibitory activity described in Patent Document 1 and which has an
A.beta. production inhibitory effect or a BACE1 inhibitory effect
and is useful as a therapeutic agent for a neurodegenerative
disease caused by A.beta. and typified by Alzheimer-type dementia,
and pharmaceutical use thereof.
Means for Solving the Problem
[0031] The present invention relates to:
[1] A compound represented by the formula (I):
##STR00002##
or a pharmaceutically acceptable salt thereof, or a solvate
thereof, wherein
[0032] Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha.,
[0033] L is a single bond, an oxygen atom, --NR.sup.LCO-- (wherein
R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.),
an --NR.sup.LCO-C.sub.1-6 alkyl group (wherein R.sup.L is a
hydrogen atom or a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha.),
--NR.sup.LSO.sub.2-- (wherein R.sup.L is a hydrogen atom or a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), a C.sub.1-6 alkylene group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.2-6 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-6
alkynylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0034] Ring B is a C.sub.3-8 cycloalkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
aryl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0035] X is a single bond or a C.sub.1-3 alkylene group which may
have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0036] Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-3
alkenylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0037] Z is an oxygen atom, a sulfur atom, a sulfoxide, a sulfone
or --NR.sup.M-- (wherein R.sup.M is a hydrogen atom, a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.3-8 cycloalkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha., a
C.sub.1-6 alkylcarbonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 arylcarbonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkylsulfonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a
C.sub.6-14 arylsulfonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 aryl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha.),
[0038] R.sup.1 and R.sup.2 are each independently a hydrogen atom,
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., and
[0039] R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a
hydrogen atom, a halogen atom, a hydroxy group, a C.sub.1-6alkyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkoxy group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 3- to
10-membered carbocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha., or
[0040] R.sup.4 and R.sup.6 together may form a ring represented by
the formula (II):
##STR00003##
wherein Y, Z, R.sup.5 and R.sup.3 are the same as defined above and
Q is an oxygen atom, a methylene group or an ethylene group
[0041] [Substituent Group .alpha.: a hydrogen atom, a halogen atom,
a hydroxy group, a nitro group, a C.sub.1-6 alkylthio group, a
C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group, a
C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-6 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .beta.,
[0042] Substituent Group .beta.: a halogen atom, a cyano group, a
hydroxy group and a C.sub.1-6 alkoxy group (wherein the alkoxy
group may be substituted with a phenyl group which may be
substituted with 1 to 3 substituents selected from a hydrogen atom,
a halogen atom, a hydroxy group and a nitro group)];
[2] A compound represented by the formula (I):
##STR00004##
or a pharmaceutically acceptable salt thereof, or a solvate
thereof, wherein
[0043] Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha.,
[0044] L is a single bond, an oxygen atom, --NR.sup.LCO-- (wherein
R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.),
--NR.sup.LSO.sub.2-- (wherein R.sup.L is a hydrogen atom or a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), a C.sub.1-6 alkylene group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.2-6 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-6
alkynylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0045] Ring B is a C.sub.3-8 cycloalkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
aryl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0046] X is a single bond or a C.sub.1-3 alkylene group which may
have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0047] Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-3
alkenylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0048] Z is an oxygen atom, a sulfur atom, a sulfoxide, a sulfone
or --NR.sup.M-- (wherein R.sup.M is a hydrogen atom, a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.3-8 cycloalkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha., a
C.sub.1-6 alkylcarbonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 arylcarbonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkylsulfonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a
C.sub.6-14 arylsulfonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 aryl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha.),
[0049] R.sup.1 and R.sup.2 are each independently a hydrogen atom,
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., and
[0050] R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a
hydrogen atom, a halogen atom, a hydroxy group, a C.sub.1-6 alkyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkoxy group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 3- to
10-membered carbocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha., or
[0051] R.sup.4 and R.sup.6 together may form a ring represented by
the formula (II):
##STR00005##
wherein Y, Z, R.sup.5 and R.sup.3 are the same as defined above and
Q is an oxygen atom, a methylene group or an ethylene group
[0052] [Substituent Group .alpha.: a hydrogen atom, a halogen atom,
a hydroxy group, a nitro group, a C.sub.1-6 alkylthio group, a
C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group, a
C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-6 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .beta.,
[0053] Substituent Group .beta.: a halogen atom, a cyano group, a
hydroxy group and a C.sub.1-6 alkoxy group];
[3] A compound represented by the formula (I):
##STR00006##
or a pharmaceutically acceptable salt thereof, or a solvate
thereof, wherein
[0054] Ring A is a C.sub.6-14 aryl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 5- to
6-membered heteroaryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 9- to 10-membered
benzo-fused heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha.,
[0055] L is a single bond, an oxygen atom, --NR.sup.LCO-- (wherein
R.sup.L is a hydrogen atom or a C.sub.1-6 alkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.),
--NR.sup.LSO.sub.2-- (wherein R.sup.L is a hydrogen atom or a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha.), a C.sub.1-6 alkylene group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.2-6 alkenylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-6
alkynylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0056] Ring B is a C.sub.3-8 cycloalkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
aryl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 5- to 10-membered heterocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0057] X is a single bond or a C.sub.1-3 alkylene group which may
have 1 to 3 substituents selected from Substituent Group
.alpha.,
[0058] Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a C.sub.2-3
alkenylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.,
[0059] Z is an oxygen atom, a sulfur atom, a sulfoxide, a sulfone
or --NR.sup.M-- (wherein R.sup.M is a hydrogen atom, a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.3-8 cycloalkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha., a
C.sub.1-6 alkylcarbonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 arylcarbonyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkylsulfonyl group which may have 1 to
3 substituents selected from Substituent Group .alpha., a
C.sub.6-14 arylsulfonyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha., a C.sub.6-14 aryl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha. or a 5- to 10-membered heterocyclic group which may have 1
to 3 substituents selected from Substituent Group .alpha.),
[0060] R.sup.1 and R.sup.2 are each independently a hydrogen atom,
a C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 carbocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., and
[0061] R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a
hydrogen atom, a halogen atom, a hydroxy group, a C.sub.1-6 alkyl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.1-6 alkoxy group which may have 1 to 3
substituents selected from Substituent Group .alpha., a 3- to
10-membered carbocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha.
[0062] [Substituent Group .alpha.: a hydrogen atom, a halogen atom,
a hydroxy group, a nitro group, a C.sub.1-6 alkylthio group, a
C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group, a
C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-4 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .beta.,
[0063] Substituent Group .beta.: a halogen atom, a cyano group, a
hydroxy group and a C.sub.1-6 alkoxy group];
[4] The compound or pharmaceutically acceptable salt thereof, or
solvate thereof according to any one of [1] to [3] above, wherein X
is a methylene group which may have 1 to 2 substituents selected
from Substituent Group .alpha.; [5] The compound or
pharmaceutically acceptable salt thereof; or solvate thereof
according to any one of [1] to [4] above, wherein Z is an oxygen
atom and Y is a C.sub.1-3 alkylene group which may have 1 to 3
substituents selected from Substituent Group .alpha.; [6] The
compound or pharmaceutically acceptable salt thereof; or solvate
thereof according to any one of [1] to [4] above, wherein Z is an
oxygen atom and Y is a C.sub.2-3 alkenylene group which may have 1
to 3 substituents selected from Substituent Group .alpha.; [7] The
compound or pharmaceutically acceptable salt thereof; or solvate
thereof according to any one of [1] to [4] above, wherein Z is a
sulfur atom or a sulfone and Y is a C.sub.1-3 alkylene group which
may have 1 to 3 substituents selected from Substituent Group
.alpha.; [.sup.8] The compound or pharmaceutically acceptable salt
thereof; or solvate thereof according to any one of [1] to [4]
above, wherein L is --NR.sup.LCO-- (wherein R.sup.L is a hydrogen
atom or a C.sub.1-6 alkyl group which may have 1 to 3 substituents
selected from Substituent Group .alpha.); [9] The compound or
pharmaceutically acceptable salt thereof; or solvate thereof
according to any one of [1] to [8] above, wherein the substituents
selected from Substituent Group .alpha. is a hydrogen atom, a
halogen atom, a C.sub.1-6 alkoxy group which may have 1 to 3
substituents selected from Substituent Group .beta. or a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .beta.. [10] A compound or a pharmaceutically
acceptable salt thereof; or a solvate thereof; wherein the compound
is selected from the following compounds: [0064] 1)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide, [0065] 2)
N-[3-((8S*,8aR*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide,
[0066] 3)
N-[3((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide,
[0067] 4)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-trifluoromethoxyphenyl]-5-cyanopyridine-2-carboxamide,
[0068] 5)
N-[3-((8S*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azan-
aphthalen-8a-yl)-4-trifluoromethoxyphenyl]-5-chloropyridine-2-carboxamide,
[0069] 6)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-ox-
a-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxa-
mide, [0070] 7)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0071] 8)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-ox-
a-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine--
2-carboxamide, [0072] 9)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0073] 10)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamid-
e, [0074] 11)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide-
, [0075] 12)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-ca-
rboxamide, [0076] 13)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamid-
e, [0077] 14)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-car-
boxamide, [0078] 15)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-c-
arboxamide, [0079] 16)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0080] 17)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxam-
ide, [0081] 18)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0082] 19)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxa-
mide, [0083] 20)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide-
, [0084] 21)
N-[3-((4a-8,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-a-
zanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide,
[0085] 22)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide-
, [0086] 23)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0087] 24)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0088] 25)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0089] 26)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0090] 27)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0091] 28)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0092] 29)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de, [0093] 30)
N-[3-((4aS*,5R*,8aS*)-2-amino-5-methoxy-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0094] 31)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0095] 32)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de, [0096] 33)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0097] 34)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0098] 35)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxami-
de, [0099] 36)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4-a,
5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difl-
uoromethoxypyrazine-2-carboxamide, [0100] 37)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxam-
ide, [0101] 38)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyridine-2-carboxamide,
[0102] 39)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-c-
arboxamide, [0103] 40)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyrimidine-4-carboxamide,
[0104] 41)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2-carb-
oxamide, [0105] 42)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-
-carboxamide, [0106] 43)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2--
carboxamide, [0107] 44)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0108] 45)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0109] 46)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carbo-
xamide, [0110] 47)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxa-
mide, [0111] 48)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carbox-
amide, [0112] 49)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide, [0113] 50)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide, [0114] 51)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide, [0115]
52)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide, [0116]
53)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxamide, [0117] 54)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dibromopyridine-2-carboxamide, [0118]
55)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxamide,
[0119] 56)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanapht-
halen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyridine-2-carboxamide,
[0120] 57)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide,
[0121] 58)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanapht-
halen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide,
[0122] 59)
(.+-.)-(4aR*,6R*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-tri-
fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamin-
e, [0123] 60)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-fluoromethyl--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
[0124] 61)
(.+-.)-(4aR*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0125] 62)
(.+-.)-(4aR*,8aS*)-8a-(2-fluoro-5-pyrimidin-5-ylphenyl)-4,4a,5,6,8,8a-hex-
ahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0126] 63)
(.+-.)-(4aR*,8aS*)-8a-[5-(5-chloropyridin-3-yl)-2-fluorophenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0127] 64)
N-[5-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)thiophen-3-yl]-5-cyanopyridine-2-carboxamide, [0128] 65)
(.+-.)-(4aR*,8aR*)-8a-[4-(2-fluoropyridin-3-yl)-thiophen-2-yl]-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0129] 66)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-benzyloxymeth-
yl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
[0130] 67)
(.+-.)-N-[7-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-a-
zanaphthalen-8a-yl)-2,2-difluorobenzo[1,3]dioxol-5-yl]-5-cyanopyridine-2-c-
arboxamide, [0131] 68)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-(2-methoxyethoxy)-pyrazine-2-carboxamide,
[0132] 69)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-2-methylthiazole-4-carboxamide, [0133] 70)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-2,5-dimethylfuran-3-carboxamide,
[0134] 71)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-4-methyl-[1,2,3]thiadiazole-5-carbox-
amide, [0135] 72)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-3-piperidin-1-ylpropionamide
and [0136] 73)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-2-methyloxazole-4-carboxamide,
or a pharmaceutically acceptable salt thereof, or a solvate
thereof; [11] A pharmaceutical composition comprising the compound
or pharmaceutically acceptable salt thereof, or solvate thereof
according to any one of [1] to [10] above as an active ingredient;
[12] The pharmaceutical composition according to [11] above for
inhibiting production of amyloid-13 protein; [13] The
pharmaceutical composition according to [11] above for inhibiting
beta-site amyloid-.beta. precursor protein cleaving enzyme 1
(BACE1); [14] The pharmaceutical composition according to any one
of [11] to [13] above for treating a neurodegenerative disease; and
[15] The pharmaceutical composition according to [14] above,
wherein the neurodegenerative disease is Alzheimer-type dementia or
Down's syndrome.
Advantages of the Invention
[0137] The present invention can provide a compound represented by
the general formula:
##STR00007##
wherein Ring A is a C.sub.6-14 aryl group or the like, L is
--NR.sup.LCO-- or the like (wherein is a hydrogen atom or the
like), Ring B is a C.sub.6-14 aryl group or the like, X is a
C.sub.1-3 alkylene group or the like, Y is a C.sub.1-3 alkylene
group or the like, Z is an oxygen atom or the like, R.sup.1 and
R.sup.2 are each independently a hydrogen atom or the like, and
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a hydrogen
atom, a halogen atom or the like, or a pharmaceutically acceptable
salt thereof, or a solvate thereof. The compound of the present
invention has an A.beta. production inhibitory effect or a BACE1
inhibitory effect and is useful as a therapeutic agent for a
neurodegenerative disease caused by A.beta. and typified by
Alzheimer-type dementia.
MODE FOR CARRYING OUT THE INVENTION
[0138] Meanings of symbols, terms and the like used in the present
specification will be explained and the present invention will be
described in detail below.
[0139] In the present specification, a structural formula of a
compound may represent a certain isomer for convenience. However,
the present invention includes all isomers and isomer mixtures such
as geometric isomers which can be generated from the structure of a
compound, optical isomers based on asymmetric carbon, stereoisomers
and tautomers. The present invention is not limited to the
description of a chemical formula for convenience and may include
any one of the isomers or mixtures thereof. Accordingly, the
compound of the present invention may have an asymmetric carbon
atom in the molecule and exist as an optically active compound or
racemate, and the present invention includes each of the optically
active compound and the racemate without limitations. Although
crystal polymorphs of the compound may be present, the compound is
similarly not limited thereto and may be present as a single
crystal form or a mixture of single crystal forms. The compound may
be an anhydride or a hydrate. Any of these forms is included in the
claims of the present specification.
[0140] The "halogen atom" herein refers to a fluorine atom, a
chlorine atom, a bromine atom, an iodine atom or the like and is
preferably a fluorine atom or a chlorine atom.
[0141] The "C.sub.1-6 alkyl group" refers to an alkyl group having
1 to 6 carbon atoms. Preferable examples of the group include
linear or branched alkyl groups such as a methyl group, an ethyl
group, an n-propyl group, an isopropyl group, an n-butyl group, an
isobutyl group, a t-butyl group, an n-pentyl group, an isopentyl
group, a neopentyl group, an n-hexyl group, a 1-methylpropyl group,
an 1,2-dimethylpropyl group, a 1-ethylpropyl group, a
1-methyl-2-ethylpropyl group, a 1-ethyl-2-methylpropyl group, a
1,1,2-trimethylpropyl group, a 1-methylbutyl group, a 2-methylbutyl
group, a 1,1-dimethylbutyl group, a 2,2-dimethylbutyl group, a
2-ethylbutyl group, a 1,3-dimethylbutyl group, a 2-methylpentyl
group and a 3-methylpentyl group. The group is more preferably a
methyl group, an ethyl group or an n-propyl group.
[0142] The "C.sub.2-6 alkenyl group" refers to an alkenyl group
having 2 to 6 carbon atoms. Preferable examples of the group
include linear or branched alkenyl groups such as a vinyl group, an
allyl group, a 1-propenyl group, an isopropenyl group, a
1-buten-1-yl group, a 1-buten-2-yl group, a 1-buten-3-yl group, a
2-buten-1-yl group and a 2-buten-2-yl group.
[0143] The "C.sub.2-6 alkynyl group" refers to an alkynyl group
having 2 to 6 carbon atoms. Preferable examples of the group
include linear or branched alkynyl groups such as an ethynyl group,
a 1-propynyl group, a 2-propynyl group, a butynyl group, a pentynyl
group and a hexynyl group.
[0144] The "C.sub.1-6 alkoxy group" refers to an alkyl group having
1 to 6 carbon atoms in which one hydrogen atom is replaced by an
oxygen atom. Examples of the group include a methoxy group, an
ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy
group, an isobutoxy group, a sec-butoxy group, a t-butoxy group, an
n-pentoxy group, an isopentoxy group, a sec-pentoxy group, a
t-pentoxy group, an n-hexoxy group, an isohexoxy group, a
1,2-dimethylpropoxy group, a 2-ethylpropoxy group, a
1-methyl-2-ethylpropoxy group, a 1-ethyl-2-methylpropoxy group, a
1,1,2-trimethylpropoxy group, a 1,1-dimethylbutoxy group, a
2,2-dimethylbutoxy group, a 2-ethylbutoxy group, a
1,3-dimethylbutoxy group, a 2-methylpentoxy group, a
3-methylpentoxy group and a hexyloxy group.
[0145] The "C.sub.1-6 alkylthio group" refers to an alkyl group
having 1 to 6 carbon atoms in which one hydrogen atom is replaced
by a sulfur atom. Examples of the group include a methylthio group,
an ethylthio group, an n-propylthio group, an isopropylthio group,
an n-butylthio group, an isobutylthio group, a t-butylthio group,
an n-pentylthio group, an isopentylthio group, a neopentylthio
group, an n-hexylthio group and a 1-methylpropylthio group.
[0146] The "C.sub.1-6 alkylsulfonyl group" refers to an alkyl group
having 1 to 6 carbon atoms in which one hydrogen atom is replaced
by a sulfonyl group. Examples of the group include a methylsulfonyl
group, an ethylsulfonyl group, an n-propylsulfonyl group, an
isopropylsulfonyl group, an n-butylsulfonyl group, an
isobutylsulfonyl group, a t-butylsulfonyl group, an
n-pentylsulfonyl group, an isopentylsulfonyl group, a
neopentylsulfonyl group, an n-hexylsulfonyl group and a
1-methylpropylsulfonyl group.
[0147] The "C.sub.1-6 alkylcarbonyl group" refers to an alkyl group
having 1 to 6 carbon atoms in which one hydrogen atom is replaced
by a carbonyl group. Preferable examples of the group include an
acetyl group, a propionyl group and a butyryl group.
[0148] The "C.sub.6-14 aryl group" refers to an aromatic
hydrocarbon ring group having 6 to 14 carbon atoms. Examples of the
group include a phenyl group, a naphthyl group and an anthryl
group. A phenyl group is particularly preferable.
[0149] The "C.sub.7-12 aralkyl group" refers to a group having 7 to
12 carbon atoms in which an aromatic ring such as a phenyl group or
a naphthyl group is substituted with a C.sub.1-6 alkyl group.
Examples of the group include a benzyl group, a phenethyl group, a
phenylpropyl group and a naphthylmethyl group. A benzyl group is
particularly preferable.
[0150] The "C.sub.6-14 aryloxycarbonyl group" refers to a group in
which carbonyl is bonded to an aromatic ring phenol having 6 to 14
carbon atoms. Preferable examples of the group include a
phenyloxycarbonyl group, a naphthyloxycarbonyl group and an
anthryloxycarbonyl group. A phenyloxycarbonyl group is more
preferable.
[0151] The "C.sub.6-14 arylcarbonyl group" refers to a group in
which a carbonyl group is bonded to an aromatic ring having 6 to 14
carbon atoms. Preferable examples of the group include a benzoyl
group and a naphthoyl group. A benzoyl group is more
preferable.
[0152] The "C.sub.6-14 arylsulfonyl group" refers to a group in
which a sulfonyl group is bonded to an aromatic ring having 6 to 14
carbon atoms. Preferable examples of the group include a
benzenesulfonyl group and a naphthylsulfonyl group. A
benzenesulfonyl group is more preferable.
[0153] The "C.sub.3-8 cycloalkyl group" refers to a cyclic alkyl
group having 3 to 8 carbon atoms. Preferable examples of the group
include a cyclopropyl group, a cyclobutyl group, a cyclopentyl
group, a cyclohexyl group, a cycloheptyl group and a cyclooctyl
group.
[0154] The "C.sub.3-8 cycloalkoxy group" refers to a cyclic alkyl
group having 3 to 8 carbon atoms in which one hydrogen atom is
replaced by an oxygen atom. Examples of the group include a
cyclopropoxy group, a cyclobutoxy group, a cyclopentoxy group, a
cyclohexoxy group, a cycloheptyloxy group and a cyclooctyloxy
group.
[0155] The "C.sub.3-8 cycloalkylthio group" refers to a cyclic
alkyl group having 3 to 8 carbon atoms in which one hydrogen atom
is replaced by a sulfur atom. Examples of the group include a
cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio
group, a cyclohexylthio group, a cycloheptylthio group and a
cyclooctylthio group.
[0156] The "5- to 10-membered heterocyclic group" refers to a
heteroatom-containing cyclic group having 5 to 10 members in total.
Preferable examples of the group include a piperidinyl group, a
pyrrolidinyl group, an azepinyl group, an azocanyl group, a
piperazinyl group, a 1,4-diazepanyl group, a morpholinyl group, a
thiomorpholinyl group, a pyrrolyl group, an imidazolyl group, a
pyrazolyl group, a pyridinyl group, a pyridazinyl group, a
pyrimidinyl group, a pyrazinyl group, a triazolyl group, a
triazinyl group, a tetrazolyl group, an isoxazolyl group, an
oxazolyl group, an oxadiazolyl group, an isothiazolyl group, a
thiazolyl group, a thiadiazolyl group, a furyl group, a thienyl
group, a quinolinyl group, an isoquinolinyl group, a benzofuryl
group, a benzopyranyl group, a benzimidazolyl group, a
benzotriazolyl group, a benzisothiazolyl group, an indolinyl group,
an isoindolinyl group, a chromanyl group, an isochromanyl group, a
1,3-dioxaindanyl group, a 1,4-dioxatetralinyl group, a
tetrahydrofuranyl group and a tetrahydropyranyl group.
[0157] The "5- to 6-membered heteroaryl group" refers to the "5- to
10-membered heterocyclic group" which is a heteroatom-containing
aromatic cyclic group having 5 to 6 members in total. Examples of
the group include a pyrrolyl group, an imidazolyl group, a
pyrazolyl group, a pyridinyl group, a pyridazinyl group, a
pyrimidinyl group, a pyrazinyl group, a triazolyl group, a
triazinyl group, a tetrazolyl group, an isoxazolyl group, an
oxazolyl group, an oxadiazolyl group, an isothiazolyl group, a
thiazolyl group, a thiadiazolyl group, a furyl group and a thienyl
group.
[0158] The "9- to 10-membered benzo-fused heterocyclic group"
refers to the "5- to 10-membered heterocyclic group" which is a
heteroatom-containing cyclic group having 9 to 10 members in total
fused with a benzene ring. Preferable examples of the group include
an indolinyl group, an isoindolinyl group, a chromanyl group, an
isochromanyl group, a 1,3-dioxaindanyl group and a
1,4-dioxatetralinyl group.
[0159] The "3- to 10-membered carbocyclic group" refers to a
carbocyclic group having 3 to 10 members in total. Preferable
examples of the group include a cyclopropyl group, a cyclobutyl
group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl
group, a cyclooctyl group, a spiro[3.4]octanyl group, a decanyl
group, an indanyl group, a 1-acenaphthenyl group, a
cyclopentacyclooctenyl group, a benzocyclooctenyl group, an indenyl
group, a tetrahydronaphthyl group, a
6,7,8,9-tetrahydro-5H-benzocycloheptenyl group and a
1,4-dihydronaphthalenyl group.
[0160] The "C.sub.1-6 alkylene group" refers to a divalent group
derived by excluding any one hydrogen atom from the "C.sub.1-6
alkyl group" as defined above. Examples of the group include a
methylene group, a 1,2-ethylene group, a 1,1-ethylene group, a
1,3-propylene group, a tetramethylene group, a pentamethylene group
and a hexamethylene group.
[0161] The "C.sub.2-6 alkenylene group" refers to a divalent group
derived by excluding any one hydrogen atom from the "C.sub.2-6
alkenyl group" as defined above. Examples of the group include a
1,2-vinylene group (ethenylene group), a propenylene group, a
butenylene group, a pentenylene group and a hexenylene group.
[0162] The "C.sub.2-6 alkynylene group" refers to a divalent group
derived by excluding any one hydrogen atom from the "C.sub.2-6
alkynyl group" as defined above. Examples of the group include an
ethynylene group, a propynylene group, a butynylene group, a
pentynylene group and a hexynylene group.
[0163] Examples of the "C.sub.1-3 alkylene group" include a
methylene group, an ethylene group and a propylene group.
[0164] Examples of the "C.sub.2-3 alkynylene group" include an
ethynylene group and a propynylene group.
[0165] Examples of the sulfonylamino group which may be substituted
with a C.sub.1-6 alkyl group in the "sulfonylamino group (wherein
the sulfonylamino group may be substituted with a C.sub.1-6 alkyl
group)" include a methylsulfonylmethylamino group, an
ethylsulfonylmethylamino group and an ethylsulfonylethylamino
group.
[0166] "Substituent Group .alpha." refers to a hydrogen atom, a
halogen atom, a hydroxy group, a nitro group, a C.sub.1-6 alkylthio
group, a C.sub.6-14 aryl group, a C.sub.6-14 aryloxycarbonyl group,
a C.sub.6-14 arylcarbonyl group, a cyano group, a C.sub.3-8
cycloalkoxy group, a C.sub.3-8 cycloalkyl group, a C.sub.3-8
cycloalkylthio group, a sulfonylamino group (wherein the
sulfonylamino group may be substituted with 1 to 2 C.sub.1-6 alkyl
groups), a C.sub.2-6 alkenyl group which may have 1 to 2
substituents selected from Substituent Group .beta., a C.sub.2-6
alkynyl group which may have 1 to 2 substituents selected from
Substituent Group .beta., a carbamoyl group which may be
substituted with 1 to 2 C.sub.1-6 alkyl groups, a C.sub.1-6 alkoxy
group which may have 1 to 3 substituents selected from Substituent
Group .beta., a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .beta. and a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .beta..
[0167] "Substituent Group .beta." refers to a halogen atom, a cyano
group, a hydroxy group and a C.sub.1-6 alkoxy group (wherein the
alkoxy group may be substituted with a phenyl group which may be
substituted with 1 to 3 substituents selected from a hydrogen atom,
a halogen atom, a hydroxy group and a nitro group).
[0168] The fused aminodihydrothiazine derivative of the formula (I)
according to the present invention may be a pharmaceutically
acceptable salt. Specific examples of the pharmaceutically
acceptable salt include inorganic acid salts (such as sulfates,
nitrates, perchlorates, phosphates, carbonates, bicarbonates,
hydrofluorides, hydrochlorides, hydrobromides and hydroiodides),
organic carboxylates (such as acetates, oxalates, maleates,
tartrates, fumarates and citrates), organic sulfonates (such as
methanesulfonates, trifluoromethanesulfonates, ethanesulfonates,
benzenesulfonates, toluenesulfonates and camphorsulfonates), amino
acid salts (such as aspartates and glutamates), quaternary amine
salts, alkali metal salts (such as sodium salts and potassium
salts) and alkali earth metal salts (such as magnesium salts and
calcium salts).
[0169] The fused aminodihydrothiazine derivative of the formula (I)
or pharmaceutically acceptable salt thereof according to the
present invention may be a solvate thereof. Examples of the solvate
include a hydrate.
[0170] The compound (I) is not limited to a specific isomer and
includes all possible isomers (such as a keto-enol isomer, an
imine-enamine isomer, a diastereoisomer, an optical isomer and a
rotamer) and racemates. For example, the compound (I) wherein
R.sup.1 is hydrogen includes the following tautomers.
##STR00008##
[0171] The fused aminodihydrothiazine derivative of the formula (I)
according to the present invention is preferably a compound of the
formula (I), wherein X is a methylene group which may have 1 to 2
substituents selected from Substituent Group .alpha..
[0172] The fused aminodihydrothiazine derivative of the formula (I)
according to the present invention is also preferably a compound of
the formula (I), wherein Z is an oxygen atom and Y is a C.sub.1-3
alkylene group which may have 1 to 3 substituents selected from
Substituent Group .alpha.; or Z is a sulfur atom or a sulfone and Y
is a C.sub.1-3 alkylene group which may have a substituent selected
from Substituent Group .alpha..
[0173] The fused aminodihydrothiazine derivative of the formula (I)
according to the present invention is further preferably a compound
of the formula (I), wherein L is --NR.sup.LCO-- (wherein R.sup.L is
a hydrogen atom or a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha.).
[0174] Preferable compounds in the present invention include the
following compounds: [0175] 1)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide, [0176] 2)
N-[3-((8S*,8aR*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide,
[0177] 3)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide,
[0178] 4)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphth-
alen-8a-yl)-4-trifluoromethoxyphenyl]-5-cyanopyridine-2-carboxamide,
[0179] 5)
N-[3-((8S*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-aza-
naphthalen-8a-yl)-4-trifluoromethoxyphenyl]-5-chloropyridine-2-carboxamide-
, [0180] 6)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0181] 7)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-ox-
a-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxam-
ide, [0182] 8)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxam-
ide, [0183] 9)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0184] 10)
N-[3-((4aR*,6S*,8aS*)-2-amino-6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamid-
e, [0185] 11)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide-
, [0186] 12)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-ca-
rboxamide, [0187] 13)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamid-
e, [0188] 14)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-car-
boxamide, [0189] 15)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-
-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-c-
arboxamide, [0190] 16)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0191] 17)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxam-
ide, [0192] 18)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0193] 19)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxa-
mide, [0194] 20)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide-
, [0195] 21)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide,
[0196] 22)
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-az-
anaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide-
, [0197] 23)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0198] 24)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0199] 25)
N-[3-((4aR*,5S*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0200] 26)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0201] 27)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0202] 28)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxam-
ide, [0203] 29)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de, [0204] 30)
N-[3-((4aS*,5R*,8aS*)-2-amino-5-methoxy-4,4a,5,6-tetrahydro-7-oxa-3-thia--
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0205] 31)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0206] 32)
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de, [0207] 33)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0208] 34)
N-[3-((4aR,6R,8aS)-2-amino-6-hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-th-
ia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0209] 35)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxami-
de, [0210] 36)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-
-carboxamide, [0211] 37)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxam-
ide, [0212] 38)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyridine-2-carboxamide,
[0213] 39)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-c-
arboxamide, [0214] 40)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-pyrimidine-4-carboxamide,
[0215] 41)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2-carb-
oxamide, [0216] 42)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-
-carboxamide, [0217] 43)
N-[3-((4aR*,6R*,8aS*)-2-amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-oxa-
-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2--
carboxamide, [0218] 44)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide,
[0219] 45)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide,
[0220] 46)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carbo-
xamide, [0221] 47)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thi-
a-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxa-
mide,
[0222] 48)
N-[3-((4aR,6R,8aS)-2-amino-6-fluoromethyl-4,4a,5,6-tetrahydro-7-
-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazin-
e-2-carboxamide, [0223] 49)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-carboxamide, [0224] 50)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-bromopyridine-2-carboxamide, [0225] 51)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-difluoropyridine-2-carboxamide, [0226]
52)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide, [0227]
53)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-fluoropyridine-2-carboxamide, [0228] 54)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-3,5-dibromopyridine-2-carboxamide, [0229]
55)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-trifluoromethylpyridine-2-carboxamide,
[0230] 56)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanapht-
halen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyridine-2-carboxamide,
[0231] 57)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide,
[0232] 58)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanapht-
halen-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide,
[0233] 59)
(.+-.)-(4aR*,6R*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-tri-
fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamin-
e, [0234] 60)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-fluoromethyl--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
[0235] 61)
(.+-.)-(4aR*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0236] 62)
(.+-.)-(4aR*,8aS*)-8a-(2-fluoro-5-pyrimidin-5-ylphenyl)-4,4a,5,6,8,8a-hex-
ahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0237] 63)
(.+-.)-(4aR*,8aS*)-8a-[5-(5-chloropyridin-3-yl)-2-fluorophenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0238] 64)
N-[5-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)thiophen-3-yl]-5-cyanopyridine-2-carboxamide, [0239] 65)
(.+-.)-(4aR*,8aR*)-8a-[4-(2-fluoropyridin-3-yl)-thiophen-2-yl]-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine, [0240] 66)
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-benzyloxymeth-
yl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine,
[0241] 67)
(.+-.)-N-[7-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-a-
zanaphthalen-8a-yl)-2,2-difluorobenzo[1,3]dioxol-5-yl]-5-cyanopyridine-2-c-
arboxamide, [0242] 68)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-(2-methoxyethoxy)-pyrazine-2-carboxamide,
[0243] 69)
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-2-methylthiazole-4-carboxamide, [0244] 70)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-2,5-dimethylfuran-3-carboxamide,
[0245] 71)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-4-methyl-[1,2,3]thiadiazole-5-carbox-
amide, [0246] 72)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-3-piperidin-1-ylpropionamide
and [0247] 73)
N-[3-((4aR*,5R*,8aS*)-2-amino-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-2-methyloxazole-4-carboxamide.
[0248] Next, methods for preparing the compound of the formula (I)
[hereinafter referred to as compound (I); a compound represented by
another formula is similarly described] or pharmaceutically
acceptable salt thereof according to the present invention will be
described.
[0249] The "leaving group" in the raw material compound used in
preparation of the compound of the formula (I) according to the
present invention may be any leaving group used for nucleophilic
substitution reaction. Preferable examples of the leaving group
include a halogen atom, a C.sub.1-6 alkylsulfonyloxy group which
may be substituted with the above Substituent Group .alpha. and an
arylsulfonyloxy group which may be substituted with the above
Substituent Group .alpha.. Specific examples of the leaving group
include a chlorine atom, a bromine atom, an iodine atom, a
methanesulfonyloxy group, a trifluoromethanesulfonyloxy group and a
p-toluenesulfonyloxy group.
1. General Preparation Method 1:
##STR00009## ##STR00010##
[0251] In the formula, R.sup.7 represents a C.sub.1-6 alkyl group
such as a methyl group or an ethyl group, a C.sub.7-12 aralkyl
group such as a benzyl group, or the like, LV is a leaving group
and represents a halogen atom (such as a chlorine atom, a bromine
atom or an iodine atom), for example, or a sulfonyloxy group such
as a methanesulfonyloxy group, a p-toluenesulfonyloxy group or a
trifluoromethanesulfonyloxy group, for example, and Ring A,
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, Y and Z are
as defined above.
[0252] General Preparation Method 1 is a method for preparing a
compound (1-7) which is a synthetic intermediate of the compound
(I) according to the present invention from a compound (1-1) as a
raw material through multiple steps of Step 1-1 to Step 1-6.
[0253] The compound (1-1) can be a commercially available product
used as is, can also be prepared from a commercially available
product by a method known to a person skilled in the art, and can
further be prepared by a method described in Preparation Examples
among Examples.
1-1. Step 1-1:
[0254] This step is a step of obtaining a compound (1-2) by
trifluoromethanesulfonylation of the compound (1-1).
[0255] The reaction in this step can be performed under the same
conditions as those usually used in trifluoromethanesulfonylation
reaction of a carbonyl compound (such as the conditions described
in J. Org. Chem., 57, 6972-6975 (1992), Tetrahedron Letters., 40,
8133-8136 (1999) and Tetrahedron., 61, 4129-4140 (2005)).
[0256] Specifically, the compound (1-2) can be obtained by causing
a base to act on the compound (1-1), and then reacting the compound
with N-phenyltrifluoromethanesulfonimide or
trifluoromethanesulfonic anhydride, for example. This reaction can
be performed by causing one or more equivalents of a base to act on
the compound (1-1) in an organic solvent such as ether,
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloromethane,
1,2-dichloroethane, benzene or toluene, for example. Examples of
the base used include sodium hydride, LDA (lithium
diisopropylamide), lithium bis(trimethylsilyl)amide,
diisopropylethylamine, pyridine and 2,6-lutidine. The reaction time
is not particularly limited and is usually 5 minutes to 24 hours,
and preferably 5 minutes to 12 hours. The reaction temperature is
usually -100.degree. C. to room temperature, and more preferably
-78.degree. C. to room temperature.
1-2. Step 1-2:
[0257] This step is a step of obtaining a compound (1-3) by
coupling reaction of the compound (1-2) using a transition
metal.
[0258] This reaction can be performed under the conditions usually
used in coupling reaction using a transition metal (such as Suzuki
coupling reaction or Stille coupling reaction).
[0259] Examples of the reaction using an organoboron reagent as an
organometallic compound include reactions in documents such as
Tetrahedron: Asymmetry 16 (2005) 2, 529-539 and Org. Lett. 6 (2004)
2, 277-279. Examples of the reaction using an organotin reagent
include reaction in a document such as Tetrahedron 61 (2005) 16,
4129-4140. Examples of the reaction using an organozinc reagent as
an organometallic compound include reaction in a document such as
Tetrahedron 61 (2005) 16, 4129-4140. The organometallic catalyst
used in this reaction is not particularly limited. Preferable
examples of the organometallic catalyst include
tetrakis(triphenylphosphine)palladium (0),
dichlorobis(triphenylphosphine)palladium (II),
[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride,
bis(tert-butylphosphine)palladium (0), palladium (II) acetate and
[1,3-bis(diphenylphosphino)propane]nickel (II). The amount of the
organometallic catalyst used is about 0.001 to 0.1 equivalent with
respect to the raw material. The organometallic compound is not
particularly limited. Preferable examples of the organometallic
compound include organotin reagents such as aryltri-n-butyltin, and
organoboron reagents such as arylboronic acid. The amount of the
organometallic compound used is one to five equivalents with
respect to the raw material. The solvent used in this reaction is
not particularly limited insofar as it does not inhibit the
reaction. Preferable examples of the solvent include benzene,
toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone,
tetrahydrofiman, 1,4-dioxane, acetonitrile and propionitrile. The
reaction temperature is not particularly limited and is usually
ice-cold temperature to solvent reflux temperature, and preferably
room temperature to solvent reflux temperature, for example. The
reaction time is not particularly limited and is usually 0.5 to 48
hours, and preferably 0.5 to 24 hours.
[0260] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in the presence of a base.
Such a base is not particularly limited. Preferable examples of the
base include bases such as sodium carbonate, potassium carbonate,
cesium carbonate, potassium phosphate and solutions thereof, and
triethylamine.
1-3. Step 1-3:
[0261] This step is a step of obtaining an alcohol compound (1-4)
by subjecting the ester compound (1-3) to reduction reaction. The
alcohol compound (1-4) can be obtained from the ester compound
(1-3) by a method known to a person skilled in the art.
[0262] Examples of the reducing agent used in the reaction include
lithium aluminum hydride, lithium borohydride and
diisobutylaluminum hydride. The reaction temperature is not
particularly limited and is usually -78.degree. C. to solvent
reflux temperature, and preferably -78.degree. C. to room
temperature. The solvent used in the reaction is not particularly
limited insofar as it does not inhibit the reaction and allows the
starting material to be dissolved therein to a certain extent.
Preferable examples of the solvent include tetrahydrofuran, diethyl
ether, toluene and dichloromethane.
1-4. Step 1-4:
[0263] This step is a step of obtaining a compound (1-5) by
converting the hydroxyl group of the compound (1-4) to a leaving
group.
[0264] Examples of the leaving group include halogen atoms (such as
a chlorine atom, a bromine atom and an iodine atom) and sulfonyloxy
groups such as a methanesulfonyloxy group, a p-toluenesulfonyloxy
group and a trifluoromethanesulfonyloxy group.
[0265] The reaction can be performed under the same conditions as
those usually used in reaction of converting a hydroxyl group to
such a leaving group. When the leaving group is a halogen atom, for
example, the compound (1-5) can be prepared by reacting the
compound (1-4) with thionyl chloride, thionyl bromide, phosphorus
tribromide or tetrahalogenomethane-triphenylphosphine, for example.
The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Preferable
examples of the solvent include benzene, toluene, xylene,
dichloromethane and chloroform. The reaction temperature is usually
-78.degree. C. to solvent reflux temperature, and preferably
ice-cold temperature to solvent reflux temperature. The reaction
time is not particularly limited and is usually 5 minutes to 48
hours, and preferably 5 minutes to 12 hours.
[0266] When the leaving group is a sulfonyloxy group, the compound
(1-5) can be prepared by reacting the compound (1-4) with
methanesulfonyl chloride, p-toluenesulfonyl chloride or
trifluoromethanesulfonic anhydride, for example.
[0267] The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Preferable
examples of the solvent include tetrahydrofuran, toluene, xylene,
dichloromethane, chloroform and N,N-dimethylformamide. The reaction
temperature is usually -78.degree. C. to solvent reflux
temperature, and preferably -78.degree. C. to room temperature. A
favorable result such as an improved yield may be achieved by
addition of a base. The base used is not particularly limited
insofar as it does not inhibit the reaction. Preferable examples of
the base include sodium carbonate, potassium carbonate,
triethylamine, pyridine and diisopropylethylamine.
1-5. Step 1-5:
[0268] This step is a step of obtaining a compound (1-6) from the
compound (1-5). The thiourea compound (1-6) can be obtained from
the compound (1-5) by a method known to a person skilled in the
art.
[0269] Specifically, the compound (1-6) can be obtained by reacting
the compound (1-5) with thiourea in a solvent, for example. This
reaction can be performed by causing one or more equivalents of
thiourea to act on the compound (1-5) in an organic solvent such as
ethanol, 1-propanol, 2-propanol, 1-butanol, tetrahydrofuran,
1,4-dioxane or N,N-dimethylformamide, for example. The reaction
time is not particularly limited and is usually 5 minutes to 24
hours, and preferably 5 minutes to 12 hours. The reaction
temperature is usually 0.degree. C. to 150.degree. C., and more
preferably room temperature to 100.degree. C.
1-6, Step 1-6:
[0270] This step is a method of obtaining the compound (1-7) by
cyclizing the compound (1-6) with an acid.
[0271] This reaction is not particularly limited insofar as it does
not inhibit the reaction and allows the starting material to be
dissolved therein to a certain extent. For example, the reaction
can be performed by causing one equivalent to a large excess of an
appropriate acid to act on the compound in the presence or absence
of a solvent such as benzene, toluene or dichloromethane. Further,
an acid may also be used as a solvent. Examples of the acid used
include sulfuric acid, trifluoroacetic acid, methanesulfonic acid,
trifluoromethanesulfonic acid and mixtures thereof. The reaction
time is not particularly limited and is usually 1 to 72 hours, and
preferably 1 to 48 hours. The reaction temperature is usually
ice-cold temperature to solvent reflux temperature.
[0272] The compound (1-7), wherein both R.sup.1 and R.sup.2 are
hydrogen atoms, can be obtained by the above reaction.
[0273] The compound (1-7), wherein both R.sup.1 and R.sup.2 are
hydrogen atoms, can be converted to the compound (1-7), wherein at
least one of R.sup.1 and R.sup.2 is substituted with a substituent,
by further reaction with a corresponding halide compound or the
like such as a C.sub.1-6 alkyl halide, a C.sub.1-6 alkylcarbonyl
halide, a C.sub.6-14 arylcarbonyl halide, a C.sub.1-6 alkylsulfonyl
halide, a C.sub.6-14 arylsulfonyl halide, a 3- to 10-membered
carbocyclic halide or a 5- to 10-membered heterocyclic halide.
2. General Preparation Method 2:
##STR00011##
[0275] In the formula, Ring A, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
Y and Z are as defined above.
[0276] General Preparation Method 2 is a method for preparing a
compound of the general formula (1-4) which is a synthetic
intermediate of the compound (I) according to the present invention
from a compound (2-1) as a raw material through multiple steps of
Step 2-1 to Step 2-3.
[0277] The compound (2-1) can be a commercially available product
used as is, can also be prepared from a commercially available
product by a method known to a person skilled in the art, and can
further be prepared by a method described in Preparation Examples
among Examples.
2-1. Step 2-1:
[0278] This step is a step of obtaining a compound (2-2) from the
compound (2-1). This reaction can be performed under the same
conditions as those usually used in reaction of synthesizing a
compound (2-2) from a carbonyl compound (such as the conditions
described in J. Org. Chem., 47, 3597-3607 (1982)).
2-2. Step 2-2:
[0279] This step is a step of synthesizing a compound (2-3) from
the compound (2-2) as a raw material using a method described in
the above preparation method (Step 1-2).
2-3. Step 2-3:
[0280] This step is a step of obtaining the alcohol compound (1-4)
by subjecting the aldehyde compound (2-3) to reduction
reaction.
[0281] The alcohol compound (1-4) can be obtained from the aldehyde
compound (2-3) by a method known to a person skilled in the art.
Examples of the reducing agent used in the reaction include sodium
borohydride, sodium cyanoborohydride and sodium
triacetoxyborohydride. The reaction temperature is not particularly
limited and is usually -78.degree. C. to solvent reflux
temperature, and preferably -20.degree. C. to room temperature. The
solvent used in the reaction is not particularly limited insofar as
it does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent. Preferable examples of
the solvent include methanol, ethanol, tetrahydrofuran, ether,
toluene and dichloromethane.
3. General Preparation Method 3:
##STR00012##
[0283] In the formula, L.sub.1 represents a single bond or a
C.sub.1-6 alkyl group and Ring A, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, X, Y, Z and Ring B are as defined
above.
[0284] General Preparation Method 3 is a method for preparing the
compound of the general formula (I) according to the present
invention, wherein L is a --NHCO--C.sub.1-6 alkyl group and R.sup.1
and R.sup.2 are hydrogen atoms, from a compound (3-1) as a raw
material through multiple steps of Step 3-1 to Step 3-4.
[0285] The compound (3-1) can be prepared from a commercially
available product by General Preparation Method 1, General
Preparation Method 2, General Preparation Method 4 or a combination
of these three methods, and can also be prepared by a method
described in Preparation Examples among Examples. Compounds (3-4)
and (3-5) can be commercially available products used directly, can
also be prepared from a commercially available product by a method
known to a person skilled in the art, and can further be prepared
by a method described in Preparation Examples among Examples.
3-1. Step 3-1:
[0286] This step is a step of obtaining a compound (3-2) by
t-butoxycarbonylation of the amino group of the compound (3-1) when
R.sup.1 and R.sup.2 are both hydrogen.
[0287] The reaction can be performed under the same conditions as
those generally used in t-butoxycarbonylation of an amino compound
such as the conditions described in a document such as T. W. Green
and P. G. M. Wuts, "Protective Groups in Organic Chemistry, Second
Edition", John Wiley & Sons (1991), p. 327-330. The compound
(3-2) can be obtained by reacting the compound (3-1) with
di-tert-butyl dicarbonate using triethylamine as a base in a
solvent such as tetrahydrofuran, for example.
3-2. Step 3-2:
[0288] This step is a step of obtaining a compound (3-3) from the
compound (3-2).
[0289] The compound (3-3) is synthesized by reducing the nitro
compound (3-2) by a synthesis method known to a person skilled in
the art. Examples of the method include reduction by catalytic
hydrogenation using a noble metal catalyst such as Raney nickel,
palladium, ruthenium, rhodium or platinum. In this case, reduction
reaction with iron under neutral conditions using ammonium chloride
is preferable, for example.
3-3. Step 3-3:
[0290] This step is a step of obtaining a compound (3-6) by
condensing the compound (3-3) with the compound (3-4) using a
condensing agent. Alternatively, this step is a step of obtaining a
compound (3-6) by condensing the compound (3-3) with the compound
(3-5) by acylation reaction.
[0291] The condensation reaction of the compound (3-3) with the
compound (3-4) using a condensing agent can be performed under the
same conditions as those usually used and described in the
following documents. Examples of the known method include those in
Rosowsky, A.; Forsch, R. A.; Moran, R. G; Freisheim, J. H.; J. Med.
Chem., 34 (1), 227-234 (1991), Brzostwska, M.; Brossi, A.;
Flippen-Anderson, J. L.; Heterocycles, 32 (10), 1969-1972 (1991),
and Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May,
P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; Tan,
C.-K.; Voorman, R. L.; Reusser, F.; Althaus, I. W; Downey, K. M.;
So, A. G; Resnick, L.; Tarpley, W. G, Aristoff, P. A.; J. Med.
Chem., 37 (7), 999-1014 (1994).
[0292] The compound (3-3) may be a free form or a salt.
[0293] The solvent in this reaction is not particularly limited
insofar as it does not inhibit the reaction. Examples of the
solvent include tetrahydrofuran, 1,4-dioxane, ethyl acetate, methyl
acetate, dichloromethane, chloroform, N,N-dimethylformamide,
toluene and xylene. Examples of the condensing agent include CDI
(N,N-carbonyldiimidazole), Bop
(1H-1,2,3-benzotriazol-1-yloxy(tri(dimethylamino))phosphonium
hexafluorophosphate), WSC
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride),
DCC(N,N-dicyclohexylcarbodiimide), diethylphosphoryl cyanide, PyBOP
(benzotriazol-1-yloxytris(pyrrolidino)phosphonium
hexafluorophosphate) and EDC-HCl
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride). One
equivalent to a large excess of the compound (3-4) is used with
respect to the compound (3-3). One equivalent to a large excess of
an organic base such as triethylamine may be added where
necessary.
[0294] The reaction time is not particularly limited and is usually
0.5 to 48 hours, and preferably 0.5 to 24 hours. The reaction
temperature varies according to the raw material used, the solvent
and the like and is not particularly limited. Ice-cold temperature
to solvent reflux temperature is preferable.
3-4. Step 3-4:
[0295] This step is a step of obtaining the compound (I-a) by
deprotection reaction of the t-butoxycarbonyl group of the compound
(3-6).
[0296] The reaction can be performed under the same conditions as
those generally used in deprotection reaction of a t-butoxycarbonyl
group such as the conditions described in a document such as T. W.
Green and P. G M. Wuts, "Protective Groups in Organic Chemistry,
Second Edition", John Wiley & Sons (1991), p. 327-330. The
compound (I-a) can be obtained by reacting trifluoroacetic acid
with the compound (3-6) in a solvent such as dichloromethane, for
example.
[0297] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., can be obtained by further
reacting the compound (I-a) obtained in General Preparation Method
3 with a corresponding halide compound or the like such as a
C.sub.1-6 alkyl halide. Alternatively, the compound of the formula
(I) according to the present invention, wherein L is --NR.sup.LCO--
(wherein R.sup.L is a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha.), can be
obtained by further reacting the compound (I-a) obtained in General
Preparation Method 3 with a corresponding halide compound or the
like such as a C.sub.1-6 alkyl halide.
[0298] The compound of the formula (I) according to the present
invention, wherein L is --NR.sup.LSO.sub.2-- (wherein R.sup.L is a
hydrogen atom), can be obtained using a corresponding sulfonyl
compound or sulfonyl halide compound in place of the compound (3-4)
or (3-5) used in General Preparation Method 3. The compound of the
formula (I) according to the present invention, wherein L is
--NR.sup.LSO.sub.2-- (wherein R.sup.L is a C.sub.1-6 alkyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.), can be obtained by further reacting this compound with a
corresponding halide compound or the like such as a C.sub.1-6 alkyl
halide.
[0299] In Step 3-3 of General Preparation Method 3, the compound
(3-6) can also be prepared from the compound (3-3) and the compound
(3-4) by a method described in the following alternative method (1)
or (2).
Alternative Method (1):
[0300] The compound (3-6) can be obtained by converting the
compound (3-4) to a mixed acid anhydride and then reacting the
mixed acid anhydride with the compound (3-3). The mixed acid
anhydride can be synthesized by a means known to a person skilled
in the art. The synthesis is performed by reacting the compound
(3-4) with a chloroformate such as ethyl chloroformate in the
presence of a base such as triethylamine, for example. One to two
equivalents of the chloroformate and the base are used with respect
to the compound (3-4). The reaction temperature is -30.degree. C.
to room temperature, and preferably -20.degree. C. to room
temperature.
[0301] The step of condensing the mixed acid anhydride with the
compound (3-3) is performed by reacting the mixed acid anhydride
with the compound (3-3) in a solvent such as dichloromethane,
tetrahydrofuran or N,N-dimethylformamide, for example. One
equivalent to a large excess of the compound (3-3) is used with
respect to the mixed acid anhydride.
[0302] The reaction time is not particularly limited and is usually
0.5 to 48 hours, and preferably 0.5 to 12 hours. The reaction
temperature is -20.degree. C. to 50.degree. C., and preferably
-20.degree. C. to room temperature.
Alternative Method (2):
[0303] The compound (3-6) can be obtained by converting the
compound (3-4) to an active ester and then reacting the active
ester with the compound (3-3). The step of obtaining the active
ester is performed by reacting the compound (3-4) with an active
ester synthesis reagent in a solvent such as 1,4-dioxane,
tetrahydrofuran or N,N-dimethylformamide in the presence of a
condensing agent such as DCC, for example. Examples of the active
ester synthesis reagent include N-hydroxysuccinimide. One to 1.5
equivalents of the active ester synthesis reagent and the
condensing agent are used with respect to the compound (3-4). The
reaction time is not particularly limited and is usually 0.5 to 48
hours, and preferably 0.5 to 24 hours.
[0304] The reaction temperature is -20.degree. C. to 50.degree. C.,
and preferably -20.degree. C. to room temperature.
[0305] The step of condensing the active ester with the compound
(3-3) is performed by reacting the active ester with the compound
(3-3) in a solvent such as dichloromethane, tetrahydrofuran or
N,N-dimethylformamide, for example. One equivalent to a large
excess of the compound (3-3) is used with respect to the active
ester. The reaction time is not particularly limited and is usually
0.5 to 48 hours, and preferably 0.5 to 24 hours. The reaction
temperature is -20.degree. C. to 50.degree. C., and preferably
-20.degree. C. to room temperature.
[0306] In this acylation reaction, the compound (3-6) can be
obtained from the compounds (3-3) and (3-5) by a method known to a
person skilled in the art.
[0307] Examples of the base used in the reaction include
triethylamine, pyridine, potassium carbonate and
diisopropylethylamine. The reaction temperature is not particularly
limited and is usually -78.degree. C. to solvent reflux
temperature, and preferably -20.degree. C. to room temperature. The
solvent used in the reaction is not particularly limited insofar as
it does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent. Preferable examples of
the solvent include tetrahydrofuran, ether, toluene and
dichloromethane.
4. General Preparation Method 4:
##STR00013##
[0309] In the formula, Ring A, R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, X, Y and Z are as defined above.
[0310] General Preparation Method 4 is a method for preparing a
compound of the general formula (3-1) which is a synthetic
intermediate of the compound according to the present invention
from a compound (4-1) as a raw material through Step 4-1.
[0311] The compound (4-1) can be prepared from a commercially
available product by General Preparation Method 1, General
Preparation Method 2, General Preparation Method 5 or a combination
of these methods, and can also be prepared by a method described in
Preparation Examples among Examples.
4-1. Step 4-1:
[0312] This step is a step of obtaining the compound (3-1) by
nitration reaction of the compound (4-1). In this nitration
reaction, the compound (3-1) can be obtained from the compound
(4-1) by a method known to a person skilled in the art. Examples of
the nitrating agent used in the reaction include potassium
nitrate/concentrated sulfuric acid and fuming nitric acid/acetic
anhydride. The reaction temperature is not particularly limited and
is usually -20.degree. C. to room temperature.
5. General Preparation Method 5:
##STR00014## ##STR00015##
[0314] In the formula, Pit represents a protecting group such as a
benzoyl group, an acetyl group or a 9-fluorenemethyloxycarbonyl
group (Fmoc group), and Ring A, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
Y and Z are as defined above.
[0315] General Preparation Method 5 is a method for preparing a
compound (1-7) which is a synthetic intermediate of the compound
(I) according to the present invention from a compound (5-1) as a
raw material through multiple steps of Step 5-1 to Step 5-7.
[0316] The compound (5-1) can be prepared from a commercially
available product by a method known to a person skilled in the art,
and can further be prepared by a method described in Preparation
Examples among Examples.
5-1. Step 5-1:
[0317] This step is a step of obtaining a compound (5-2) by
oximation of the compound (5-1).
[0318] The reaction in this step can be performed under the same
conditions as those usually used in oximation reaction of a
carbonyl compound such as the conditions described in Org. Lett. 9
(2007) 5, 753-756, Tetrahedron: Asymmetry 5 (1994) 6, 1018-1028 and
Tetrahedron 54 (1998) 22, 5869-5882.
[0319] Specifically, the compound (5-2) can be obtained by reacting
the compound (5-1) with hydroxylamine or a hydroxylamine salt (such
as hydroxylamine hydrochloride or hydroxylamine sulfate) in the
presence of a base or in the absence of a base, for example.
[0320] The solvent used in this reaction is not particularly
limited insofar as it does not inhibit the reaction. Preferable
examples of the solvent include organic solvents such as ethanol,
methanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and
dichloromethane, and mixtures of these solvents and water. Examples
of the base used include sodium acetate, pyridine, sodium
hydroxide, cesium hydroxide, barium hydroxide and 2,6-lutidine. The
reaction time is not particularly limited and is usually 5 minutes
to 24 hours, and preferably 5 minutes to 12 hours. The reaction
temperature is usually -20.degree. C. to solvent reflux
temperature, and more preferably 0.degree. C. to solvent reflux
temperature.
5-2. Step 5-2:
[0321] This step is a step of obtaining a compound (5-3) by
converting the compound (5-2) to a nitrile oxide derivative and
performing 1,3-dipolar cycloaddition reaction with the olefin
moiety in the same molecule.
[0322] The reaction in this step can be performed under the same
conditions as those usually used in 1,3-dipolar cycloaddition
reaction such as the conditions described in a document such as
Org. Lett. 9 (2007) 5, 753-756, Tetrahedron: Asymmetry 5 (1994) 6,
1018-1028 and Tetrahedron 54 (1998) 22, 5869-5882. Examples of the
reagent for converting the oxime compound to the nitrile oxide
include N-chlorosuccinimide and sodium hypochlorite. The solvent
used in this reaction is not particularly limited insofar as it
does not inhibit the reaction. Preferable examples of the solvent
include dichloromethane, chloroform, benzene, toluene, xylene,
N,N-dimethylformamide, tetrahydrofuran and 1,4-dioxane. The
reaction temperature is not particularly limited and is usually
ice-cold temperature to solvent reflux temperature. The reaction
time is not particularly limited and is usually 0.5 to 48 hours,
and preferably 0.5 to 24 hours.
[0323] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in the presence of a base.
Such a base is not particularly limited. Examples of the base
include bases such as sodium carbonate, potassium carbonate, cesium
carbonate, potassium phosphate and solutions thereof, and
triethylamine and pyridine.
5-3. Step 5-3:
[0324] This step is a step of obtaining a compound (5-4) by
addition reaction of an aryllithium reagent (including
heterocyclic) or a Grignard reagent (including heterocyclic) with
the compound (5-3).
[0325] The reaction in this step can be performed under the same
conditions as those described in J. Am. Chem. Soc. 2005, 127,
5376-5383, Bull. Chem. Soc. Jpn., 66, 2730-2737 (1993) and SYNLETT
2004, No. 8, pp 1409-1413, for example.
[0326] The aryllithium reagent (including heterocyclic) or the
Grignard reagent (including heterocyclic) can be prepared by a
method known to a person skilled in the art. Specifically, a
corresponding aryl (including heterocyclic) lithium reagent or aryl
(including heterocyclic) magnesium reagent can be prepared by
halogen-metal exchange between an aryl halide compound and a
commercially available organometallic reagent such as an
alkyllithium reagent such as n-, sec- or tert-butyllithium or a
Grignard reagent such as isopropylmagnesium bromide, or metallic
magnesium, for example.
[0327] The solvent used in this step varies according to the
starting material and the reagent used, and is not particularly
limited insofar as it does not inhibit the reaction, allows the
starting material to be dissolved therein to a certain extent, and
is always inert during the reaction. Preferable examples of the
solvent include organic solvents such as diethyl ether,
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene and
toluene, and mixed solvents thereof. The reaction time is not
particularly limited and is usually 0.1 to 48 hours, and preferably
0.1 to 12 hours. The reaction temperature varies according to the
starting material, the reagent used and the like, and is preferably
maintained to be low, for example, at -78.degree. C. to minimize
formation of a by-product.
[0328] Favorable results such as an improved yield and a reduced
reaction time may be achieved by addition of TMEDA
(tetramethylethylenediamine), HMIPA (hexamethylphosphoramide) or a
Lewis acid such as a boron trifluoride-diethyl ether complex
(BF3.OEt2) as an additive, for example.
5-4. Step 5-4:
[0329] This step is a step of obtaining a compound (5-5) by
subjecting the compound (5-4) to reductive cleavage reaction of the
N--O bond.
[0330] The reductive cleavage reaction of the N--O bond can be
performed under the conditions using zinc-acetic acid, a metal
catalyst such as hydrogen-platinum oxide, or lithium aluminum
hydride, for example.
[0331] The reaction using zinc such as zinc-acetic acid can be
performed under the same conditions as those described in J. Org.
Chem. 2003, 68, 1207-1215 and Org. Lett. 7 (2005) 25, 5741-5742,
for example. Examples of the acid used include acetic acid, formic
acid and hydrochloric acid. The solvent used in the reaction is not
particularly limited insofar as it does not inhibit the reaction
and allows the starting material to be dissolved therein to a
certain extent. Examples of the solvent include methanol, ethanol,
1,4-dioxane, THF and water. The above acid may also be used as a
solvent. The reaction temperature is usually -20.degree. C. to
solvent reflux temperature, and preferably ice-cold temperature to
solvent reflux temperature. The reaction time is not particularly
limited and is usually 5 minutes to 48 hours, and preferably 5
minutes to 24 hours.
[0332] The reaction using a metal catalyst such as
hydrogen-platinum oxide can be performed under the same conditions
as those described in Tetrahedron: Asymmetry 5 (1994) 6, 1019-1028
and Tetrahedron, Vol. 53, No. 16, pp 5752-5746, 1997, for example.
The compound (5-5) can be obtained by hydrogenating the compound
(5-4) using platinum oxide as a catalyst in a solvent such as
methanol, for example.
[0333] The reaction using lithium aluminum hydride can be performed
under the same conditions as those described in Bull. Chem. Soc.
Jpn., 66, 2730-2737 (1993), for example. The compound (5-5) can be
obtained by reducing the compound (5-4) using lithium aluminum
hydride in a solvent such as ether, for example.
5-5. Step 5-5:
[0334] This step is a step of obtaining a compound (5-6) from the
compound (5-5). The thiourea derivative (5-6) can be obtained from
the compound (5-5) by a method known to a person skilled in the
art.
[0335] When the protecting group is a benzoyl group, the compound
(5-6) can be obtained in this step by reacting the compound (5-5)
with benzoyl isothiocyanate in a solvent such as dichloromethane or
toluene. This reaction can be performed under the same conditions
as those described in J. Org. Chem. 1994, 59, 1912-1917, for
example. The solvent used in the reaction is not particularly
limited insofar as it does not inhibit the reaction and allows the
starting material to be dissolved therein to a certain extent.
Examples of the solvent include dichloromethane, chloroform,
toluene, methanol, ethanol, 1,4-dioxane and THF. The reaction
temperature is usually -20.degree. C. to solvent reflux
temperature, and preferably ice-cold temperature to solvent reflux
temperature. The reaction time is not particularly limited and is
usually 5 minutes to 48 hours, and preferably 5 minutes to 24
hours.
[0336] When the protecting group is a 9-fluorenemethyloxycarbonyl
group (Fmoc group), the compound (5-6) can be obtained in this step
by reacting the compound (5-5) with fluorenemethyloxycarbonyl
isothiocyanate in a solvent such as dichloromethane or toluene.
This reaction can be performed under the same conditions as those
described in J. Org. Chem. 1998, 63, 196-200, for example. The
solvent used in the reaction is not particularly limited insofar as
it does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent. Examples of the
solvent include dichloromethane, chloroform, toluene, methanol,
ethanol, 1,4-dioxane and THF. The reaction temperature is usually
-20.degree. C. to solvent reflux temperature, and preferably
ice-cold temperature to solvent reflux temperature. The reaction
time is not particularly limited and is usually 5 minutes to 48
hours, and preferably 5 minutes to 24 hours.
5-6. Step 5-6:
[0337] This step is a method of obtaining a compound (5-7) by
cyclizing the compound (5-6).
[0338] In this reaction, the compound (5-6) can be cyclized under
various conditions to obtain the compound (5-7) by selecting a
protecting group of the compound (5-6).
[0339] When the protecting group is an Fmoc group or a benzoyl
group, for example, the compound (5-7) can be obtained in this
reaction by heating the compound (5-6) in a solvent such as
methanol in the presence of an acid such as concentrated
hydrochloric acid, for example.
[0340] The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Examples of
the solvent include solvents such as methanol, ethanol, 1-propanol
and water, mixed solvents thereof, and acids used as a solvent. The
reaction can be performed by causing one equivalent to a large
excess of an appropriate acid to act in the presence or absence of
such a solvent.
[0341] Examples of the acid used include concentrated hydrochloric
acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid,
methanesulfonic acid, trifluoromethanesulfonic acid and mixtures
thereof. The reaction time is not particularly limited and is
usually 0.5 to 72 hours, and preferably 0.5 to 24 hours. The
reaction temperature is usually ice-cold temperature to solvent
reflux temperature.
[0342] When the protecting group is an Fmoc group or a benzoyl
group, the compound (5-7) can be obtained by an alternative method
1 of reacting the compound (5-6) with trifluoromethanesulfonic
anhydride in a solvent such as dichloromethane in the presence of a
base such as pyridine. This reaction can be performed under the
same conditions as those described in Chem Bio Chem. 2005, 6,
186-191, for example. The solvent used in the reaction is not
particularly limited insofar as it does not inhibit the reaction
and allows the starting material to be dissolved therein to a
certain extent. Examples of the solvent include solvents such as
dichloromethane, 1,2-dichloroethane, THF, 1,2-dimethoxyethane and
toluene, and mixed solvents thereof. The reaction can be performed
using 1 to 20 equivalents of an appropriate base in such a solvent.
Examples of the base used include pyridine, 2,6-lutidine, sodium
carbonate, potassium carbonate and mixtures thereof. The reaction
time is not particularly limited and is usually 0.5 to 24 hours,
and preferably 0.5 to 12 hours. The reaction temperature is usually
-78.degree. C. to room temperature. When the protecting group is a
benzoyl group, the compound (5-7) can be obtained by an alternative
method 2 of reacting the compound (5-6) with triphenylphosphine and
carbon tetrabromide (or bromine) in a solvent such as
dichloromethane. The reaction conditions are the same as those of
bromination of a primary alcohol which are known to a person
skilled in the art.
5-7. Step 5-7:
[0343] This step is a method of obtaining the compound (1-7) by
deprotecting the protecting group of the compound (5-7). The
compound (1-7) can be obtained under deprotection conditions known
to a person skilled in the art.
[0344] When the protecting group is an Fmoc group, for example, the
compound (1-7) can be obtained under the same conditions as those
generally used in deprotection of a protecting group of an amine
compound (such as the conditions described in a document such as T.
W Green and P. G M. Wuts, "Protective Groups in Organic Chemistry,
Third Edition", John Wiley & Sons, p. 506-507 and J. Org. Chem.
1998, 63, 196-200). In this reaction, the compound (1-7) can be
obtained by reacting the compound (5-7) with an excess of an amine
such as pyrrolidine in a solvent such as acetonitrile, for example.
The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Examples of
the solvent include dichloromethane, THF and acetonitrile. The
reaction can be performed by causing one equivalent to a large
excess of an appropriate base to act in the presence of such a
solvent. Examples of the base used include piperidine, morpholine,
pyrrolidine, TBAF and DBU. The reaction time is not particularly
limited and is usually 0.5 to 72 hours, and preferably 0.5 to 24
hours. The reaction temperature is usually ice-cold temperature to
solvent reflux temperature.
[0345] Favorable results such as an improved yield and a reduced
reaction time may be achieved by addition of a thiol compound such
as 1-octanethiol as an additive, for example.
[0346] When the protecting group is a benzoyl group, the compound
(1-7) can be obtained in this reaction by heating the compound
(5-7) in a solvent such as methanol in the presence of a base such
as DBU, for example. This reaction can be performed under the same
conditions as those described in Synth. Commun. 32 (2), 265-272
(2002), for example. The solvent used in the reaction is not
particularly limited insofar as it does not inhibit the reaction
and allows the starting material to be dissolved therein to a
certain extent. Examples of the solvent include solvents such as
methanol, ethanol and 1-propanol. The reaction can be performed
using 1 to 20 equivalents of an appropriate base in such a solvent.
Examples of the base used include DBU. The reaction time is not
particularly limited and is usually 0.5 to 24 hours, and preferably
0.5 to 12 hours. The reaction temperature is usually room
temperature to solvent reflux temperature.
[0347] The compound of the formula (I-7), wherein at least one
hydrogen atom of the amino group is a C.sub.1-6 alkyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.1-6 alkylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.6-14
arylcarbonyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkylsulfonyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylsulfonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.3-8
hydrocarbon ring group which may have 1 to 3 substituents selected
from Substituent Group .alpha. or a 5- to 10-membered heterocyclic
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., can be obtained by further reacting the compound
(1-7) obtained in General Preparation Method 5 with a corresponding
halide compound or the like such as a C.sub.1-6 alkyl halide.
6. General Preparation Method 6:
##STR00016##
[0349] In the formula, Ring A, R.sup.3, R.sup.4, R.sup.6, R.sup.6,
Y, Z, L, LV and Ring B are as defined above, Alk represents a C1-6
alkyl group, R.sup.8 represents a hydrogen atom or a C1-4 alkyl
group, and L.sub.1 represents a single bond or a C1-4 alkyl group,
provided that R.sup.8 and L.sub.1 in the compound (6-6) have up to
four carbon atoms in total.
[0350] General Preparation Method 6 is a method for preparing the
compound (I-b) of the general formula (I) according to the present
invention, wherein L is a single bond, a C2-6 alkenylene group or a
C2-6 alkynylene group and R.sup.1 and R.sup.2 are hydrogen atoms,
from a compound (6-1) as a raw material through multiple steps of
Step 6-1 to Step 6-3.
[0351] The compound (6-1) can be prepared from a commercially
available product by General Preparation Method 1, General
Preparation Method 5 or a combination of General Preparation Method
1 and General Preparation Method 11, and can also be prepared by a
method described in Preparation Examples among Examples. The
compounds (6-3), (6-4), (6-5) and (6-6) can be commercially
available products used directly, can also be prepared from a
commercially available product by a method known to a person
skilled in the art, and can further be prepared by a method
described in Preparation Examples among Examples.
6-1. Step 6-1:
[0352] This step is a step of obtaining a compound (6-2) by
di-t-butoxycarbonylating the compound (6-1). This reaction can be
performed under the same conditions as those generally used in
t-butoxycarbonylation of an amide compound such as the conditions
described in T. W Green and P. G. M. Wuts, "Protective Groups in
Organic Chemistry, Third Edition", John Wiley & Sons, P.
642-643 and J. Org. Chem. 2005, 70, 2445-2454. The compound (6-2)
can be obtained by reacting the compound (6-1) with di-tert-butyl
dicarbonate using 4-dimethylaminopyridine as a base in a solvent
such as THF, for example.
[0353] The solvent used in this reaction is not particularly
limited insofar as it does not inhibit the reaction. Preferable
examples of the solvent include organic solvents such as
tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloromethane,
DMF and acetonitrile, and mixed solvents thereof. Examples of the
base used include triethylamine, 4-dimethylaminopyridine, DBU and
mixtures thereof. A catalytic amount to an excess of, and more
preferably 0.1 to 5 equivalents of the base is used with respect to
the compound (6-1). Two equivalents to an excess of, and more
preferably 2 to 10 equivalents of di-tert-butyl dicarbonate is used
with respect to the compound (6-1). The reaction time is not
particularly limited and is usually 5 minutes to 24 hours, and
preferably 5 minutes to 12 hours. The reaction temperature is
usually -20.degree. C. to solvent reflux temperature, and more
preferably 0.degree. C. to solvent reflux temperature.
6-2. Step 6-2:
[0354] This step is a step of obtaining a compound (6-7) by
coupling reaction of the compound (6-2) with the compound (6-3),
(6-4), (6-5) or (6-6) using a transition metal. This reaction can
be performed under the conditions usually used in coupling reaction
using a transition metal (such as Suzuki coupling reaction, Stille
coupling reaction, Sonogashira reaction or Heck reaction).
[0355] Examples of the Suzuki coupling reaction include reactions
in documents such as J. Org. Chem. 2007, 72, 7207-7213, J. Am.
Chem. Soc. 2000, 122, 4020-4028 and J. Org. Chem. 2007, 72,
5960-5967. Examples of the Stille coupling reaction include
reaction in a document such as J. Am. Chem. Soc. 1990, 112,
3093-3100. Examples of the Sonogashira reaction include reactions
in documents such as J. Org. Chem. 2007, 72, 8547-8550 and J. Org.
Chem. 2008, 73, 234-240. Examples of the Heck reaction include
reaction in a document such as J. Am. Chem. Soc. 2005, 127,
16900-16911. The organometallic catalyst used in this reaction is
not particularly limited. Preferable examples of the organometallic
catalyst include metal catalysts such as
tetrakis(triphenylphosphine)palladium (0),
dichlorobis(triphenylphosphine)palladium (II),
[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride,
bis(tert-butylphosphine)palladium (0), palladium (II) acetate and
[1,3-bis(diphenylphosphino)propane]nickel (II), and mixtures of
these metal catalysts. The amount of the organometallic catalyst
used is about 0.001 to 0.5 equivalent with respect to the raw
material. The amount of the compound (6-3), (6-4), (6-5) or (6-6)
used is not particularly limited and is usually 1 to 5 equivalents
with respect to the compound (6-2). The solvent used in this
reaction is not particularly limited insofar as it does not inhibit
the reaction. Preferable examples of the solvent include benzene,
toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone,
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, acetonitrile and
propionitrile. The reaction temperature is not particularly limited
and is usually ice-cold temperature to solvent reflux temperature,
and preferably room temperature to solvent reflux temperature, for
example. The reaction time is not particularly limited and is
usually 0.5 to 48 hours, and preferably 0.5 to 24 hours.
[0356] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in the presence of a base or
a salt. Such a base or salt is not particularly limited. Preferable
examples of the base or salt include bases or salts such as sodium
carbonate, potassium carbonate, barium hydroxide, cesium carbonate,
potassium phosphate, potassium fluoride and solutions thereof, and
triethylamine, N,N-diisopropylethylamine, lithium chloride and
copper (I) iodide.
6-3. Step 6-3:
[0357] This step is a step of synthesizing the compound (I-b) from
the compound (6-7) as a raw material using a method described in
the above preparation method (Step 3-4).
[0358] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group cc, can be obtained by further
reacting the compound (1-b) obtained in General Preparation Method
6 with a corresponding halide compound or the like such as a
C.sub.1-6 alkyl halide.
7. General Preparation Method 7:
##STR00017##
[0360] In the formula, Ring A, Ring B, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, Z, Y, L and LV are as defined above.
[0361] General Preparation Method 7 is a method for preparing the
compound (I-b) of the general formula (I) according to the present
invention, wherein L is a single bond and R.sup.1 and R.sup.2 are
hydrogen atoms, from a compound (7-1) as a raw material through
Step 7-1 to Step 7-2.
[0362] The compound (7-1) can be prepared from a commercially
available product by General Preparation Method 1, General
Preparation Method 5 or a combination of General Preparation Method
1 and General Preparation Method 11, and can also be prepared by a
method described in Preparation Examples among Examples.
7-1. Step 7-1:
[0363] This step is a step of obtaining a compound (7-2) by
benzyloxycarbonylation of the compound (7-1).
[0364] The reaction can be performed under the same conditions as
those generally used in benzyloxycarbonylation (modification with Z
group) of an amino compound such as the conditions described in a
document such as T. W. Green and P. G. M. Wuts, "Protective Groups
in Organic Chemistry, Third Edition", John Wiley & Sons, P.
531-537. The compound (7-2) can be obtained by reacting the
compound (7-1) with benzyl chloroformate in a mixed solvent of
1,4-dioxane and a saturated sodium bicarbonate solution, for
example.
7-2. Step 7-2:
[0365] This step is a step of synthesizing the compound (I-b) from
the compound (7-2) as a raw material using a method described in
the above preparation method (Step 6-2).
[0366] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., can be obtained by further
reacting the compound (I-b) obtained in General Preparation Method
7 with a corresponding halide compound or the like such as a
C.sub.1-6 alkyl halide.
[0367] 8. General Preparation Method 8:
##STR00018##
[0368] In the formula, Ring A, Ring B, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, Y, Z, L and LV are as defined above.
[0369] General Preparation Method 8 is a method for preparing the
compound (1-b) of the general formula (I) according to the present
invention, wherein L is a single bond and R.sup.1 and R.sup.2 are
hydrogen atoms, from a compound (6-2) as a raw material through
multiple steps of Step 8-1 to Step 8-3.
[0370] The compound (6-2) can be prepared from a commercially
available product by General Preparation Method 6, and can also be
prepared by a method described in Preparation Examples among
Examples. A compound (8-2) can be a commercially available product
used as is, can also be prepared from a commercially available
product by a method known to a person skilled in the art, and can
further be prepared by a method described in Preparation Examples
among Examples.
8-1. Step 8-1:
[0371] This step is a step of obtaining a compound (8-1) by
coupling reaction of the compound (6-2) using a transition
metal.
[0372] The reaction in this step can be performed under the same
conditions as those usually used in coupling reaction using a
transition metal such as the conditions described in Org. Lett.
2007, Vol. 9, No. 4, 559-562 and Bioorg. Med. Chem., 14 (2006)
4944-4957. Specifically, the compound (8-1) can be obtained by
reacting the compound (6-2) with bis(pinacolato)diborane under
heating conditions in a solvent such as DMF in the presence of a
catalyst such as potassium acetate or
[1,1'-bis(diphenylphosphino)ferrocene]palladium (H) dichloride, for
example.
[0373] The organometallic catalyst used in this reaction is not
particularly limited. Preferable examples of the organometallic
catalyst include metal catalysts such as
dichlorobis(triphenylphosphine)palladium (II),
[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloride,
bis(tert-butylphosphine)palladium (0), palladium (II) acetate and
[1,3-bis(diphenylphosphino)propane]nickel (II). The amount of the
organometallic catalyst used is about 0.001 to 0.5 equivalent with
respect to the raw material. The solvent used in this reaction is
not particularly limited insofar as it does not inhibit the
reaction. Preferable examples of the solvent include benzene,
toluene, xylene, N,N-dimethylformamide, 1-methyl-2-pyrrolidone,
dimethyl sulfoxide, tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, acetonitrile and propionitrile. The reaction
temperature is not particularly limited and is usually ice-cold
temperature to solvent reflux temperature, and preferably room
temperature to solvent reflux temperature, for example. The
reaction time is not particularly limited and is usually 0.5 to 72
hours, and preferably 0.5 to 24 hours.
[0374] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in the presence of a base.
Such a base is not particularly limited. Preferable examples of the
base include bases such as potassium acetate, sodium acetate,
sodium carbonate, potassium carbonate, cesium carbonate, potassium
phosphate, potassium fluoride, triethylamine and
N,N-diisopropylethylamine.
8-2. Step 8-2:
[0375] This step is a step of synthesizing a compound (8-3) from
the compound (8-1) as a raw material using a method described in
the above preparation method (Step 6-2).
8-3. Step 8-3:
[0376] This step is a step of synthesizing the compound (I-b) from
the compound (8-3) as a raw material using a method described in
the above preparation method (Step 3-4).
[0377] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., can be obtained by further
reacting the compound (1-b) obtained in General Preparation Method
8 with a corresponding halide compound or the like such as a
C.sub.1-6 alkyl halide.
9. General Preparation Method 9:
##STR00019##
[0379] In the formula, Ring A, Ring B, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, Y and Z are as defined above.
[0380] General Preparation Method 9 is a method for preparing the
compound (I-a) of the general formula (I) according to the present
invention, wherein L is --NHCO-- and R.sup.1 and R.sup.2 are
hydrogen atoms, from a compound (8-1) as a raw material through
multiple steps of Step 9-1 to Step 9-4.
[0381] The compound (8-1) can be prepared from a commercially
available product by General Preparation Method 8, and can also be
prepared by a method described in Preparation Examples among
Examples.
9-1. Step 9-1:
[0382] This step is a step of obtaining a compound (9-1) by
reaction of the compound (8-1) with sodium azide in the presence of
a copper catalyst.
[0383] The reaction in this step can be performed under the same
conditions as those described in Org. Lett. 2007, Vol. 9, No. 5,
761-764 and Tetrahedron Lett. 2007, 48, 3525-3529, for example.
Specifically, the compound (9-1) can be obtained by reacting the
compound (8-1) with sodium azide at room temperature using a
solvent such as methanol in the presence of a catalyst such as
copper (II) acetate, for example.
[0384] The catalyst used in this reaction is not particularly
limited. Preferable examples of the catalyst include metal
catalysts such as copper (II) acetate, copper (II) sulfate, copper
(I) iodide and copper (I) chloride. The amount of the catalyst used
is not particularly limited and is usually about 0.1 to 0.5
equivalent with respect to the raw material. The solvent used in
this reaction is not particularly limited insofar as it does not
inhibit the reaction and allows the starting material to be
dissolved therein to a certain extent. Preferable examples of the
solvent include methanol, N,N-dimethylformamide,
1-methyl-2-pyrrolidone, tetrahydrofuran, 1,2-dimethoxyethane,
1,4-dioxane, acetonitrile, propionitrile and dichloromethane. The
reaction temperature is not particularly limited and is usually
ice-cold temperature to solvent reflux temperature, and preferably
room temperature to solvent reflux temperature, for example. The
reaction time is not particularly limited and is usually 0.5 to 100
hours, and preferably 1 to 72 hours.
[0385] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in an oxygen atmosphere.
9-2. Step 9-2:
[0386] This step is a step of obtaining a compound (9-2) by
reduction reaction of the azide of the compound (9-1). The reaction
in this step can be performed under the same conditions as those
described in J. Org. Chem. 2003, 68, 4693-4699, for example.
Specifically, the compound (9-2) can be obtained by dissolving the
compound (9-1) in a solvent such as methanol, and reacting the
solution with sodium borohydride, for example.
9-3. Step 9-3:
[0387] This step is a step of synthesizing a compound (9-3) from
the compound (9-2) as a raw material using a method described in
the above preparation method (Step 3-3).
9-4. Step 9-4:
[0388] This step is a step of synthesizing the compound (I-a) from
the compound (9-3) as a raw material using a method described in
the above preparation method (Step 3-4).
[0389] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., can be obtained by further
reacting the compound (I-a) obtained in General Preparation Method
9 with a corresponding halide compound or the like such as a
C.sub.1-6 alkyl halide. Alternatively, the compound of the formula
(I) according to the present invention, wherein L is --NR.sup.LCO--
(wherein R.sup.L is a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha.), can be
obtained by further reacting the compound (1-a) obtained in General
Preparation Method 9 with a corresponding halide compound or the
like such as a C.sub.1-6 alkyl halide.
[0390] The compound of the formula (I) according to the present
invention, wherein L is --NR.sup.LSO.sub.2-- (wherein R.sup.L is a
hydrogen atom), can be obtained using a corresponding sulfonyl
compound or sulfonyl halide compound in place of the compound (3-4)
or (3-5) used in General Preparation Method 9. The compound of the
formula (I) according to the present invention, wherein L is
--NR.sup.LSO.sub.2-- (wherein R.sup.L is a C.sub.1-6 alkyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.), can be obtained by further reacting this compound with a
corresponding halide compound or the like such as a C.sub.1-6 alkyl
halide.
10. General Preparation Method 10:
##STR00020## ##STR00021##
[0392] In the formula, Ring A, Ring B, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, L and LV are as defined above; Ring D represents a
C.sub.6-14 aryl group which may have 1 to 3 substituents selected
from Substituent Group .alpha. or a 5- to 6-membered heteroaryl
group which may have 1 to 3 substituents selected from Substituent
Group .alpha.; R.sup.9 represents a C.sub.6-14 aryl group which may
have 1 to 3 substituents selected from Substituent Group .alpha., a
5- to 10-membered heterocyclic group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.3-8
cycloalkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkyl group which may have 1
to 3 substituents selected from Substituent Group .alpha. or a 3-
to 10-membered carbocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha.; R.sup.10 and R.sup.11 are
each independently a hydrogen atom, a C.sub.6-14 aryl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a 5- to 10-membered heterocyclic group which may have 1 to
3 substituents selected from Substituent Group .alpha., a C.sub.3-8
cycloalkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkyl group which may have 1
to 3 substituents selected from Substituent Group .alpha. or a 3-
to 10-membered carbocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha.; or R.sup.10 and R.sup.11
together may form a C.sub.3-8 cycloalkyl group which may be
substituted at the carbon atom(s) with 1 to 2 substituents selected
from an oxygen atom, a sulfur atom, a sulfone and --N(R.sup.M)--
(wherein R.sup.M is as defined above); R.sup.12 represents a
C.sub.6-14 aryl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a 5- to 10-membered heterocyclic
group which may have 1 to 3 substituents selected from Substituent
Group .alpha., a C.sub.3-8 cycloalkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha. or a 3- to 10-membered carbocyclic group
which may have 1 to 3 substituents selected from Substituent Group
.alpha.; R.sup.13 represents a C.sub.7-12 aralkyl group which may
have 1 to 3 substituents selected from Substituent Group .alpha.;
and Prt2 represents an amine protecting group such as a
2,4-dimethoxybenzyl group or a benzyloxycarbonyl group.
[0393] General Preparation Method 10 is a method for preparing the
compounds (I-m) to (I-q) of the general formula (I) according to
the present invention, wherein Z is --NR.sup.M-- (wherein R.sup.M
is a hydrogen atom, a C.sub.1-6 alkyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.3-8
cycloalkyl group which may have 1 to 3 substituents selected from
Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group which
may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 aryl group which may have 1 to 3 substituents
selected from Substituent Group .alpha. or a 5- to 10-membered
heterocyclic group which may have 1 to 3 substituents selected from
Substituent Group .alpha.) and R.sup.1 and R.sup.2 are hydrogen
atoms, from a compound (10-1) as a raw material through various
steps of Step 10-1 to Step 10-6.
[0394] The compound (10-1) can be prepared from a commercially
available product by General Preparation Method 5, General
Preparation Method 6, General Preparation Method 8, General
Preparation Method 9 or a combination of these methods, and can
also be prepared by a method described in Preparation Examples
among Examples.
10-1. Step 10-1:
[0395] This step is a step of obtaining a compound (10-2) by
deprotecting the amino group of the compound (10-1).
[0396] The reaction can be performed under the same conditions as
those generally used in deprotection of a protecting group of an
amino compound such as the conditions described in a document such
as T. W. Green and P. G. M. Wuts, "Protective Groups in Organic
Chemistry, Third Edition", John Wiley & Sons, P. 494-572.
[0397] The amino protecting group used in this step is not
particularly limited. When Prt2 is a 2,4-dimethoxybenzyl group, for
example, the compound (10-2) can be obtained in this step under the
same conditions as those generally used (such as the conditions
described in a document such as Tetrahedron Vol. 47, No. 26, pp
4591-4602, 1991). In this step, when Prt2 is a 2,4-dimethoxybenzyl
group, one Boc group can be deprotected simultaneously with
deprotection of the 2,4-dimethoxybenzyl group. When Prt2 is a
2,4-dimethoxybenzyl group in this step, the solvent used in this
step is not particularly limited insofar as it does not inhibit the
reaction and allows the starting material to be dissolved therein
to a certain extent. For example, the first-step reaction solvent
may be methylene chloride or chloroform, and the second-step
reaction solvent may be methanol. The reaction temperature in this
step is usually 0.degree. C. to room temperature. The reaction time
in this step is not particularly limited and is usually 0.5 to 24
hours, and preferably 0.5 to 12 hours. When Prt2 is a
benzyloxycarbonyl group, the compound (10-2) can be obtained by
deprotecting the compound (10-1) by hydrogenation using
palladium-carbon as a catalyst in a solvent such as an alcohol, for
example.
10-2. Step 10-2:
[0398] This step is a step of synthesizing the compound (I-m) from
the compound (10-2) as a raw material using a method described in
the above preparation method ((Step 3-3) and (Step 3-4)).
10-3. Step 10-3:
[0399] This step is a step of synthesizing the compound (I-n) from
the compound (10-2) as a raw material using a method described in
Step 3-4 after reductive amination reaction with a reducing agent
such as borane or a boron hydride complex compound, for example.
Examples of the reductive amination reaction using a boron hydride
complex compound include a method described in a document such as
J. Org. Chem. 1996, 61, 3849. Examples of the boron hydride complex
compound that can be used include sodium borohydride, sodium
cyanoborohydride and sodium triacetoxyborohydride.
10-4. Step 10-4:
[0400] This step is a step of synthesizing the compound (I-o) from
the compound (10-2) as a raw material using a method described in
Step 3-4 after sulfonylating the amino group using a sulfonyl
chloride derivative known to a person skilled in the art.
10-5. Step 10-5:
[0401] This step is a step of synthesizing the compound (I-p) from
the compound (10-2) as a raw material using a method described in
Step 3-4 after coupling reaction with a compound (15-1) or (15-2).
Reaction such as coupling using a transition metal complex or the
like or nucleophilic aromatic substitution (SNAr reaction) is used
in the first step of this step.
[0402] The reaction in the first step of this step can be performed
under the same conditions as those described in Org. Lett. 2007,
Vol. 9, No. 5, 761-764 and Org. Lett. 2003, Vol. 5, No. 23,
4397-4400, for example. Specifically, the compound (10-2) can be
reacted with the compound (15-1) at room temperature to 50.degree.
C. using a solvent such as dichloromethane in the presence of
molecular sieve 4A and a catalyst such as copper (II) acetate, for
example.
[0403] The catalyst used in this reaction is not particularly
limited. Preferable examples of the catalyst include metal
catalysts such as copper (II) acetate, copper (II) sulfate, copper
(I) iodide and copper (I) chloride. The amount of the catalyst used
is not particularly limited and is usually about 0.1 to 0.5
equivalent with respect to the raw material. The solvent used in
this reaction is not particularly limited insofar as it does not
inhibit the reaction and allows the starting material to be
dissolved therein to a certain extent. Preferable examples of the
solvent include N,N-dimethylformamide, 1-methyl-2-pyrrolidone,
tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, acetonitrile,
propionitrile and dichloromethane. The reaction temperature is not
particularly limited and is usually ice-cold temperature to solvent
reflux temperature, and preferably room temperature to solvent
reflux temperature, for example. The reaction time is not
particularly limited and is usually 0.5 to 100 hours, and
preferably 1 to 72 hours.
[0404] A more preferable result such as an improved yield may be
achieved by carrying out this reaction in an oxygen atmosphere.
[0405] When the first step in this step is coupling using a
transition metal complex or the like as a catalyst, the reaction
can be performed using the compound (10-2) and the compound (15-2)
which is an aryl halide derivative, a heteroaryl halide derivative,
an aryloxy trifluoromethanesulfonate derivative or a heteroaryloxy
trifluoromethanesulfonate derivative under the same conditions as
those usually used (such as the conditions described in a document
such as Org. Lett. 2002, Vol. 4, No. 4, 581). The aryl halide
derivative, the heteroaryl halide derivative, the aryloxy
trifluoromethanesulfonate derivative or the heteroaryloxy
trifluoromethanesulfonate derivative used in this step can be a
commercially available product used as is, and can also be prepared
from a commercially available product by a method known to a person
skilled in the art. Examples of the transition metal complex used
in this step include dichlorobis(triphenylphosphine)palladium (II),
tetrakis(triphenylphosphine)palladium (0),
tris(dibenzylideneacetone)palladium (0) and a copper-diol ligand
complex. In this reaction, a phosphorus ligand (such as preferably
triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine,
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl or
1,1'-bis(diphenylphosphino)ferrocene) may be further added in order
to obtain favorable results (such as a reduced reaction
temperature, a reduced reaction time and an improved yield). When
the transition metal complex used is a palladium complex, the
reaction in this step is preferably performed in a nitrogen or
argon atmosphere. The solvent used in this step is not particularly
limited insofar as it does not inhibit the reaction and allows the
starting material to be dissolved therein to a certain extent. For
example, when the transition metal complex used is a palladium
complex, N,N-dimethylformamide, N-methyl-2-pyrrolidone,
1,4-dioxane, toluene, xylene or the like can be used. When the
transition metal complex used is a copper-diol complex, 2-propanol
or the like can be used. The reaction temperature in this step is
usually room temperature to solvent reflux temperature. The
reaction time in this step is not particularly limited and is
usually 0.5 to 72 hours, and preferably 0.5 to 24 hours.
[0406] When the first step in this step is nucleophilic aromatic
substitution (SNAr reaction), the reaction can be performed using
the compound (10-2) and the compound (15-2) which is an aryl halide
derivative, a heteroaryl halide derivative, an aryloxy
trifluoromethanesulfonate derivative or a heteroaryloxy
trifluoromethanesulfonate derivative in the presence of a base
under the same conditions as those usually used. The aryl halide
derivative, the heteroaryl halide derivative, the aryloxy
trifluoromethanesulfonate derivative or the heteroaryloxy
trifluoromethanesulfonate derivative used in this step can be a
commercially available product used as is, and can also be prepared
from a commercially available product by a method known to a person
skilled in the art. The nucleophilic aromatic substitution (SNAr
reaction) used in this step can be performed under the same
conditions as those generally used (such as the conditions
according to methods described in documents such as Org. Prep.
Proced. int. 39 (2007) 4, 399-402, Bioorg. Med. Chem. Lett. 15
(2005) 9, 2409-2413 and Bioorg. Med. Chem. Lett. 15 (2005) 3,
719-723). The solvent used in this step is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Examples of
the solvent that can be used include N,N-dimethylformamide,
N-methyl-2-pyrrolidone, dimethyl sulfoxide and acetonitrile. The
base used in this step is not particularly limited. Examples of the
base include potassium carbonate, sodium carbonate, sodium hydride
and tetrabutylammonium fluoride. Potassium carbonate, sodium
carbonate and tetrabutylammonium fluoride are preferably used. The
reaction temperature in this step is usually room temperature to
solvent reflux temperature. The reaction time in this step is not
particularly limited and is usually 0.5 to 24 hours, and preferably
0.5 to 12 hours.
10-6. Step 10-6:
[0407] This step is a step of synthesizing the compound (I-q) from
the compound (10-2) as a raw material using a method described in
Step 3-4 after N-alkylation reaction of the amino compound.
[0408] The first step in this reaction can be performed under the
same conditions as those usually used in N-alkylation reaction of
an amino compound (such as the conditions described in J. Med.
Chem. 2002, 45, 3794-3804 and J. Med. Chem. 2000, 43,
3809-3812).
[0409] The compound of the formula (I) according to the present
invention, wherein at least one of R.sup.1 and R.sup.2 is a
C.sub.1-6 alkyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.1-6 alkylcarbonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.6-14 arylcarbonyl group which may have 1 to 3
substituents selected from Substituent Group .alpha., a C.sub.1-6
alkylsulfonyl group which may have 1 to 3 substituents selected
from Substituent Group .alpha., a C.sub.6-14 arylsulfonyl group
which may have 1 to 3 substituents selected from Substituent Group
.alpha., a C.sub.3-8 hydrocarbon ring group which may have 1 to 3
substituents selected from Substituent Group .alpha. or a 5- to
10-membered heterocyclic group which may have 1 to 3 substituents
selected from Substituent Group .alpha., can be obtained by further
reacting the thus-obtained compounds (I-m) to (I-q) of the general
formula (I), wherein R.sup.1 and R.sup.2 are hydrogen atoms, with a
corresponding halide compound or the like such as a C.sub.1-6 alkyl
halide.
11. General Preparation Method 11:
##STR00022##
[0411] In the formula, Ring A, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
R.sup.7, Y and Z are as defined above.
[0412] General Preparation Method 11 is a method for preparing a
compound (1-4) which is a synthetic intermediate of the compound
(1) according to the present invention from a compound (1-3) as a
raw material through Step 11-1 to Step 11-2.
[0413] The compound (1-3) can be prepared from a commercially
available product by General Preparation Method 1, and can also be
prepared by a method described in Preparation Examples among
Examples.
11-1. Step 11-1:
[0414] This step is a step of obtaining a compound (11-1) by
alkaline hydrolysis of the compound (1-3).
[0415] The reaction can be performed under the same reaction
conditions as those described in J. Med. Chem., 33 (9), 2621-2629
(1990), for example.
[0416] Specifically, the compound (11-1) can be obtained by adding
a base such as sodium hydroxide to a solution of the compound
(1-3), stirring the mixture for several hours to one day, and then
treating the solution with an acid such as a citric acid solution,
for example.
[0417] The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Examples of
the solvent include methanol, ethanol, 2-propanol, tetrahydrofuran
and 1,4-dioxane. The base used is not particularly limited and is
preferably sodium hydroxide, potassium hydroxide or lithium
hydroxide, for example. The amount of the base used is one
equivalent to a large excess, and preferably 1 to 20 equivalents
with respect to the compound (1-3). The reaction time is not
particularly limited and is usually 1 to 24 hours, and preferably 1
to 6 hours. The reaction temperature is not particularly limited
and is usually room temperature to solvent reflux temperature.
11-2. Step 11-2:
[0418] This step is a step of obtaining the compound (1-4) by
subjecting the compound (11-1) to reduction reaction.
[0419] The compound (1-4) can be obtained by converting the
compound (11-1) to a mixed acid anhydride and then reacting the
mixed acid anhydride with sodium borohydride. The mixed acid
anhydride can be synthesized by a method known to a person skilled
in the art. The synthesis is performed by reacting the compound
(11-1) with a chloroformate such as ethyl chloroformate in the
presence of a base such as triethylamine, for example. One to two
equivalents of the chloroformate and the base are used with respect
to the compound (11-1). The reaction temperature is -30.degree. C.
to room temperature, and preferably -20.degree. C. to room
temperature.
[0420] The step of reacting the mixed acid anhydride with a
reducing agent such as sodium borohydride is performed by reaction
in a solvent such as tetrahydrofuran or 1,2-dimethoxyethane or in a
mixed solution of the solvent and water, for example. One
equivalent to a large excess of the reducing agent such as sodium
borohydride is used with respect to the mixed acid anhydride.
[0421] The reaction time is not particularly limited and is usually
0.5 to 48 hours, and preferably 0.5 to 24 hours. The reaction
temperature is not particularly limited and is usually -78.degree.
C. to solvent reflux temperature, and preferably -20.degree. C. to
room temperature. The solvent used in the reaction is not
particularly limited insofar as it does not inhibit the reaction
and allows the starting material to be dissolved therein to a
certain extent. Preferable examples of the solvent include
tetrahydrofuran and ether.
12. General Preparation Method 12:
##STR00023##
[0423] In the formula, Prt.sub.3 represents a primary hydroxyl
protecting group, R.sup.14 represents a C1-6 alkyl group, or two
R.sup.14 together may form a ring, R.sup.15 represents a C1-6 alkyl
group, and Y, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and LV are as
defined above.
[0424] General Preparation Method 12 is a method for preparing a
compound (12-4) which is a synthetic intermediate of the compound
(I) according to the present invention from compounds (12-1),
(12-5), (12-7) and (12-9) as raw materials through various steps of
Step 12-1 to Step 12-8.
[0425] Compounds (12-1), (12-2), (12-5), (12-7), (12-9) and (12-10)
can be commercially available products used directly, can also be
prepared from a commercially available product by a method known to
a person skilled in the art, and can further be prepared by a
method described in Preparation Examples among Examples.
12-1. Step 12-1:
[0426] This step is a step of obtaining a compound (12-3) by
reaction of the compound (12-1) with the compound (12-2).
[0427] This reaction can be performed under the same conditions as
those usually used in O-alkylation reaction of an alcohol compound
(such as the conditions described in Tetrahedron Lett. 46 (2005)
45, 7751-7755). In this reaction, the compound (12-3) can be
obtained by adding a base such as sodium hydride to a solution of
the compound (12-1) in THF to prepare an alkoxide, and then
reacting the alkoxide with the compound (12-2), for example. The
solvent used in the reaction is not particularly limited insofar as
it does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent. Examples of the
solvent include solvents such as THE DMF and dimethyl sulfoxide.
The reaction can be performed by causing 1 to 3 equivalents of an
appropriate base to act in the presence of such a solvent. Examples
of the base used include sodium hydride, potassium hydride and
t-butoxypotassium. The reaction time is not particularly limited
and is usually 0.5 to 72 hours, and preferably 0.5 to 12 hours. The
reaction temperature is usually -20.degree. C. to 100.degree.
C.
[0428] A more preferable result such as an improved yield may be
achieved by adding a salt such as tetrabutylammonium iodide in this
reaction.
12-2. Step 12-2:
[0429] This step is a step of obtaining an aldehyde compound (12-4)
by subjecting the alcohol compound (12-3) to oxidation reaction.
The aldehyde compound can be obtained from the alcohol compound by
a method known to a person skilled in the art.
[0430] Examples of the known oxidation method used in the reaction
include Swern oxidation, Corey-Kim oxidation, Moffatt oxidation,
PCC oxidation, PDC oxidation, Dess-Martin oxidation,
SO.sub.3-pyridine oxidation and TEMPO oxidation.
[0431] The solvent used in the reaction is not particularly limited
insofar as it does not inhibit the reaction and allows the starting
material to be dissolved therein to a certain extent. Examples of
the solvent include dimethyl sulfoxide, tetrahydrofuran, toluene,
dichloromethane and chloroform.
[0432] The reaction temperature is not particularly limited and is
usually -78.degree. C. to solvent reflux temperature, and
preferably -78.degree. C. to room temperature. The reaction time is
not particularly limited and is usually 0.5 to 48 hours, and
preferably 0.5 to 24 hours.
12-3. Step 12-3:
[0433] This step is a step of synthesizing a compound (12-6) from
the compound (12-5) as a raw material using a method described in
the above preparation method (Step 12-1).
12-4. Step 12-4:
[0434] This step is a step of obtaining the compound (12-3) by
deprotecting the hydroxyl protecting group of the compound (12-6).
The hydroxylprotecting group used in this step is not particularly
limited.
[0435] This reaction can be performed under the same conditions as
those generally used in deprotection of an alcohol protecting group
such as the conditions described in a document such as T. W. Green
and P. G. M. Wuts, "Protective Groups in Organic Chemistry, Third
Edition", John Wiley & Sons, P. 17-245.
12-5. Step 12-5:
[0436] This step is a step of synthesizing a compound (12-8) from
the compound (12-7) as a raw material using a method described in
the above preparation method (Step 12-1).
12-6. Step 12-6:
[0437] This step is a step of obtaining the compound (12-4) by
deprotecting the acetal group of the compound (12-8).
[0438] This reaction can be performed under the same conditions as
those generally used in deprotection of an aldehyde group such as
the conditions described in a document such as T. W. Green and P.
G. M. Wuts, "Protective Groups in Organic Chemistry, Third
Edition", John Wiley & Sons, P. 293-329.
12-7. Step 12-7:
[0439] This step is a step of obtaining a compound (12-11) by
reaction of the compound (12-9) with the compound (12-10).
[0440] This reaction can be performed under the same conditions as
those usually used in O-alkylation reaction of an alcohol compound
(such as the conditions described in J. Chem. Soc., Perkin Trans.
1, 1999, 3143-3155). In this reaction, the compound (12-11) can be
obtained by adding a base such as sodium hydride to a solution of
the compound (12-9) in THF to prepare an alkoxide, and then
reacting the alkoxide with the compound (12-10), for example. The
solvent used in the reaction is not particularly limited insofar as
it does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent. Examples of the
solvent include solvents such as THF, DMF and dimethyl sulfoxide.
The reaction can be performed by causing 1 to 3 equivalents of an
appropriate base to act in the presence of such a solvent. Examples
of the base used include sodium hydride, potassium hydride and
t-butoxypotassium. The reaction time is not particularly limited
and is usually 0.5 to 72 hours, and preferably 0.5 to 12 hours. The
reaction temperature is usually -20.degree. C. to 100.degree.
C.
[0441] A more preferable result such as an improved yield may be
achieved by adding a salt such as tetrabutylammonium iodide in this
reaction.
12-8. Step 12-8:
[0442] This step is a step of synthesizing the compound (12-3) from
the compound (12-11) as a raw material using a method described in
the above preparation method ((Step 1-3) or (Steps 11-1 and
2)).
13. General Preparation Method 13:
##STR00024##
[0444] In the formula, R.sup.14 represents a C.sub.1-6 alkyl group,
or two R.sup.14s together may form a ring such as 1,3-dioxolane or
1,3-dioxane, Prt.sub.2 represents a protecting group such as a
2,4-dimethoxybenzyl group, and R.sup.3, R.sup.4, R.sup.5, R.sup.6,
Y and LV are as defined above.
[0445] General Preparation Method 13 is a method for preparing a
compound (13-5) which is a synthetic intermediate of the compound
(I) according to the present invention from a compound (13-1) as a
raw material through Step 13-1 to Step 13-3.
[0446] Compounds (13-1) and (13-3) can be commercially available
products used directly, can also be prepared from a commercially
available product by a method known to a person skilled in the art,
and can further be prepared by a method described in Preparation
Examples among Examples.
13-1. Step 13-1:
[0447] This step is a step of obtaining a compound (13-2) by
protecting the amino group of the compound (13-1).
[0448] This reaction can be performed under the same conditions as
those generally used in protection of an amino group such as the
conditions described in a document such as T. W. Green and P. G. M.
Wuts, "Protective Groups in Organic Chemistry, Third Edition", John
Wiley & Sons, P. 494-572 and J. Med. Chem. 2007, 50,
5493-5508.
13-2. Step 13-2:
[0449] This step is a step of obtaining a compound (13-4) by
N-alkylation reaction of the compound (13-2) with the compound
(13-3).
[0450] This reaction can be performed under the same conditions as
those usually used in N-alkylation reaction of a compound (13-2)
(such as the conditions described in J. Med. Chem. 2007, 50,
5493-5508). In this reaction, the compound (13-4) can be obtained
by adding a base such as powdery sodium hydroxide to a solution of
the compound (13-2) in toluene, and then reacting the mixture with
the compound (13-3), for example. The solvent used in the reaction
is not particularly limited insofar as it does not inhibit the
reaction and allows the starting material to be dissolved therein
to a certain extent. Examples of the solvent include solvents such
as toluene, THF, DMF and dimethyl sulfoxide. The reaction can be
performed by causing 1 to 5 equivalents of an appropriate base to
act in such a solvent. Examples of the base used include sodium
hydroxide, potassium hydroxide, sodium hydride, potassium hydride
and t-butoxypotassium. The reaction time is not particularly
limited and is usually 0.5 to 72 hours, and preferably 0.5 to 24
hours. The reaction temperature is usually -20.degree. C. to
100.degree. C.
[0451] A more preferable result such as an improved yield may be
achieved by adding a salt such as tetrabutylammonium iodide in this
reaction.
13-3. Step 13-3:
[0452] This step is a step of obtaining the compound (13-5) by
deprotecting the acetal group of the compound (13-4).
[0453] This reaction can be performed under the same conditions as
those generally used in deprotection of an aldehyde group such as
the conditions described in a document such as T. W. Green and P.
G. M. Wuts, "Protective Groups in Organic Chemistry, Third
Edition", John Wiley & Sons, P. 293-329.
[0454] The compound of the formula (I) according to the present
invention obtained in this manner can be converted to a
pharmaceutically acceptable salt by a conventional method where
necessary. The salt can be prepared by a method in which methods
typically used in the field of organic synthetic chemistry and the
like are appropriately combined. Specific examples of the method
include neutralization titration of a free solution of the compound
of the present invention with an acid solution. The compound of the
formula (I) according to the present invention can be converted to
a solvate by subjecting the compound to solvate forming reaction
known per se where necessary.
[0455] The fused aminodihydrothiazine derivative or
pharmaceutically acceptable salt thereof, or solvate thereof
according to the present invention has an extremely excellent
A.beta. production inhibitory effect or BACE1 inhibitory effect and
is extremely useful as a therapeutic agent for a neurodegenerative
disease caused by A.beta. and typified by Alzheimer-type
dementia.
[0456] The fused aminodihydrothiazine derivative or
pharmaceutically acceptable salt thereof, or solvate thereof
according to the present invention can be formulated by a
conventional method. Preferable examples of the dosage form include
tablets, coated tablets such as film tablets and sugar-coated
tablets, fine granules, granules, powders, capsules, syrups,
troches, inhalants, suppositories, injections, ointments, eye
drops, nasal drops, ear drops, cataplasms and lotions.
[0457] These solid preparations such as tablets, capsules, granules
and powders can contain generally 0.01 to 100 wt %, and preferably
0.1 to 100 wt % of the fused aminodihydrothiazine derivative or
pharmaceutically acceptable salt thereof, or solvate thereof
according to the present invention as an active ingredient.
[0458] The active ingredient is formulated by blending ingredients
generally used as materials for a pharmaceutical preparation and
adding an excipient, a disintegrant, a binder, a lubricant, a
colorant and a corrective typically used, and adding a stabilizer,
an emulsifier, an absorbefacient, a surfactant, a pH adjuster, a
preservative and an antioxidant where necessary, for example, using
a conventional method. Examples of such ingredients include animal
and vegetable oils such as soybean oil, beef tallow and synthetic
glyceride; hydrocarbons such as liquid paraffin, squalane and solid
paraffin; ester oils such as octyldodecyl myristate and isopropyl
myristate; higher alcohols such as cetostearyl alcohol and behenyl
alcohol; a silicone resin; silicone oil; surfactants such as
polyoxyethylene fatty acid ester, sorbitan fatty acid ester,
glycerol fatty acid ester, polyoxyethylene sorbitan fatty acid
ester, polyoxyethylene hydrogenated castor oil and a
polyoxyethylene-polyoxypropylene block copolymer; water-soluble
polymers such as hydroxyethylcellulose, polyacrylic acid, a
carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone and
methylcellulose; lower alcohols such as ethanol and isopropanol;
polyhydric alcohols such as glycerol, propylene glycol, dipropylene
glycol and sorbitol; sugars such as glucose and sucrose; inorganic
powders such as silicic anhydride, magnesium aluminum silicate and
aluminum silicate; and purified water. Examples of the excipient
used include lactose, corn starch, saccharose, glucose, mannitol,
sorbitol, crystalline cellulose and silicon dioxide. Examples of
the binder used include polyvinyl alcohol, polyvinyl ether,
methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin,
shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose,
polyvinylpyrrolidone, a polypropylene glycol-polyoxyethylene block
copolymer and meglumine. Examples of the disintegrant used include
starch, agar, gelatin powder, crystalline cellulose, calcium
carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin and
carboxymethylcellulose calcium. Examples of the lubricant used
include magnesium stearate, talc, polyethylene glycol, silica and
hydrogenated vegetable oil. Examples of the colorant used include
those permitted to be added to pharmaceuticals. Examples of the
corrective used include cocoa powder, menthol, empasm, mentha oil,
borneol and cinnamon powder. Obviously, the ingredients are not
limited to the above additive ingredients.
[0459] For example, an oral preparation is prepared by adding the
fused aminodihydrothiazine derivative or pharmaceutically
acceptable salt thereof, or solvate thereof according to the
present invention as an active ingredient, an excipient and, where
necessary, a binder, a disintegrant, a lubricant, a colorant, a
corrective and the like, and then forming the mixture into powder,
fine granules, granules, tablets, coated tablets, capsules or the
like by a conventional method. Obviously, tablets or granules may
be appropriately coated, for example, sugar coated, where
necessary.
[0460] For example, a syrup or an injection preparation is prepared
by adding a pH adjuster, a solubilizer, an isotonizing agent and
the like, and a solubilizing agent, a stabilizer and the like where
necessary by a conventional method. The injection may be a
previously prepared solution, or may be powder itself or powder
containing a suitable additive, which is dissolved before use. The
injection can contain usually 0.01 to 100 wt %, and preferably 0.1
to 100 wt % of the active ingredient. Further, a liquid preparation
for oral administration such as a suspension or a syrup can contain
usually 0.01 to 100 wt %, and preferably 0.1 to 100 wt % of the
active ingredient.
[0461] For example, an external preparation can be prepared by any
conventional method without specific limitations. As a base
material, any of various materials usually used for a
pharmaceutical, a quasi drug, a cosmetic or the like can be used.
Examples of the base material include materials such as animal and
vegetable oils, mineral oils, ester oils, waxes, higher alcohols,
fatty acids, silicone oils, surfactants, phospholipids, alcohols,
polyhydric alcohols, water-soluble polymers, clay minerals and
purified water. A pH adjuster, an antioxidant, a chelator, a
preservative and fungicide, a colorant, a flavor or the like can be
added where necessary. Further, ingredients such as an ingredient
having a differentiation inducing effect, a blood flow enhancer, a
bactericide, an antiphlogistic, a cell activator, vitamin, amino
acid, a humectant and a keratolytic agent can be blended where
necessary.
[0462] The dose of the fused aminodihydrothiazine derivative or
pharmaceutically acceptable salt thereof, or solvate thereof
according to the present invention varies according to the degree
of symptoms, age, sex, body weight, mode of administration, type of
salt and specific type of disease, for example. Typically, the
active ingredient is orally administered to an adult at about 30
.mu.g to 10 g, preferably 100 .mu.g to 5 g, and more preferably 100
.mu.g to 1 g per day, or is administered to an adult by injection
at about 30 .mu.g to 1 g, preferably 100 .mu.g to 500 mg, and more
preferably 100 .mu.g to 300 mg per day, in one or several doses,
respectively.
[0463] The compound of the present invention can be converted to a
chemical probe for capturing a target protein in a bioactive
low-molecular compound. Specifically, the compound of the present
invention can be converted to an affinity chromatography probe, a
photoaffinity probe or the like by introducing a labeling group, a
linker or the like into a moiety differing from a structural moiety
essential for expression of activity of the compound by a technique
described in J. Mass Spectrum. Soc. Jpn. Vol. 51, No. 5, 2003, p.
492-498 or WO 2007/139149, for example.
[0464] Examples of the labeling group, the linker or the like used
for the chemical probe include groups shown in the following group
consisting of (1) to (5):
[0465] (1) protein labeling groups such as photoaffinity labeling
groups (such as a benzoyl group, a benzophenone group, an azido
group, a carbonylazido group, a diaziridine group, an enone group,
a diazo group and a nitro group) and chemical affinity groups (such
as a ketone group substituted at the .alpha.-carbon atom with a
halogen atom, a carbamoyl group, an ester group, an alkylthio
group, Michael acceptors such as .alpha.,.beta.-unsaturated ketones
and esters, and an oxirane group),
[0466] (2) cleavable linkers such as --S--S--, --O--Si--O--,
monosaccharides (such as a glucose group and a galactose group) and
disaccharides (such as lactose), and enzymatically cleavable
oligopeptide linkers,
[0467] (3) fishing tag groups such as biotin and
3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a-diaza-4-bora-s-indacen-3-yl)propion-
yl,
[0468] (4) detectable markers such as radioactive labeling groups
such as .sup.125I, .sup.32P, .sup.3H and .sup.14C; fluorescence
labeling groups such as fluorescein, rhodamine, dansyl,
umbelliferone, 7-nitrofurazanyl and
3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a-diaza-4-bora-s-indacen-3-yl)pro-
pionyl; chemiluminescent groups such as luciferin and luminol; and
heavy metal ions such as lanthanoid metal ions and radium ions,
and
[0469] (5) groups bound to solid-phase carriers such as glass
beads, glass beds, microtiter plates, agarose beads, agarose beds,
polystyrene beads, polystyrene beds, nylon beads and nylon
beds.
[0470] When a probe is prepared by introducing a labeling group or
the like selected from the group consisting of (1) to (5) above
into the compound of the present invention in accordance with a
method described in the above documents or the like, the probe can
be used as a chemical probe for identification of labeled proteins
useful for searching for novel drug targets, for example.
[0471] The present invention will be described more specifically
below with reference to Examples, Preparation Examples and Test
Example. However, the present invention is not limited thereto. The
abbreviations used in Examples are conventional abbreviations known
to a person skilled in the art. Some abbreviations are shown
below.
THF: Tetrahydrofuran
DMF: N,N-Dimethylformamide
[0472] TFA: Trifluoroacetic acid EDC.HC1:
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride pTLC:
Preparative thin-layer chromatography LC-MS: Liquid
chromatography-mass spectrometry PyBOP:
Benzotriazol-1-yloxytris(pyrrolidino)phosphonium
hexafluorophosphate
Pd2 DBA3: Tris(dibenzylideneacetone)dipalladium
Pd(t-Bu.sub.3P).sub.2: Bis(tri-t-butylphosphine)palladium
[0473] Chemical shifts in proton nuclear magnetic resonance spectra
are recorded in .delta. units (ppm) relative to tetramethylsilane
and coupling constants are recorded in Hertz (Hz). Patterns are
designated as s: singlet, d: doublet, t: triplet, q: quartet, br:
broad.
[0474] The preparative columns (2 cm.times.25 cm) used for
preparative separation of chiral compounds, CHIRALPAK.TM. AD-H,
CHIRALPAK.TM. IA, CHIRALPAK.TM. IB and CHIRALCEL.TM. OJ-H, were all
manufactured by Daicel Chemical Industries, Ltd.
[0475] The "room temperature" in the following Examples and
Preparation Examples typically refers to about 10.degree. C. to
about 35.degree. C. "%" indicates wt % unless otherwise
specified.
Preparation Example 1
Synthesis of tert-butyl
(-)-[(4aR*,8aS*)-8a-(5-amino-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00025## ##STR00026##
[0476] (1) Synthesis of 3-butenyloxyacetaldehyde oxime
[0477] Hydroxylamine sulfate (20.5 g), sodium acetate (12.8 g) and
water (20 ml) were added to a solution of 3-butenyloxyacetaldehyde
(17.8 g; J. Chem. Soc., Perkin Trans. 1, 1999, 3143-3155) in
ethanol (200 ml). The mixture was stirred at room temperature
overnight and then water was added. The excess of ethanol was
evaporated under reduced pressure and the resulting residue was
extracted with ethyl acetate. The organic layer was washed with
brine and dried over anhydrous magnesium sulfate. The solvent was
evaporated under reduced pressure and the residue was purified by
silica gel column chromatography to obtain the title compound (6.20
g).
[0478] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.36 (m,
2H), 3.53 (dt, J=6.6, 8.4 Hz, 2H), 4.10 (d, J=5.6 Hz, 1H), 4.35 (d,
J=4.0 Hz, 1E1), 5.10 (m, 213), 5.82 (m, 1H), 6.91 (t, J=3.6 Hz,
0.5H), 7.50 (t, J=5.6 Hz, 0.5H).
(2) Synthesis of 3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole
[0479] A 5% sodium hypochlorite solution (122 ml) was added
dropwise to a solution of 3-butenyloxyacetaldehyde oxime (5.30 g)
in dichloromethane (530 ml) under ice-cooling. After stirring at
the same temperature for two hours, sodium thiosulfate was added.
The aqueous layer was extracted with dichloromethane. The organic
layers were combined and dried over anhydrous magnesium sulfate.
The solvent was evaporated under reduced pressure and the residue
was purified by silica gel column chromatography to obtain the
title compound (4.15 g).
[0480] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.79 (ddd,
J=4.4, 12.4, 24.4 Hz, 1H), 2.17 (dd, J=6.4, 13.2 Hz, 1H), 3.40
(ddd, J=6.4, 11.2, 22.0 Hz, 1H), 3.50 (dt, J=2.0, 12.4 Hz, 1H),
3.80 (dd, I=8.0, 11.6 Hz, 1H), 4.06 (dd, 4.4, 12.8 Hz, 1H), 4.12
(dd, J=1.2, 13.6 Hz, 1H), 4.63 (dd, J=8.4, 10.4 Hz, 1H), 4.70 (d,
J=13.6 Hz, 1H).
(3) Synthesis of
(.+-.)-(3aR*,7aS*)-7a-(2-fluorophenyl)hexahydropyrano[3,4-c]isoxazole
[0481] 2-Bromofluorobenzene (1.85 g) was dissolved in toluene (30
ml), and tetrahydrofuran (10 ml) was added. n-Butyllithium (2.73 M;
3.68 ml) was added dropwise at -78.degree. C. 2-Fluorophenyllithium
was prepared by stirring at the same temperature for one hour. A
boron trifluoride-ether complex (1.26 ml) was added to a solution
of 3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole (630 mg) in
toluene (70 nil) at -78.degree. C. After stirring at the same
temperature for 10 minutes, 2-fluorophenyllithium prepared above
was added to the reaction mixture through a cannula. After stirring
at the same temperature for one hour, an ammonium chloride solution
was added. The reaction mixture was returned to room temperature,
and the aqueous layer was extracted with ethyl acetate. The organic
layer was washed with brine and dried over anhydrous magnesium
sulfate. The solvent was evaporated under reduced pressure and the
residue was purified by silica gel column chromatography to obtain
the title compound (1.26 g).
[0482] ESI-MS; m/z 224 [M.sup.++H].
[0483] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.83 (m,
2H), 3.09 (m, 1H), 3.64 (m, 1H), 3.68 (ddt, J=1.2, 3.2, 11.6 Hz,
1H), 3.73 (d, J=6.8 Hz, 1H), 3.78 (d, J=12.8 Hz, 1H) 4.04 (m, 1H),
4.10 (dd, J=1.6, 12.4 Hz, 1H), 6.32 (s, 1H), 7.04 (ddd, J=1.2, 8.0,
12.4 Hz, 1H), 7.16 (dt, J=1.6, 7.6 Hz, 1H), 7.28 (m, 1H), 7.93 (dt,
J=1.6, 8.4 Hz, 1H).
(4) Synthesis of
(.+-.)-[(3S*,4R*)-3-amino-3-(2-fluorophenyl)tetrahydropyran-4-yl]methanol
[0484] Zinc (11.6 g) was added to a solution of
(.+-.)-(3aR*,7aS*)-7a-(2-fluorophenyl)hexahydropyrano[3,4-c]isoxazole
(3.95 g) in acetic acid (78.4 ml), and the mixture was stirred at
room temperature overnight. The insoluble matter was removed by
filtration through celite, and the solvent was evaporated under
reduced pressure. An ice-cooled 0.5 N sodium hydroxide solution was
added to the residue. The aqueous layer was extracted with ethyl
acetate and a mixed solution of ethyl acetate and tetrahydrofuran.
The organic layers were combined and washed with brine and then
dried over anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure and the residue was purified by silica gel
column chromatography to obtain the title compound (3.45 g).
[0485] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.61 (m,
1H), 2.28 (m, 2H), 3.35 (dd, J=2.8, 11.6 Hz, 2H), 3.55 (dd, J=1.6,
11.6 Hz, 1H), 3.63 (m, 1H), 4.16 (m, 2H), 7.06 (ddd, J=1.2, 8.0,
12.8 Hz, 1H), 7.20 (dt, J=1.6, 8.0 Hz, 1H), 7.31 (m, 1H), 7.64 (dt,
J=2.0, 8.0 Hz, 1H).
(5) Synthesis of
(.+-.)-9H-fluoren-9-ylmethyl({[(3S*,4R*)-3-(2-fluorophenyl)-4-(hydroxymet-
hyl)tetrahydro-2H-pyran-3-yl]amino}carbonothioyl)carbamic acid
[0486] Fluorenylmethyloxycarbonyl isothiocyanate (938 mg) was added
to a solution of
(.+-.)-[(3S*,4R*)-3-amino-3-(2-fluorophenyl)tetrahydropyran-4-yl]methanol
(683 mg) in dichloromethane (20 ml). The mixture was stirred at
room temperature overnight, and then the solvent was evaporated
under reduced pressure at room temperature or lower. The residue
was purified by silica gel column chromatography to obtain the
title compound (1.57 g).
[0487] ESI-MS; m/z 529 [M.sup.++Na].
[0488] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.67 (m,
1H), 1.93 (m, 2H), 3.65 (m, 4H), 4.13 (m, 2H), 4.27 (t, J=6.4 Hz,
1H), 4.55 (m, 2H), 7.02 (dd, J=4.4, 12.8 Hz, 1H), 7.16 (t, J=8.0
Hz, 1H), 7.28 (m, 1H), 7.35 (t, J=7.2 Hz, 2H), 7.44 (t, J=7.2 Hz,
2H), 7.58 (d, J=7.6 Hz, 2H), 7.59 (m, 1H), 7.79 (d, J=8.0 Hz, 2H),
7.93 (s, 1H), 10.67 (s, 1H).
(6) Synthesis of
(.+-.)-(4R*,4aS*)-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thi-
a-1-azanaphthalen-2-ylamine
[0489] Concentrated hydrochloric acid (3.00 ml) was added to a
solution of
(.+-.)-9H-fluoren-9-ylmethyl({[(3S*,4R*)-3-(2-fluorophenyl)-4-(hydroxymet-
hyl)tetrahydro-2H-pyran-3-yl]amino}carbonothioyl)carbamic acid
(8.00 g) in methanol (200 ml), and the mixture was heated under
reflux for three hours. The reaction solution was cooled to room
temperature and the solvent was evaporated under reduced pressure.
Acetonitrile (200 ml) was added to the residue, and piperidine (40
ml) was added dropwise in an water bath. The mixture was stirred at
room temperature for two hours, and then the solvent was evaporated
under reduced pressure. The residue was purified by NH-silica gel
column chromatography to obtain a crude product. The resulting
crude product was further purified by silica gel column
chromatography to obtain the title compound (3.96 g).
[0490] ESI-MS; m/z 267 [M.sup.++H].
[0491] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.43 (d,
J=17.0 Hz, 1H), 2.12 (m, 1H), 2.61 (d, J=15.0 Hz, 1H), 2.91 (m,
1H), 2.96 (dd, J=4.5, 15.5 Hz, 1H), 3.68 (t, J=15.5 Hz, 1H), 3.76
(d, J=14.0 Hz, 1H), 4.09 (m, 2H), 4.58 (brs, 2H), 7.03 (dd, J=10.0,
16.0 Hz, 1H), 7.12 (t, J=10.0 Hz, 1H), 7.25 (m, 1H), 7.36 (dt,
J=2.5, 10.0 Hz, 1H).
(7) Synthesis of tert-butyl
(.+-.)-[(4R*,4aS*)-8a-(2-fluoro-5-nitrophenyl)-4,4a,5,6,8,8a-hexahydro-7--
oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0492]
(.+-.)-(4R*,4aS*)-8a-(2-Fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-
-3-thia-1-azanaphthalen-2-ylamine obtained in Preparation Example
1-(6) (3.96 g) was dissolved in concentrated sulfuric acid (20 ml),
and fuming nitric acid (specific gravity: 1.53; 731 .mu.l) was
added dropwise in an ice bath. After stirring at the same
temperature for two hours, the reaction mixture was carefully
poured into ice. The aqueous layer was neutralized with a sodium
bicarbonate solution and a sodium hydroxide solution, followed by
extraction with ethyl acetate. The organic layer was washed with
brine and dried over anhydrous magnesium sulfate. The drying agent
was removed by filtration and the filtrate was concentrated under
reduced pressure to obtain a residue. Tetrahydrofuran (200 ml) was
added to the residue and then triethylamine (10.3 ml) and
di-tert-butyl dicarbonate (4.85 g) were sequentially added,
followed by stirring at room temperature overnight. The solvent was
evaporated under reduced pressure and the residue was purified by
silica gel column chromatography to obtain the title compound (5.30
g).
[0493] ESI-MS; m/z 412 [M.sup.++H].
[0494] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.55 (m, 1H), 2.21 (m, 1H), 2.62 (dd, I=3.2, 12.8 Hz, 1H),
2.85 (dd, J=2.8, 13.2 Hz, 1H), 3.00 (m, 1H), 3.67 (dt, J=2.4, 12.0
Hz, 1H), 3.74 (d, J=11.2 Hz, 1H), 3.97 (dd, J=2.4, 11.6 Hz, 1H),
4.12 (m, 1H), 7.25 (m, 1H), 8.22 (m, 2H).
(8) Synthesis of tert-butyl
(.+-.)-[(4R*,4aS*)-8a-(5-amino-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7--
oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0495] A saturated ammonium chloride solution (13.2 ml) was added
to a solution of tert-butyl
(.+-.)-[(4R*,4aS*)-8a-(2-fluoro-5-nitrophenyl)-4,4a,5,6,8,8a-hexahydro-7--
oxa-3-thia-1-azanaphthalen-2-yl]carbamate obtained in Preparation
Example 1-(7) (5.30 g) in ethanol (132 ml). Iron powder (5.76 g)
was added to the reaction mixture, followed by heating under reflux
for 30 minutes. The reaction mixture was cooled to room
temperature, and the insoluble matter was filtered through celite.
The filtrate was evaporated under reduced pressure. The residue was
purified by NH-silica gel column chromatography to obtain the title
compound (4.56 g).
[0496] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.53 (m, 1H), 2.23 (m, 1H), 2.54 (dd, J=2.4, 12.4 Hz, 1H),
2.98 (dd, J=4.0, 12.4 Hz, 1H), 3.03 (m, 1H), 3.66 (m, 2H), 4.07
(dd, I=1.6, 12.4 Hz, 1H), 4.12 (m, 1H), 6.57 (m, 211), 6.86 (dd,
J=8.8, 12.4 Hz, 1H).
(9) Synthesis of tert-butyl
(-)-[(4R*,4aS*)-8a-(5-amino-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-
-3-thia-1-azanaphthalen-2-yl]carbamate
[0497] tert-Butyl
(.+-.)-[(4R*,4aS*)-8a-(5-amino-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7--
oxa-3-thia-1-azanaphthalen-2-yl]carbamate obtained in Preparation
Example 1-(8) (100 mg) was purified by CHIRALPAK.TM. AD-H (mobile
phase: hexane:ethanol=8.5:1.5, flow rate: 20 ml/min), and the
fraction with a retention time of 20.9 to 27.8 minutes was
collected to obtain the title compound. The same operation was
repeated to obtain the title compound (405 mg; >99% ee) from the
raw material (1.00 g).
Preparation Example 2
Synthesis of 5-fluoromethoxypyrazine-2-carboxylic acid
##STR00027##
[0498] (1) Synthesis of methyl
5-fluoromethoxypyrazine-2-carboxylate
[0499] Fluoromethyl toluene-4-sulfonate (Journal of Labelled
Compounds & Radiopharmaceuticals, 46 (6), 555-566; 2003) (344
mg) and cesium carbonate (824 mg) were added to a solution of
methyl 5-hydroxypyrazine-2-carboxylate (130 mg) in
N,N-dimethylformamide (2.0 mL). The reaction solution was stirred
at 70.degree. C. for five hours and 30 minutes and then cooled to
room temperature. Water was added to the reaction solution,
followed by extraction with ethyl acetate. The organic layer was
concentrated under reduced pressure. The residue was purified by
NH-silica gel column chromatography to obtain the title compound
(18.0 mg).
[0500] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 4.03 (s,
3H), 6.14 (d, J=51.2 Hz, 2H), 8.42 (d, J=1.2 Hz, 1H), 8.94 (d,
J=1.2 Hz, 1H).
(2) Synthesis of 5-fluoromethoxypyrazine-2-carboxylic acid
[0501] Potassium trimethylsilanolate (18.6 mg) was added to a
solution of methyl 5-fluoromethoxypyrazine-2-carboxylate obtained
in Preparation Example 15-(1) (18.0 mg) in tetrahydrofuran (1.0
mL). The reaction solution was stirred at room temperature for one
hour. Water and ethyl acetate were added to the reaction solution,
and the organic layer was separated. The aqueous layer was made
acidic with 1M hydrochloric acid, followed by extraction with ethyl
acetate. The organic layer was dried over anhydrous magnesium
sulfate. The drying agent was removed by filtration and the
filtrate was concentrated under reduced pressure to obtain a crude
product of the title compound (10.2 mg). The compound was used for
the next reaction without further purification.
[0502] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 6.16 (d,
J=50.8 Hz, 2H), 8.34 (d, J=1.4 Hz, 1H), 9.05 (d, J=1.4 Hz, 1H).
Preparation Example 3
Synthesis of 5-cyanopyridine-2-carboxylic acid
##STR00028##
[0503] (1) Synthesis of methyl 5-cyanopyridine-2-carboxylate
[0504] A mixture of methyl 5-bromopyridine-2-carboxylate (2.8 g)
and copper cyanide (3.6 g) in NMP (30 ml) was heated with stirring
at 170.degree. C. for 1.5 hours. Water was added to the reaction
solution at room temperature, and the insoluble matter was removed
by filtration. The filtrate was extracted with ethyl acetate. The
extract was washed with brine and then dried over anhydrous
magnesium sulfate. The drying agent was filtered off and the
filtrate was concentrated under reduced pressure. The resulting
crude product was purified by silica gel column chromatography to
obtain the title compound (920 mg).
[0505] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 4.06 (s,
3H), 8.16 (dd, J=2.0, 8.0 Hz, 1H), 8.27 (d, J=8.0 Hz, 1H), 9.01 (d,
J=2.0 Hz, 1H).
(2) Synthesis of 5-cyanopyridine-2-carboxylic acid
[0506] A solution of the compound of Preparation Example 3-(1) (920
mg) and a 5 N sodium hydroxide solution (2.26 ml) in ethanol (30
ml) was stirred at room temperature for 10 minutes. 5 N
hydrochloric acid (5.2 ml) was added to the reaction solution at
room temperature, followed by extraction with ethyl acetate. The
extract was dried over anhydrous magnesium sulfate. The drying
agent was removed by filtration and the filtrate was concentrated
under reduced pressure to obtain the title compound (800 mg).
[0507] .sup.1H-NMR (400 MHz, DMSOd.sub.6) .delta. (ppm): 8.18 (d,
J=8.0 Hz, 1H), 8.51 (dd, J=2.0, 8.0 Hz, 1H), 9.12-9.18 (m, 1H).
Preparation Example 4
Synthesis of 5-difluoromethoxypyrazine-2-carboxylic acid
##STR00029##
[0508] (1) Synthesis of methyl
5-difluoromethoxypyrazine-2-carbonxylate
[0509] Potassium carbonate (8.82 g) and sodium
chlorodifluoroacetate (6.53 g) were added to a solution of methyl
5-hydroxypyrazine-2-carboxylate (3.3 g) in DMF (42.8 ml), The
reaction solution was stirred at 100.degree. C. for 30 minutes, and
then saturated aqueous ammonium chloride was added, followed by
extraction with ethyl acetate. The organic layer was washed with a
saturated sodium bicarbonate solution and brine and then dried over
magnesium sulfate. The drying agent was removed by filtration and
then the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography to obtain the
title compound (928 mg).
[0510] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 4.04 (s,
3H), 7.49 (t, J=71.2 Hz, 1H), 8.47 (d, J=0.8 Hz, 1H), 8.92 (d,
J=0.8 Hz, 1H).
(2) Synthesis of 5-difluoromethoxypyrazine-2-carboxylic acid
[0511] Water (1.54 ml) and a 5 N sodium hydroxide solution (492 ml)
were added to a solution of the compound obtained in Preparation
Example 4-(1) (250 mg) in THF (4.60 ml). The reaction solution was
stirred at room temperature for five minutes and then a 2 N
hydrochloric acid solution was added, followed by extraction with
ethyl acetate. The organic layer was washed with brine and then
dried over magnesium sulfate. The drying agent was removed by
filtration and then the solvent was concentrated under reduced
pressure to obtain the title compound (200 mg).
[0512] .sup.1H-NMR. (400 MHz, CDCl.sub.3) .delta. (ppm): 7.51 (t,
J=71.2 Hz, 1H), 8.39 (d, J=1.2 Hz, 1H), 9.04 (d, J=1.2 Hz, 1H).
Preparation Example 5
Synthesis of tert-butyl
(-)-[(4aR*,8aS*)-8a-(5-amino-2-trifluoromethoxyphenyl)-4,4a,5,6,8,8a-hexa-
hydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00030## ##STR00031##
[0514] In Preparation Example 5, the compound obtained in
Preparation Example 1-(2) was used as a starting material.
[0515] In Preparation Example 5-(1) and (2), synthesis was
performed according to Preparation Example 1-(3) and (4).
(3) Synthesis of
1-benzoyl-3-[(3S*,4R*)-4-hydroxymethyl-3-(2-trifluoromethoxyphenyl)tetrah-
ydropyran-3-yl]thiourea
[0516] Benzoyl isothiocyanate (642 .mu.l) was added to a solution
of the compound obtained in the previous step (1.26 g) in
dichloromethane (32.3 ml) at room temperature, and the mixture was
stirred for two hours and 30 minutes. The reaction solution was
concentrated under reduced pressure and the residue was purified by
silica gel column chromatography to obtain the title compound (1.67
g).
[0517] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.29-1.34
(m, 1H), 1.65-1.80 (m, 2H), 3.57-3.91 (m, 4H), 4.14-4.27 (m, 2H),
7.20-7.30 (m, 3H), 7.32-7.38 (m, 1H), 7.50-7.57 (m, 2H), 7.61-7.67
(m, 1H), 7.86-7.92 (m, 1H), 8.92 (brs, 1H).
(4) Synthesis of
N-[(4aR*,8aS*)-8a-(2-trifluoromethoxyphenyl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-yl]benzamide
[0518] Concentrated hydrochloric acid (635 .mu.l) was added to a
solution of the compound obtained in the previous step (1.67 g) in
methanol (25 ml), and the mixture was heated under reflux at
90.degree. C. for two hours and 10 minutes. The reaction solution
was returned to room temperature and concentrated under reduced
pressure. A saturated sodium bicarbonate solution was added to the
residue, followed by extraction with ethyl acetate. The organic
layer was dried over anhydrous magnesium sulfate. The drying agent
was filtered off and the filtrate was concentrated under reduced
pressure to obtain the title compound (1.65 g).
[0519] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53-1.68
(m, 1H), 2.22-2.35 (m, 1H), 2.62-2.71 (m, 1H), 2.91-2.99 (m, 1H),
3.19-3.29 (m, 1H), 3.62-3.78 (m, 2H), 4.07-4.21 (m, 2H), 7.28-7.36
(m, 2H), 7.38-7.47 (m, 3H), 7.48-7.57 (m, 2H), 8.21-8.27 (m,
2H).
(5) Synthesis of
(4aR*,8aS*)-8a-(2-trifluoromethoxyphenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-
-thia-1-azanaphthalen-2-ylamine
[0520] DBU (1.28 ml) was added to a solution of the compound
obtained in the previous step (1.65 g) in methanol (100 ml), and
the mixture was heated under reflux at 80.degree. C. for eight
hours and 10 minutes. The reaction solution was returned to room
temperature and concentrated under reduced pressure. The residue
was purified by NH-silica gel column chromatography to obtain the
title compound (870 mg).
[0521] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.40-1.50
(m, 1H), 2.02-2.16 (m, 1H), 2.61-2.70 (m, 1H), 2.87-3.01 (m, 2H),
3.60-3.75 (m, 2H), 4.03-4.15 (m, 2H), 4.51 (brs, 2H), 7.21-7.34 (m,
3H), 7.48-7.52 (m, 1H).
[0522] In Preparation Example 5-(6), (7) and (8), synthesis was
performed according to Preparation Example 1-(7) and (8).
(9) Synthesis of ten-butyl
(-)-[(4aR*,8aS*)-8a-(5-amino-2-trifluoromethoxyphenyl)-4,4a,5,6,8,8a-hexa-
hydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0523] The compound obtained in the previous step (12 mg) was
purified by CHIRALPAK.TM. AD-H (mobile phase: hexane:ethanol=8:2,
flow rate: 10 ml/min), and the fraction with a retention time of 15
to 20 minutes was collected to obtain the title compound. This
operation was repeated to obtain the title compound (112 mg;
>99% ee) from 240 mg of the racemate.
[0524] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.54-1.60 (m, 1H), 2.13-2.27 (m, 1H), 2.51-2.60 (m, 1H),
2.90-2.96 (m, 1H), 3.03-3.12 (m, 1H), 3.58-3.67 (m, 2H), 3.80 (brs,
2H), 4.05-4.17 (m, 2H), 6.60 (dd, J=8.8, 2.8 Hz, 1H), 6.67 (d,
J=2.8 Hz, 1H), 7.06-7.11 (m, 1H).
Preparation Example 6
Synthesis of ten-butyl
(-)-[(4aR*,6S*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-methyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00032## ##STR00033##
[0525] (1) Synthesis of 4-(2,2-diethoxy-ethoxy)-1-pentene
[0526] 60% sodium hydride (916 mg) was added to a solution of
4-penten-2-ol (1.8 ml) in dimethylformamide (40 ml) at 0.degree.
C., followed by stirring for 30 minutes. After heating to room
temperature, bromoacetaldehyde diethyl acetal (2.99 ml) was added
to the reaction solution and the mixture was heated for five hours.
Ice was added to the reaction solution, followed by extraction with
diethyl ether. The organic layer was concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (1.95 g).
[0527] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.15 (d,
J=5.6 Hz, 3H), 1.22 (t, J=6.8 Hz, 6H), 2.13-2.23 (m, 1H), 2.28-2.38
(m, 1H), 3.43-3.64 (m, 5H), 3.66-3.76 (m, 2H), 4.59 (t, J=5.2 Hz,
1H), 5.01-5.10 (m, 2H), 5.76-5.88 (m, 1H).
(2) Synthesis of (1-methyl-3-butenyloxy)acetaldehyde oxime
[0528] The compound obtained in the previous step (5.81 g) was
dissolved in a mixed solution of formic acid (30 ml) and water (10
ml) at room temperature, followed by stirring for six hours.
Hydroxylamine sulfate (4.42 g) and sodium acetate (4.41 g) were
added to the reaction solution, and the mixture was stirred at room
temperature for 14 hours. Saturated aqueous sodium chloride was
added to the reaction solution, followed by extraction with ethyl
acetate. The organic layer was washed with brine, and then the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain the title
compound (2.95 g).
[0529] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.17 (d,
J=6.0 Hz, 3H), 2.15-2.25 (m, 1H), 2.28-2.39 (m, 1H), 3.47-3.60 (m,
1H), 4.05-4.18 (m, 1H), 4.30-4.44 (m, 1H), 5.04-5.14 (m, 2H),
5.74-5.88 (m, 1H), 7.45-7.52 (m, 2H).
[0530] In Preparation Example 6-(3), (4) and (5), synthesis was
performed according to Preparation Example 1-(2), (3) and (4).
[0531] In Preparation Example 6-(6), (7) and (8), synthesis was
performed according to Preparation Example 5-(3), (4) and (5).
[0532] In Preparation Example 6-(9), (10) and (11), synthesis was
performed according to Preparation Example 1-(7) and (8).
(12) Synthesis of tert-butyl
(-)-[(4aR*,6S*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-methyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0533] The compound obtained in the previous step (27 mg) was
purified by CHIRALPAK.TM. AD-H (mobile phase:hexane:ethanol=7:3,
flow rate: 10 ml/min), and the fraction with a retention time of 16
to 19 minutes was collected to obtain the title compound. This
operation was repeated to obtain the title compound (228 mg;
>99% ee) from 540 mg of the racemate.
[0534] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.28 (d,
J=6.0 Hz, 3H), 1.53 (s, 9H), 1.55-1.61 (m, 1H), 1.80-1.93 (m, 1H),
2.47-2.55 (m, 1H), 2.93-3.01 (m, 1H), 3.02-3.11 (m, 1H), 3.59-3.82
(m, 4H), 4.11-4.18 (m, 1H), 6.54-6.62 (m, 2H), 6.81-6.89 (m,
1H).
Preparation Example 7
Synthesis of tert-butyl
(-)-[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-methoxymethyl-4.4a,5,6-
,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00034## ##STR00035##
[0535] (1) Synthesis of (R)-1-methoxy-4-penten-2-ol
[0536] Copper iodide (630 mg) was suspended in tetrahydrofuran (200
ml), and a 1.38 M solution of vinylmagnesium chloride in
tetrahydrofuran (32.3 ml) was added at -78.degree. C., followed by
stirring for 10 minutes. (R)-(-)Glycidyl methyl ether (2 ml) was
added to the reaction solution at the same temperature, and the
mixture was stirred at -78.degree. C. for two hours and 25 minutes
and at 0.degree. C. for 25 minutes. A saturated ammonium chloride
solution was added to the reaction solution. The mixture was
sequentially extracted with a mixed solution of hexane and ethyl
acetate (1:1), ethyl acetate and diethyl ether. The organic layer
was dried over anhydrous magnesium sulfate. The drying agent was
filtered off and the filtrate was concentrated under reduced
pressure to obtain the title compound (2.60 g).
[0537] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.21-2.30
(m, 3H), 3.29 (dd, J=9.6, 7.7 Hz, 1H), 3.39 (s, 3H), 3.43 (dd,
J=9.6, 3.1 Hz, 1H), 3.81-3.90 (m, 1H), 5.09-5.18 (m, 2H), 5.78-5.91
(m, 1H).
[0538] In Preparation Example 7-(2) and (3), synthesis was
performed according to Preparation Example 6-(1) and (2).
[0539] In Preparation Example 7-(4), (5) and (6), synthesis was
performed according to Preparation Example 1-(2), (3) and (4).
[0540] In Preparation Example 7-(7), (8) and (9), synthesis was
performed according to Preparation Example 5-(3), (4) and (5).
[0541] In Preparation Example 7-(10), (11) and (12), synthesis was
performed according to Preparation Example 1-(7) and (8).
(12) Synthesis of tert-butyl
(-)[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-methoxymethyl-4.4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0542] .sup.1H-NMR. (400 MHz, CDCl.sub.3) .delta. (ppm): 1.48-1.57
(m, 1H), 1.53 (s, 9H), 1.82-1.96 (m, 1H), 2.49-2.56 (m, 1H),
2.96-3.03 (m, 1H), 3.04-3.13 (m, 1H), 3.37-3.43 (m, 1H), 3.41 (s,
3H), 3.50-3.58 (m, 1H), 3.65 (brs, 2H), 3.70-3.77 (m, 1H),
3.82-3.91 (m, 1H) 4.13-4.20 (m, 1H), 6.54-6.61 (m, 2H), 6.82-6.89
(m, 1H).
Preparation Example 8
Synthesis of tert-butyl
[(4aS,5S,8aS)-8a-(5-amino-2-fluorophenyl)-5-fluoro-4,4a,5,6,8
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00036## ##STR00037## ##STR00038##
[0543] (1) Synthesis of
(R)-1-(tert-butyldimethylsilanyloxy)-3-buten-2-ol
[0544] n-Butyllithium (58.2 mL, 2.64 M solution in hexane) was
added dropwise to a suspension of trimethylsulfonium iodide (32.4
g) in tetrahydrofuran (400 mL) in a nitrogen atmosphere at
-20.degree. C. The reaction solution was stirred at the same
temperature for 30 minutes. tert-Butyldimethylsilyl
(R)-(-)-glycidyl ether (10 g) was added dropwise to the reaction
solution at the same temperature. The reaction solution was stirred
for three hours with gradual heating to room temperature. Aqueous
ammonium chloride and ethyl acetate were added to the reaction
solution, and the organic layer was separated. The organic layer
was washed with saturated aqueous sodium chloride twice. The
organic layer was dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound (9.6
g).
[0545] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.08 (s,
6H), 0.91 (s, 9H), 2.56 (d, J=3.6 Hz, 1H), 3.45 (dd, J=7.6, 10.0
Hz, 1H), 3.66 (dd, J=4.0, 10.0 Hz, 1H), 4.14-4.20 (m, 1H), 5.19
(ddd, J=1.6, 1.6, 10.8 Hz, 1H), 5.35 (ddd, J=1.6, 1.6, 17.6 Hz,
1H), 5.81 (ddd, J=6.0, 10.4, 17.6 Hz, 1H).
(2) Synthesis of
tert-butyl-((R)-2-methoxymethoxy-3-butenyloxy)dimethylsilane
[0546] Chloromethyl methyl ether (9.03 mL) was added dropwise to a
solution of the compound obtained in Preparation Example 8-(1) (9.6
g) and N,N-diisopropylethylamine (41.4 mL) in dichloromethane (200
mL) under ice-cooling. The reaction solution was heated to room
temperature and stirred for 14 hours. Saturated aqueous sodium
chloride was added to the reaction solution, and the organic layer
was separated. The organic layer was dried over anhydrous magnesium
sulfate and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain the title
compound (11.3 g).
[0547] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.07 (s,
6H), 0.89 (s, 9H), 3.39 (s, 3H), 3.60-3.70 (m, 2H), 4.09-4.14 (m,
1H), 4.64-4.72 (m, 2H), 5.27 (ddd, J=1.2, 2.0, 10.8 Hz, 1H), 5.30
(ddd, J=1.2, 2.0, 17.2 Hz, 1H), 5.74 (ddd, I=6.8, 10.4, 17.6 Hz,
1H).
(3) Synthesis of (R)-2-methoxymethoxy-3-buten-1-ol
[0548] Tetrabutylammonium fluoride (55 mL, 1 M solution in
tetrahydrofuran) was added dropwise to a solution of the compound
obtained in Preparation Example 8-(2) (11.3 g) in tetrahydrofuran
(220 mL), and the mixture was stirred at room temperature for two
hours. Saturated aqueous sodium chloride and ethyl acetate were
added to the reaction solution, and the organic layer was
separated. Ethyl acetate was added to the aqueous layer, and the
organic layer was separated again. The combined organic layers were
dried over anhydrous magnesium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (4.15 g).
[0549] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.37-2.41
(m, 1H), 3.42 (s, 3H), 3.58-3.64 (m, 2H), 4.11-4.15 (m, 1H),
4.65-4.4.75 (m, 2H), 5.27-5.34 (m, 2H), 5.75 (ddd, J=6.4, 10.0,
17.2 Hz, 1H).
(4) Synthesis of ethyl
((R)-2-methoxymethoxy-3-butenyloxy)acetate
[0550] Sodium hydride (2.5 g) was added to a solution of the
compound obtained in Preparation Example 8-(3) (4.15 g) in
1-methyl-2-pyrrolidinone (60 mL) under ice-cooling. The reaction
solution was stirred at the same temperature for 30 minutes. Ethyl
bromoacetate (10.4 mL) was added dropwise to the reaction solution.
The reaction solution was heated to room temperature and stirred at
the same temperature for five hours. Saturated aqueous ammonium
chloride and ethyl acetate were added to the reaction solution, and
the organic layer was separated. The organic layer was washed with
aqueous sodium chloride and then dried over anhydrous magnesium
sulfate. The organic layer was concentrated under reduced pressure.
The residue was purified by silica gel column chromatography to
obtain the title compound (4.77 g).
[0551] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.24-1.31
(m, 3H), 3.39 (s, 3H), 3.59-3.69 (m, 2H), 4.10-4.22 (m, 4H),
4.23-4.32 (m, 1H), 4.64-4.74 (m, 2H), 5.28 (ddd, J=1.2, 1.2, 9.6
Hz, 1H), 5.35 (ddd, J=1.6, 1.6, 16.8 Hz, 1H), 5.78 (ddd, J=6.8,
10.4, 17.2 Hz, 1H).
(5) Synthesis of 2-((R)-2-methoxymethoxy-3-butenyloxy)ethanol
[0552] Lithium aluminum hydride (826 mg) was added to a solution of
the compound obtained in Preparation Example 8-(4) (4.77 g) in
tetrahydrofuran (100 mL) in a nitrogen atmosphere. The mixture was
stirred at the same temperature for one hour. Methanol was added
dropwise to the reaction solution, and then water was added
dropwise. The insoluble matter in the reaction mixture was
separated by filtration through celite and washed with ethyl
acetate. Saturated aqueous sodium chloride was added to the
filtrate, and the organic layer was separated. The organic layer
was dried over anhydrous magnesium sulfate and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (2.13 g).
[0553] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.38 (t,
J=6.0 Hz, 1H), 3.40 (s, 3H), 3.56-3.67 (m, 4H), 3.72-3.76 (m, 2H),
4.26 (q, J=6.0 Hz, 1H), 4.63-4.74 (m, 2FI), 5.26-5.36 (m, 2H), 5.76
(ddd, J=6.8, 10.4, 15.6 Hz, 1H).
(6) Synthesis of ((R)-2-methoxymethoxy-3-butenyloxy)acetaldehyde
oxime
[0554] A solution of dimethyl sulfoxide (605 .mu.L) in
dichloromethane (1 mL) was added dropwise to a solution of oxalyl
chloride (633 .mu.L) in dichloromethane (25 mL) in a nitrogen
atmosphere at -78.degree. C. The reaction solution was stirred at
the same temperature for 10 minutes. A solution of the compound
obtained in Preparation Example 8-(5) (1 g) in dichloromethane (4
mL) was added dropwise to the reaction solution at the same
temperature. The reaction solution was stirred at the same
temperature for 45 minutes. Triethylamine (3.81 mL) was added to
the reaction solution, followed by heating to room temperature. The
reaction solution was stirred at room temperature for one hour.
Saturated aqueous ammonium chloride and ethyl acetate were added to
the reaction solution, and the organic layer was separated. The
organic layer was washed with saturated aqueous sodium chloride and
dried over anhydrous magnesium sulfate. The organic layer was
concentrated under reduced pressure, and ethanol (20 mL) and water
(5 mL) were added to the residue. Sodium acetate (1.12 g) and
hydroxylamine sulfate (1.12 g) were added to the reaction solution,
and the mixture was stirred at room temperature for 13 hours. Ethyl
acetate and saturated aqueous sodium chloride were added to the
reaction solution, and the organic layer was separated. The organic
layer was dried over anhydrous magnesium sulfate. The organic layer
was concentrated under reduced pressure and the residue was
purified by silica gel column chromatography to obtain the title
compound (900 mg).
[0555] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 3.39 (s,
1.5H), 3.40 (s, 1.5H), 3.54-3.58 (m, 2H), 4.14-4.16 (m, 1H),
4.22-4.29 (m, 1H), 4.40-4.41 (m, 1H), 4.62-4.74 (m, 2H), 5.26-5.37
(m, 2H), 5.71-5.81 (m, 1H), 6.93 (t, I=4.0 Hz, 0.5H), 7.51 (t,
J=5.6 Hz, 0.5H).
(7) to (9) Synthesis of
[(3S,4R,5R)-3-amino-3-(2-fluorophenyl)-5-methoxymethoxytetrahydropyran-4--
yl]methanol
[0556] The title compound (1 g) was obtained from the compound
obtained in Preparation Example 8-(6) (900 mg) according to
Preparation Example 1.
[0557] ESI-MS; m/z 286 [M.sup.++H].
[0558] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.15-2.19
(m, 1H), 3.30-3.42 (m, 6H), 3.75 (dd, J=3.2, 12.0 Hz, 1H),
4.13-4.20 (m, 2H), 4.30 (dd, J=5.6, 10.8 Hz, 1H), 4.69-4.82 (m,
2H), 7.07 (ddd, J=1.6, 8.4, 12.8 Hz, 1H), 7.20-7.24 (m, 1H),
7.29-7.35 (m, 1H), 7.60-7.65 (m, 1H).
(10) Synthesis of
1-benzoyl-3-[(3S,4R,5R)-3-(2-fluorophenyl)-4-hydroxymethyl-5-methoxymetho-
xytetrahydropyran-3-yl]thiourea
[0559] Benzoyl isocyanate (667 mg) was added to a solution of the
compound obtained in Preparation Example 8-(9) (1 g) in
dichloromethane (25 mL), and the mixture was stirred at room
temperature for 15 hours. The reaction solution was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography to obtain the title compound (1.45 g).
[0560] ESI-MS; m/z 471 [M.sup.++Na].
[0561] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.30-2.50
(brm, 1H), 3.0-3.2 (brm, 1H), 3.38-3.48 (m, 1H), 3.45 (s, 3H),
3.60-4.05 (m, 3H), 4.20-4.34 (m, 2H), 4.77 (s, 2H), 7.03-7.09 (m,
1H), 7.15-7.20 (m, 1H), 7.28-7.35 (m, 1H), 7.49-7.54 (m, 3H),
7.60-7.65 (m, 1H), 7.86-7.90 (m, 2H), 8.92 (s, 1H), 11.7 (s,
1H).
(11) Synthesis of
N-[(4aS,5R,8aR)-8a-(2-fluorophenyl)-5-hydroxy-4,4a,5,6,8.8a-hexahydro-7-o-
xa-3-thia-1-azanaphthalen-2-yl]benzamide
[0562] Concentrated hydrochloric acid (2 mL) was added to a
solution of the compound obtained in Preparation Example 8-(10)
(1.45 g) in methanol (20 mL), and the mixture was heated under
reflux for one hour. The reaction solution was returned to room
temperature and concentrated under reduced pressure. Ethyl acetate
and aqueous sodium bicarbonate were added to the residue, and the
organic layer was separated. The organic layer was washed with
saturated aqueous sodium chloride and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (895 mg).
[0563] ESI-MS; m/z 387 [M.sup.++H].
[0564] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm); 2.82 (dd,
J=4.0, 12.8 Hz, 1H), 2.97-3.02 (m, 1H), 3.26-3.34 (m, 2H), 3.72 (d,
J=12.0 Hz, 1H), 3.87 (dd, J=4.8, 6.8 Hz, 1H), 4.09-4.16 (m, 2H),
7.08-7.14 (m, 1H), 7.17-7.21 (m, 1H), 7.32-7.39 (m, 2H), 7.42-7.46
(m, 2H), 7.49-7.54 (m, 1H), 8.15-8.18 (m, 2H).
(12) Synthesis of
N-[(4aS,5S,8aS)-5-fluoro-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-yl]benzamide
[0565] [Bis(2-methoxyethyl)amino]sulfur trifluoride (892 .mu.l) was
added dropwise to a solution of the compound obtained in
Preparation Example 8-(11) (895 mg) in dichloromethane (25 mL)
under ice-cooling. The reaction solution was stirred at the same
temperature for two hours. Aqueous sodium bicarbonate and
chloroform were added to the reaction solution, and the organic
layer was separated. The organic layer was dried over anhydrous
magnesium sulfate. The organic layer was concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography to obtain the title compound (255 mg). The recovered
raw material (335 mg) was subjected to the same reaction as
described above to obtain the title compound (120 mg).
[0566] ESI-MS; m/z 389 [M.sup.++H].
[0567] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.88 (dd,
J=3.2, 13.2 Hz, 1H), 3.12-3.25 (m, 2H), 3.56-3.62 (m, 1H),
3.74-3.78 (m, 1H), 4.18 (d, J=12.0 Hz, 1H), 4.32 (dd, J=5.2, 10.8
Hz, 1H), 4.96-5.16 (m, 1H), 7.10-7.16 (m, 1H), 7.19-7.23 (m, 1H),
7.34-7.47 (m, 4H), 7.50-7.55 (m, 1H), 8.14-8.24 (m, 2H).
(13) Synthesis of
(4aS,5S,8aS)-5-fluoro-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-
-thia-1-azanaphthalen-2-ylamine
[0568] 1,8-Diazabicyclo[5,4,0]-7-undecene (312 .mu.L) was added to
a solution of the compound obtained in Preparation Example 8-(12)
(370 mg) in methanol (13 mL), and the mixture was heated under
reflux for eight hours. The reaction solution was returned to room
temperature and concentrated under reduced pressure. The residue
was purified by NH-silica gel column chromatography to obtain the
title compound (262 mg).
[0569] ESI-MS; m/z 285 [M.sup.++H].
[0570] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.81 (dd,
J=3.6, 12.4 Hz, 1H), 2.95-3.02 (m, 1H), 3.11-3.15 (m, 1H),
3.49-3.56 (m, 1H), 3.69-3.84 (m, 1H), 4.08-4.12 (m, 1H), 4.25 (dd,
J=5.6, 10.8 Hz, 1H), 4.50-4.65 (brm, 2H), 4.80-4.98 (m, 1H), 7.05
(ddd, J=1.2, 8.0, 12.8 Hz, 1H), 7.12-7.17 (m, 1H), 7.27-7.34 (m,
2H).
(14) to (15) Synthesis of tert-butyl
[(4aS,5S,8aS)-8a-(5-amino-2-fluorophenyl)-5-fluoro-4,4a,5,6,8,8a-hexahydr-
o-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0571] The title compound (195 mg) was obtained from the compound
obtained in Preparation Example 8-(13) (262 mg) according to
Preparation Example 1.
[0572] ESI-MS; m/z 400 [M.sup.++H].
[0573] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.52 (s,
9H), 2.82-2.87 (m, 1H), 3.02-3.10 (m, 2H), 3.53 (dd, J=4.0, 10.4
Hz, 1H), 3.64 (brs, 2H), 3.65-3.68 (m, 1H), 4.09 (dd, J=1.6, 11.6
Hz, 1H), 4.26 (dd, J=6.0, 10.8 Hz, 1H), 4.86-5.05 (m, 1H), 6.49
(dd, J=2.4, 6.8 Hz, 1H), 6.56-6.60 (m, 1H), 6.88 (dd, J=8.4, 12.0
Hz, 1H).
Preparation Example 9
Synthesis of tert-butyl
(-)-[(4aR*,5R*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyloctahydro-7-oxa--
3-thia-1-azanaphthalen-2-yl]carbamate and tert-butyl
(-)-[(4aR*,5S*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyloctahydro-7-oxa--
3-thia-1-azanaphthalen-2-yl]carbamate
##STR00039## ##STR00040##
[0574] (1) Synthesis of
4-(2,2-dimethoxyethoxy)-3-methyl-1-butene
[0575] Sodium hydride (60 wt %, 928 mg) was added to a solution of
2-methyl-3-buten-1-01 (2 g) in DMF (30 mL) under ice-cooling, and
the mixture was stirred at the same temperature for 30 minutes.
Bromoacetaldehyde dimethyl acetal (5.45 mL) was added dropwise to
the reaction solution at the same temperature. The reaction
solution was stirred for 16 hours with gradual heating to room
temperature. Ethyl acetate and aqueous sodium chloride were added
to the reaction solution, and the organic layer was separated. The
same operation was performed on the same scale. The combined
organic layers were washed with saturated aqueous sodium chloride
and dried over anhydrous magnesium sulfate. The organic layer was
concentrated under reduced pressure and the residue was purified by
silica gel column chromatography to obtain the title compound (4.92
g).
[0576] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.02 (d,
J=6.8 Hz, 3H), 2.45-2.52 (m, 1H), 3.32 (dd, J=7.2, 9.2 Hz, 1H),
3.36-3.40 (m, 2H), 3.40 (s, 6H), 3.49 (d, J=4.8 Hz, 1H), 4.51 (t,
J=4.8 Hz, 1H), 4.99-5.09 (m, 2H), 5.77 (ddd, J=17.2, 10.8, 6.4 Hz,
1H).
(2) Synthesis of (2-methyl-3-butenyloxy)acetaldehyde oxime
[0577] A solution of the compound obtained in Preparation Example
9-(1) (4.92 g) in formic acid/water (20 mL/5 mL) was stirred at
room temperature for 16 hours. Ethanol (30 mL), water (10 mL),
sodium acetate (4.63 g) and hydroxylamine sulfate (4.63 g) were
added to the reaction solution, and the mixture was stirred at room
temperature for eight hours. Saturated aqueous sodium chloride and
ethyl acetate were added to the reaction solution, and the organic
layer was separated. The organic layer was washed again with
saturated aqueous sodium chloride and then dried over anhydrous
magnesium sulfate. The organic layer was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (1.57 g).
[0578] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.02 (d,
J=7.2 Hz, 1.5H), 1, 04 (d, J=6.4 Hz, 1.5H), 2.44-2.51 (m, 1H),
3.28-3.41 (m, 2H), 4.09 (d, J=6.4 Hz, 1H), 4.33 (d, J=3.6 Hz, 1H),
5.01-5.11 (m, 2H), 5.72-5.82 (m, 1H), 6.90 (t, J=3.6 Hz, 0.5H),
7.45 (brs, 1H), 7.49 (t, J=6.4 Hz, 0.5 Hz).
(3) to (7) Synthesis of
(.+-.)-N-[(4aR*,5S*,8aS*)-8a-(2-fluorophenyl)-5-methyl-4,4a,5,6,8,8a-hexa-
hydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide and
(.+-.)-N-[(4aR*,5R*,8aS*)-8a-(2-fluorophenyl)-5-methyl-4,4a,5,6,8,8a-hexa-
hydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide
[0579] A mixture of the title compound (2.15 g) was obtained from
the compound obtained in Preparation Example 9-(2) (1.57 g)
according to Preparation Example 8.
[0580] ESI-MS; m/z 385 [M.sup.++H].
(8) to (9) Synthesis of
(.+-.)-N-[(4aR*,5S*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide and
(.+-.)--N-[(4aR*,5R*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide
[0581] The title compound
(.+-.)-N-[(4aR*,5S*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide (440 mg)
and the title compound
(.+-.)-N-[(4aR*,5R*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide (1.37 g)
were obtained from the compound obtained in Preparation Example
9-(7) (2.15 g) according to Preparation Example 8.
[0582] ESI-MS; m/z 426 [M.sup.++H].
(10) Synthesis of tert-butyl
(.+-.)-[(4aR*,5S*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyl-4,
4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]
carbamate
[0583] The title compound (225 mg) was obtained from
(.+-.)-N-[(4aR*,5S*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide obtained
in Preparation Example 9-(9) (440 mg) according to Preparation
Example 8.
[0584] ESI-MS; m/z 396 [M.sup.++H].
(11) Synthesis of tert-butyl
(.+-.)-[(4aR*,5R*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyl-4,4a,5,6,8,8-
a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0585] The title compound (953 mg) was obtained from
(.+-.)-N-[(4aR*,5R*,8aS*)-8a-(2-fluoro-5-nitrophenyl)-5-methyl-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide obtained
in Preparation Example 9-(9) (1.37 g) according to Preparation
Example 8.
[0586] ESI-MS; m/z 396 [M.sup.++H].
(12) Synthesis of tert-butyl
(-)[(4aR*,5S*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyl-4.4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0587] The compound obtained in Preparation Example 9-(10) was
purified by CHIRALPAK.TM. AD-H (mobile phase: ethanol, flow rate:
10 ml/min), and the fraction with a retention time of 12.5 to 14.7
minutes was collected to obtain the title compound. The same
operation was repeated to obtain the title compound (100 mg;
>99% ee) from the raw material (225 mg).
[0588] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.92 (d,
J=6.8 Hz, 3H), 1.45 (s, 9H), 2.01-2.07 (m, 1H), 2.78-2.83 (m, 2H),
3.23-3.30 (m, 1H), 3.39-3.44 (m, 1H), 3.63-3.71 (m, 2H), 4.12 (d,
J=12.8 Hz, 1H), 6.56-6.60 (m, 1H), 6.86 (dd, J=8.8, 11.6 Hz, 1H),
7.05-7.07 (m, 1H).
[0589] ESI-MS; m/z 396 [M.sup.++H].
(13) Synthesis of tert-butyl
(-)-[(4aR*,5R*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methyl-4,4-a.,
5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0590] The compound obtained in Preparation Example 9-(11) was
purified by CHIRALCEL.TM. OJ-H (mobile phase: hexane:ethanol=1:1,
flow rate: 10 ml/min), and the fraction with a retention time of
21.8 to 41.7 minutes was collected to obtain the title compound.
The same operation was repeated to obtain the title compound (230
mg; >99% ee) from the raw material (500 mg).
[0591] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.92 (d,
J=6.4 Hz, 3H), 1.52 (s, 9H), 2.20-2.34 (m, 1H), 2.56-2.60 (m, 1H),
2.75-2.87 (m, 2H), 3.28 (t, J=11.6 Hz, 1H), 3.65 (brs, 213), 3.67
(d, J=12.0 Hz, 1H), 3.96 (dd, J=4.8, 11.2 Hz, 1H), 4.11 (dd, J=1.6,
12.0 Hz, 1H), 6.54-6.60 (m, 2H), 6.82-6.88 (m, 1H).
[0592] ESI-MS; m/z 396 [M.sup.++H].
Preparation Example 10
Synthesis of tert-butyl
(-)-[(4aS*,5R*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methoxy-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00041## ##STR00042##
[0593] (1) Synthesis of
1-[2-(tert-butyldimethylsilanyloxy)ethoxy]-3-buten-2-ol
[0594] A solution of oxalyl chloride (8.38 mL) in dichloromethane
(470 mL) was cooled to -78.degree. C. in a nitrogen atmosphere. A
solution of dimethyl sulfoxide (8.01 mL) in dichloromethane (10 mL)
was added dropwise to the reaction solution at the same
temperature. The reaction solution was stirred at the same
temperature for 10 minutes. A solution of
2-[2-(tert-butyldimethylsilanyloxy)ethoxy]ethanol (25.9 g) in
dichloromethane (20 mL) was added dropwise to the reaction solution
at the same temperature. The reaction solution was stirred at the
same temperature for 30 minutes. Triethylamine (52.1 mL) was added
to the reaction solution at the same temperature. The reaction
solution was stirred for one hour while gradually returning to room
temperature. Aqueous ammonium chloride was added to the reaction
solution, and the organic layer was separated. The organic layer
was washed with saturated aqueous sodium chloride and dried over
anhydrous magnesium sulfate. The organic layer was filtered through
a silica pad and the filtrate was concentrated. Tetrahydrofuran
(500 mL) was added to the residue. The reaction solution was cooled
to -78.degree. C. in a nitrogen atmosphere. Vinylmagnesium chloride
(148 mL, 1.38 M solution in tetrahydrofuran) was added dropwise to
the reaction solution at the same temperature. The reaction
solution was heated to room temperature with stirring over six
hours. Aqueous ammonium chloride and ethyl acetate were added to
the reaction solution, and the organic layer was separated. The
organic layer was washed with saturated aqueous sodium chloride and
dried over anhydrous magnesium sulfate. The organic layer was
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound
(10.03 g).
[0595] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.08 (s,
6H), 0.91 (s, 913), 2.82 (d, J=3.2 Hz, 1H), 3.38 (dd, J=8.0, 10.0
Hz, 1H), 3.57-3.63 (m, 3H), 3.78 (t, J=5.2 Hz, 2H), 4.29-4.36 (m,
1H), 5.19 (ddd, J=1.6, 1.6, 10.8 Hz, 1H), 5.36 (ddd, J=1.6, 1.6,
15.6 Hz, 1H), 5.83 (ddd, J=5.2, 10.4, 15.6 Hz, 1H).
(2) Synthesis of
tert-butyl-[2-(2-methoxy-3-butenyloxy)ethoxy]dimethylsilane
[0596] Sodium hydride (357 mg, 60 wt %) was added to a solution of
the compound obtained in Preparation Example 10-(1) (2 g) in DMF
(20 mL) under ice-cooling, and the mixture was stirred at the same
temperature for one hour. Methyl iodide (1.01 mL) was added to the
reaction solution at the same temperature. The reaction solution
was stirred at the same temperature for one hour. Aqueous ammonium
chloride and ethyl acetate were added to the reaction solution, and
the organic layer was separated. The organic layer was washed with
saturated aqueous sodium chloride. The organic layer was dried over
anhydrous magnesium sulfate. The organic layer was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography to obtain the title compound (1.30 g).
[0597] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.06 (s,
6H), 0.89 (s, 9H), 3.34 (s, 3H), 3.49-3.76 (m, 4H), 3.76-3.81 (m,
3H), 5.25-5.33 (m, 2H), 5.72 (ddd, J=7.2, 10.4, 15.2 Hz, 1H).
(3) Synthesis of 2-(2-methoxy-3-butenyloxy)ethanol
[0598] Tetrabutylammonium fluoride (7.47 mL, 1 M solution in
tetrahydrofuran) was added dropwise to a solution of the compound
obtained in Preparation Example 1042) (1.3 g) in tetrahydrofuran
(25 mL) under ice-cooling. The reaction solution was stirred at the
same temperature for 10 minutes. The reaction solution was returned
to room temperature and further stirred for five hours. Saturated
aqueous sodium chloride and ethyl acetate were added to the
reaction solution, and the organic layer was separated. Ethyl
acetate was added to the aqueous layer, and the organic layer was
separated. The organic layers were combined and dried over
anhydrous magnesium sulfate. The organic layer was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography to obtain the title compound (500 mg).
[0599] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 2.41 (s,
1H), 3.35 (s, 3H), 3.54-3.57 (m, 2H), 3.61-3.64 (m, 2H), 3.72-3.75
(m, 2H), 3.79-3.84 (m, 1H), 5.28-5.35 (m, 2H), 5.71 (ddd, J=7.6,
10.4, 15.6 Hz, 1H).
(4) Synthesis of (2-methoxy-3-butenyloxy)acetaldehyde oxime
[0600] The title compound (280 mg) was obtained from the compound
obtained in Preparation Example 10-(3) (500 mg) according to
Preparation Example 8.
[0601] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 3.34 (s,
1.5H), 3.35 (s, 1.5H), 3.50-3.54 (m, 2H), 3.78-3.84 (m, 1H),
4.10-4.16 (m, 1H), 4.40 (d, J=4.0 Hz, 1H), 5.28-5.36 (m, 2H),
5.66-5.76 (m, 1H), 6.94 (t, J=3.2 Hz, 0.5H), 7.51 (t, J=5.2 Hz,
0.5H).
(5) to (12) Synthesis of tert-butyl
(.+-.)-[(4aS*,5R*,8aS*)-8a-(5-amino-2-fluoronhenyl)-5-methoxy-4,4a,5,6,8,-
8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0602] The title compound (74 mg) was obtained from the compound
obtained in Preparation Example 10-(4) (280 mg) according to
Preparation Example 9.
[0603] ESI-MS; m/z 412 [M.sup.++H].
(13) Synthesis of tert-butyl
(-)-[(4aS*,5R*,8aS*)-8a-(5-amino-2-fluorophenyl)-5-methoxy-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0604] The compound obtained in Preparation Example 10-(12) was
purified by CHIRALCEL.TM. OJ-H (mobile phase:hexane:ethanol=1:1,
flow rate: 10 ml/min), and the fraction with a retention time of
18.6 to 22.0 minutes was collected to obtain the title compound.
The same operation was repeated to obtain the title compound (25
mg; >99% ee) from the raw material (70 mg).
[0605] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.52 (s,
9H), 2.77 (dd, J=7.6, 12.8 Hz, 1H), 2.84-2.89 (m, 1H), 3.10 (dd,
J=3.2, 12.8 Hz, 1H), 3.32 (dd, J=10.4, 10.4 Hz, 1H), 3.48 (s, 3H),
3.61-3.75 (m, 2H), 4.08 (dd, J=1.2, 12.0 Hz, 1H), 4.29 (dd, J=4.8,
10.8 Hz, 1H), 6.53 (dd, J=3.2, 6.4 Hz, 1H), 6.55-6.59 (m, 1H), 6.86
(dd, J=8.4, 12.0 Hz, 1H). ESI-MS; m/z 412 [M.sup.++H].
Preparation Example 11
Synthesis of tert-butyl
(.+-.)-[(2R*,4aR,8aS)-8a-(5-amino-2-fluorophenyl)-4-methyl-4,4a,5.6.8.8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00043## ##STR00044##
[0606] (1) to (10) Synthesis of tert-butyl
(.+-.)-[(2R*,4aR,8aS)-8a-(5-amino-2-fluorophenyl)-4-methyl-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0607] The title compound (384 mg) was obtained from
trans-3-penten-1-ol (4.71 g) according to Preparation Example
9.
[0608] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.18 (d,
J=7.2 Hz, 3H), 1.53 (s, 9H), 1.85-1.96 (m, 1H), 2.80 (ddd, J=4.0,
4.0, 12.0 Hz, 1H), 3.22 (qd, J=7.2, 3.2 Hz, 1H), 3.61-3.70 (m, 3H),
4.05-4.17 (m, 2H), 6.54-6.58 (m, 2H), 6.83-6.88 (m, 1H).
[0609] ESI-MS; m/z 396 [M.sup.++H].
Preparation Example 12
Synthesis of 5-difluoromethylpyrazine-2-carboxylic acid
##STR00045##
[0610] (1) Synthesis of t-butyl 5-methylpyrazine-2-carboxylate
[0611] A boron trifluoride-diethyl ether complex (91.7 .mu.L) was
added dropwise to a suspension of 2-methylpyrazine-5-carboxylic
acid (1 g) and tert-butyl 2,2,2-trichloroacetimidate (4.75 g) in
tetrahydrofuran (20 mL) under ice-cooling. The reaction solution
was heated to room temperature and stirred for two hours. A
saturated sodium chloride solution and ethyl acetate were added to
the reaction solution, and the organic layer was separated. The
organic layer was dried over anhydrous magnesium sulfate, and the
insoluble matter was separated by filtration. The filtrate was
concentrated and purified by silica gel column chromatography to
obtain the title compound (1.4 g).
[0612] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.65 (s, 9H), 2.65
(s, 3H), 8.57 (d, J=1.2 Hz, 1H), 9.10 (d, J=1.6 Hz, 1H).
(2) Synthesis of t-butyl
5-((E)-2-dimethylaminovinyl)pyrazine-2-carboxylate
[0613] A mixture of t-butyl 5-methylpyrazine-2-carboxylate (1.35
g), N,N-dimethylformamide (25 mL) and N,N-dimethylformamide
dimethylacetal (25 mL) was stirred at 130.degree. C. for five
hours. The reaction solution was cooled to room temperature and
diluted with ethyl acetate. The mixture was washed with a saturated
sodium chloride solution three times. The organic layer was dried
over anhydrous magnesium sulfate, and the insoluble matter was
separated by filtration. The filtrate was concentrated and the
residue was purified by silica gel column chromatography to obtain
the title compound (648 mg).
[0614] 1H-NMR (CDCl.sub.3) .delta. (ppm): 1.63 (s, 9H), 3.00 (s,
6H), 5.16 (d, J=12.8 Hz, 1H), 7.72 (d, J=12.8 Hz, 1H), 8.16 (d,
J=1.2 Hz, 1H), 8.81 (d, J=1.6 Hz, 1H).
(3) Synthesis of t-butyl 5-formylpyrazine-2-carboxylate
[0615] Sodium periodate (1.67 g) was added to a solution of t-butyl
5-((E)-2-dimethylamino-vinyl)pyrazine-2-carboxylate (645 mg) in 50%
tetrahydrofuran-water (26 mL), and the mixture was stirred at room
temperature for four hours. A saturated sodium bicarbonate solution
and ethyl acetate were added to the reaction solution, and the
organic layer was separated. The organic layer was washed with a
saturated sodium chloride solution and dried over anhydrous
magnesium sulfate. The insoluble matter was separated by filtration
and the filtrate was concentrated. The residue was purified by
silica gel column chromatography to obtain the title compound (249
mg).
[0616] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.68 (s, 9H), 9.25
(d, J=1.2 Hz, 1H), 9.36 (d, J=1.6 Hz, 1H), 10.2 (s, 1H).
(4) Synthesis of t-butyl 5-difluoromethylpyrazine-2-carboxylate
[0617] [Bis(2-methoxyethyl)amino]sulfur trifluoride (662 .mu.L) was
added dropwise to a solution of t-butyl
5-formylpyrazine-2-carboxylate (249 mg) in dichloromethane (12 mL)
in a nitrogen atmosphere under ice-cooling. The reaction solution
was stirred for two hours while gradually returning to room
temperature. A saturated sodium bicarbonate solution and ethyl
acetate were added to the reaction solution, and the organic layer
was separated. The organic layer was washed with a saturated sodium
chloride solution and dried over anhydrous magnesium sulfate. The
insoluble matter was separated by filtration and the filtrate was
concentrated. The residue was purified by silica gel column
chromatography to obtain the title compound (175 mg).
[0618] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.67 (s, 9H), 6.75
(t, J=54.4 Hz, 1H), 9.02 (d, J=0.8 Hz, 1H), 9.25 (d, =0.8 Hz,
1H).
(5) Synthesis of 5-difluoromethylpyrazine-2-carboxylic acid
[0619] Trifluoroacetic acid (1 mL) was added to a solution of
t-butyl 5-difluoromethylpyrazine-2-carboxylate (175 mg) in
dichloromethane (1 mL), and the mixture was stirred at room
temperature for five hours. Ether and 5 N sodium hydroxide were
added to the reaction solution. The aqueous layer was separated and
made acidic with 5 N hydrochloric acid. Ethyl acetate was added to
the aqueous layer, and the organic layer was separated. The organic
layer was dried over anhydrous magnesium sulfate, and the insoluble
matter was separated by filtration. The filtrate was concentrated
to obtain the title compound (100 mg).
[0620] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 6.80 (t, J=54.4 Hz,
1H), 9.02 (s, 1H), 9.47 (s, 1H).
Preparation Example 13
Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-amino-2-fluorophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00046## ##STR00047##
[0621] (1) Synthesis of (R)-1-benzyloxy-4-penten-2-ol
[0622] Ether (100 ml) and copper (I) iodide (580 mg) were added to
a solution of (R)-benzyl glycidyl ether (10.0 g) in THF (100 ml).
The mixture was cooled to -78.degree. C., and vinylmagnesium
chloride (1.38 M, 53.0 ml) was added dropwise. The mixture was
stirred overnight with gradual heating to room temperature. Ice was
added to the reaction solution, and an ammonium chloride solution
was further added. The aqueous layer was extracted with ethyl
acetate, and the organic layer was washed with an ammonium chloride
solution. The insoluble matter was removed by filtration through
celite, and the solvent was evaporated under reduced pressure to
obtain the title compound (12.5 g).
[0623] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.59 (d,
J=2.0 Hz, 1H), 2.25-2.29 (m, 2H), 3.38 (dd, J=72, 9.2 Hz, 1H), 3.52
(dd, J=3.2, 9.2 Hz, 1H), 3.86-3.91 (m, 1H), 4.56 (s, 2H), 5.08-5.15
(m, 2H), 5.78-5.88 (m, 1H), 7.28-7.38 (m, 5H).
(2) Synthesis of
[(R)-2-(2,2-diethoxyethoxy)-4-pentenyloxymethyl]benzene
[0624] (R)-1-Benzyloxy-4-penten-2-ol (3.13 g) was dissolved in DMF
(32 ml), and sodium hydride (60%, 0.91 g) was added in an ice bath.
After stirring at the same temperature for 30 minutes,
bromoacetaldehyde diethyl acetal (3.03 ml) was added. The mixture
was heated to room temperature and stirred for two hours, and then
heated to 50.degree. C. and stirred for one hour. After cooling to
room temperature, ice was added to the reaction solution. The
reaction solution was extracted with ethyl acetate. The organic
layer was washed with water and brine. The organic layer was dried
over anhydrous magnesium sulfate, and the solvent was evaporated
under reduced pressure. The residue was purified by silica gel
column chromatography to obtain the title compound. The mixture
containing the recovered raw material was reacted under the same
conditions. The title compound was obtained by purification by the
same method (total yield: 5.00 g).
[0625] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.20 (t,
J=7.2 Hz, 3H), 1.21 (t, J=7.2 Hz, 3H), 2.31-2.34 (m, 2H), 3.50 (dd,
J=1.2, 5.2 Hz, 2H), 3.53-3.71 (m, 7H), 4.54 (s, 2H), 4.60 (t, J=5.2
Hz, 1H), 5.02-5.11 (m, 2H), 5.78-5.88 (m, 1H), 7.25-7.35 (m,
5H).
(3) Synthesis of ((R)-1-benzyloxymethyl-3-butenyloxy)acetaldehyde
oxime
[0626] [(R)-2-(2,2-Diethoxyethoxy)-4-pentenyloxymethyl]benzene
(20.0 g) was dissolved in formic acid (160 ml) and water (40 ml),
and the mixture was stirred at room temperature for 30 minutes.
Next, water (161 ml) and ethanol (400 ml) were added, and then
hydroxylamine sulfate (6.38 g) and sodium acetate (8.82 g) were
added, followed by stirring at room temperature overnight. Water
was added to the reaction solution, and the insoluble matter was
dissolved. Then, the excess of ethanol was evaporated under reduced
pressure. The aqueous layer was extracted with ethyl acetate. The
organic layer was washed with water and brine. The organic layer
was dried over anhydrous magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography to obtain the title compound (13.7
g).
[0627] .sup.1H-NMR. (400 MHz, CDCl.sub.3) .delta. (ppm): 2.30-2.35
(m, 2H), 3.47-3.62 (m, 3H), 4.17-4.27 (m, 1H), 4.46-4.47 (m, 1H),
4.55 (d, J=4.4 Hz, 2H), 5.04-5.11 (m, 2H), 5.74-5.85 (m, 1H), 6.94
(t, I=3.6 Hz, 0.35H), 7.28-7.37 (m, 5H), 7.50 (t, J=6.0 Hz, 0.65
Hz).
(4) Synthesis of
(3aR,5R)-5-benzyloxymethyl-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole
[0628] ((R)-1-Benzyloxymethyl-3-butenyloxy)acetaldehyde oxime (13.7
g) was dissolved in dichloromethane (164 ml). A 5% sodium
hypochlorite solution (164 ml) was added dropwise in an ice bath,
and the mixture was stirred at the same temperature for two hours.
The reaction solution was diluted with water, and the aqueous layer
was extracted with dichloromethane. The organic layer was dried
over anhydrous magnesium sulfate, and the solvent was evaporated
under reduced pressure. The residue was purified by silica gel
column chromatography to obtain the title compound (12.2 g).
[0629] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.52-1.61
(m, 1H), 2.19 (ddd, J=0.8, 6.8, 14.4 Hz, 1H), 3.43-3.50 (m, 2H),
3.56 (dd, J=6.4, 10.0 Hz, 1H), 3.69-3.75 (m, 1H), 3.79 (dd, J=8.0,
12.0 Hz, 1H), 4.21 (dd, J=1.6 Hz, 13.6 Hz, 1H), 4.54-4.64 (m, 3H),
4.77 (d, J=13.2 Hz, 1H), 7.30-7.38 (m, 5H).
(5) Synthesis of
(3aR,5R,7aS)-5-benzyloxymethyl-7a-(2-fluorophenyl)hexahydropyrano[3,4-c]i-
soxazole
[0630] Toluene (100 ml) and THF (10 ml) were added to
2-bromoftuorobenzene (3.11 g). The reaction solution was cooled to
-78.degree. C., and n-butyllithium (2.63 M, 6.15 ml) was added
dropwise. After stirring at the same temperature for one hour, a
mixed solution of
(3aR,5R)-5-benzyloxymethyl-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole
(2.00 g) in toluene (20 ml) and THF (2 ml) and a boron
trifluoride-diethyl ether complex (2.03 ml) were added dropwise at
the same time. After stirring at the same temperature for two
hours, an ammonium chloride solution was added to the reaction
solution. The aqueous layer was extracted with ethyl acetate, and
the organic layer was dried over anhydrous magnesium sulfate. The
solvent was evaporated under reduced pressure and the residue was
purified by silica gel column chromatography to obtain the title
compound (2.29 g).
[0631] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.51-1.60
(m, 1H), 1.81-1.88 (m, 1H), 3.10-3.18 (m, 1H), 3.49 (dd, J=4.0,
10.4 Hz, 1H), 3.54-3.58 (m, 2H), 3.70 (d, J=7.6 Hz, 1H), 3.88 (d,
J=12.4 Hz, 2H), 4.19 (dd, J=2.0, 12.4 Hz, 1H), 4.57 (d, J=12.0,
1H), 4.63 (d, J=12.0, 1H), 6.30 (s, 1H), 7.03 (ddd, J=1.2, 8.0,
12.4 Hz, 1H), 7.16 (dt, J=1.2, 8.0 Hz, 1H), 7.23-7.37 (m, 6H), 7.93
(dt, I=1.6, 8.0 Hz, 1H).
(6) Synthesis of
[(2R,4R,53)-5-amino-2-benzyloxymethyl-5-(2-fluorophenyl)tetrahydropyran-4-
-yl]methanol
[0632] Zinc powder (4.36 g) was added to a solution of
(3aR,5R,7aS)-5-benzyloxymethyl-7a-(2-fluorophenyl)hexahydropyrano[3,4-c]i-
soxazole (2.29 g) in acetic acid (50 ml), and the mixture was
stirred at room temperature overnight. The insoluble matter was
removed by filtration through celite, and the solvent was
evaporated under reduced pressure. Ice was added to the residue,
followed by neutralization with a 5 N sodium hydroxide solution.
The aqueous layer was extracted with dichloromethane, and the
organic layer was dried over anhydrous magnesium sulfate. The
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain the title
compound (2.08 g).
[0633] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.61-1.67
(m, 1H), 1.98-2.08 (m, 1H), 2.30-2.35 (m, 1H), 3.33 (dd, J=2.8,
11.2 Hz, 1H), 3.44 (d, J=11.2 Hz, 1H), 3.53-3.57 (m, 2H), 3.62 (dd,
J=6.8, 10.4 Hz, 1H), 3.86-3.90 (m, 1H), 4.27 (dd, J=2.4, 11.2 Hz,
1H), 4.59 (d, J=12.0 Hz, 1H), 4.66 (d, J=12.0 Hz, 1H), 7.06 (ddd,
J=1.6, 8.0 Hz, 13.2 Hz, 1H), 7.20 (dt, J=1.2, 7.6 Hz, 1H),
7.26-7.39 (m, 6H), 7.63 (dt, J=1.6, 7.6 Hz, 1H).
(7) Synthesis of
(4aR,6R,8aS)-6-benzyloxymethyl-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydr-
o-7-oxa-3-thia-1-azanaphthalen-2-ylamine
[0634] Benzoyl isothiocyanate (893 .mu.l) was added dropwise to a
solution of
[(2R,4R,5S)-5-amino-2-benzyloxymethyl-5-(2-fluorophenyl)tetrahydropyra-
n-4-yl]methanol (2.08 g) in dichloromethane (30 ml). The reaction
solution was stirred at room temperature for three hours, and then
the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography. Several drops of
concentrated hydrochloric acid were added to a solution of the
resulting intermediate in methanol (40 ml), and the mixture was
heated under reflux for five hours. The reaction solution was
returned to room temperature, and then the solvent was evaporated
under reduced pressure. The residue was dissolved in methanol (40
ml) and DBU (2 ml) was added, followed by heating under reflux for
five hours. The solvent was evaporated under reduced pressure and
the residue was purified by NH-silica gel column chromatography to
obtain the title compound (1.61 g).
[0635] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppmm): 1.51 (ddd,
J=2.4, 3.6, 13.2 Hz, 1H), 1.74-1.84 (m, 1H), 2.55-2.60 (m, 1H),
2.92-2.98 (m, 2H), 3.47 (dd, J=4.4, 9.6 Hz, 1H), 3.62 (dd, J=6.4,
10.0 Hz, 1H), 3.83 (d, J=10.8 Hz, 1H), 3.87-3.93 (m, 1H), 4.17 (dd,
J=2.4, 11.2 Hz, 1H), 4.51 (brs, 2H), 4.56 (d, J=12.0 Hz, 1H), 4.63
(d, J=12.0 Hz, 1H), 7.02 (ddd, J=1.6, 8.0, 12.8 Hz, 1H), 7.12 (dt,
J=1.6, 7.6 Hz, 1H), 7.22-7.37 (m, 7H).
(8) Synthesis of
[(4aR,6R,8aS)-2-amino-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-
-thia-1-azanaphthalen-6-yl]methanol
[0636] Concentrated hydrochloric acid (25.2 ml) was added to
(4aR,6R,8aS)-6-benzyloxymethyl-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydr-
o-7-oxa-3-thia-1-azanaphthalen-2-ylamine (1.26 g), and the mixture
was heated under reflux for two hours. After cooling the reaction
solution to room temperature, the reaction mixture was poured into
ice. The mixture was neutralized with 5 N sodium hydroxide, and the
aqueous layer was extracted with dichloromethane. The organic layer
was dried over anhydrous magnesium sulfate. The solvent was
evaporated under reduced pressure, and the residual solid was
washed with a mixed solvent of heptane and ether to obtain the
title compound (890 mg).
[0637] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.40 (ddd,
J=2.0, 6.0, 12.8 Hz, 1H), 1.81-1.90 (m, 1H), 2.59 (dd, J=4.4, 14.0
Hz, 1H), 2.95-2.99 (m, 2H), 3.61-3.69 (m, 2H), 3.69-3.81 (m, 1H),
3.83 (d, J=11.2 Hz, 1H), 4.17 (dd, J=2.0, 13.2 Hz, 1H), 7.03 (ddd,
J=1.2, 8.4, 13.2 Hz, 1H), 7.13 (dt, J=1.6, 7.6 Hz, 1H), 7.24-7.29
(m, 1H), 7.35 (dt, J=1.6, 8.0 Hz, 1H),
(9) Synthesis of
[(4aR,6R,8aS)-2-amino-8a-(2-fluoro-5-nitrophenyl)-4,4a,5,6,8,8a-hexahydro-
-7-oxa-3-thia-1-azanaphthalen-6-yl]methanol
[0638] Concentrated sulfuric acid (2.5 ml) was added dropwise to a
solution of
[(4aR,6R,8aS)-2-amino-8a-(2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-
-thia-1-azanaphthalen-6-yl]methanol (700 mg) in TFA (5 ml) in an
ice bath. Then, fuming nitric acid (specific gravity: 1.52, 103
.mu.l) was added dropwise at the same temperature, followed by
stirring for one hour. The reaction mixture was poured into ice and
made basic with a 5 N sodium hydroxide solution, followed by
stirring at room temperature for two hours. The aqueous layer was
extracted with dichloromethane, and the organic layer was dried
over anhydrous magnesium sulfate. The solvent was evaporated under
reduced pressure to obtain the title compound (1.0 g).
[0639] .sup.1H-NMR. (400 MHz, CDCl.sub.3) 6 (ppm): 1.46 (ddd,
J=2.4, 4.0, 13.2 Hz, 1H), 1.84-1.94 (m, 1H), 2.66 (dd, J=2.4, 12.4
Hz, 1H), 2.93 (dd, J=4.4, 12.4 Hz, 1H), 2.96-3.02 (m, 1H),
3.63-3.71 (m, 2H), 3.76-3.82 (m, 1H), 3.86 (d, J=11.2 Hz, 1H), 4.11
(dd, J=2.8, 10.4 Hz, 1H), 7.21 (dd, J=8.8, 10.8 Hz, 1E1), 8.19
(ddd, J=3.2, 4.0, 8.8 Hz, 1H), 8.30 (dd, J=3.2, 6.8 Hz, 1H).
(10) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(2-fluoro-5-nitrophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0640] Triethylamine (1 ml) was added to a solution of
[(4aR,6R,8aS)-2-amino-8a-(2-fluoro-5-nitrophenyl)-4,4a,5,6,8,8a-hexahydro-
-7-oxa-3-thia-1-azanaphthalen-6-yl]methanol (1.0 g) in THF (100
ml). Then, di-tert-butyl dicarbonate (1.28 g) was added and the
mixture was stirred at room temperature overnight. The solvent was
evaporated under reduced pressure and the residue was purified by
NH-silica gel column chromatography to obtain the title compound
(1.05 g).
[0641] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.47-1.54
(m, 1H), 1.86-1.97 (m, 1H), 2.59 (dd, J=2.8, 12.8 Hz, 1H), 2.86
(dd, J=3.6, 12.8 Hz, 1H), 3.04-3.08 (m, 1H), 3.67 (d, J=6.0 Hz,
2H), 3.76-3.82 (m, 1H), 3.83 (d, J=11.6 Hz, 1H), 4.09 (dd, J=2.4,
11.2 Hz, 1H), 7.22-7.25 (m, 1H), 8.20-8.24 (m, 2H).
(11) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-amino-2-fluorophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0642] Iron powder (121 mg) and a saturated ammonium chloride
solution (1 ml) were added to a solution of tert-butyl
[(4aR,6R,8aS)-8a-(2-fluoro-5-nitrophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (120 mg) in
ethanol (20 ml). The reaction solution was heated under reflux for
40 minutes and then cooled to room temperature. The insoluble
matter was filtered off through celite, and the filtrate was
evaporated under reduced pressure. The residue was purified by
NH-silica gel column chromatography to obtain the title compound
(67 mg).
[0643] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.47-1.54
(m, 1H), 1.53 (s, 9H), 1.86-1.96 (m, 1H), 2.53 (dd, 2.8, 12.8 Hz,
1H), 2.99 (dd, J=4.0, 12.4 Hz, 1H), 3.07-3.11 (m, 1H), 3.65-3.81
(m, 4H), 4.18 (dd, J=1.2, 12.0 Hz, 1H), 6.56-6.60 (m, 2H),
6.84-6.89 (m, 1H).
Preparation Example 14
Synthesis of tert-butyl
(+)-[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-trifluoromethyl-4,4a,5-
,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00048##
[0644] (1) Synthesis of
(.+-.)-(3aR*5R*)-5-trifluoromethyl-3.3a,4,5-tetrahydro-7H-pyrano[3,4-c]is-
oxazole
[0645] The title compound (6.6 g) was obtained from
1,1,1-trifluoro-4-penten-2-ol (10.0 g) according to the method of
Preparation Example 6.
[0646] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.80 (dd,
J=11.6, 24.4 Hz, 1H), 2.40 (ddd, J=2.0, 6.4, 12.8 Hz, 1H), 3.52
(ddd, J=6.4, 10.8, 22.0 Hz, 1H), 3.85-3.96 (m, 2H), 4.30 (dd,
J=1.2, 13.6 Hz, 1H), 4.69 (dd, J=8.4, 10.4 Hz, 1H), 4.88 (d, J=13.2
Hz, 1H).
(2) Synthesis of tert-butyl
(.+-.)-[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-trifluoromethyl-4,4-
a,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0647] The title compound (1.54 g) was obtained from
(.+-.)-(3aR*,5R*)-5-trifluoromethyl-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]i-
soxazole (2.00 g) according to the method of Preparation Example
6.
[0648] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.74-1.79 (m, 1H), 2.50-2.20 (m, 1H), 2.57 (dd, J=2.8, 12.4
Hz, 1H), 2.99-3.07 (m, 2H), 3.66 (s, 2H), 3.85 (d, J=11.6 Hz, 1H),
4.03-4.06 (m, 1H), 4.17 (d, J=12.0 Hz, 1H), 6.53-6.60 (m, 2H), 6.86
(dd, J=8.8, 12.0 Hz, 1H).
(3) Synthesis of tert-butyl
(+)-[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-trifluoromethyl-4,4a,5-
,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0649] tert-Butyl
(.+-.)-[(4aR*,6R*,8aS*)-8a-(5-amino-2-fluorophenyl)-6-trifluoromethyl-4,4-
a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
(25 mg) was purified by CHIRALPAK.TM. AD-H (mobile phase:
hexane:ethanol=81:19, flow rate: 10 ml/min). The fraction with a
retention time of 17.7 to 22.6 minutes was collected to obtain the
title compound. The same operation was repeated to obtain the title
compound (580 mg; >99% ee) from the racemate (1.45 g).
[0650] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.74-1.79 (m, 1H), 2.50-2.20 (m, 1H), 2.57 (dd, J=2.8, 12.4
Hz, 1H), 2.99-3.07 (m, 2H), 3.66 (s, 2H), 3.85 (d, J=11.6 Hz, 1H),
4.03-4.06 (m, 1H), 4.17 (d, J=12.0 Hz, 1H), 6.53-6.60 (m, 2H), 6.86
(dd, J=8.8, 12.0 Hz, 11-1).
Preparation Example 15
Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-amino-2-fluorophenyl)-6-fluoromethyl-4.4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00049##
[0651] (1) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-nitro-2-fluorophenyl)-6-fluoromethyl-4,4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0652] [Bis(2-methoxyethyl)amino]sulfur trifluoride (285 .mu.l) was
added dropwise to a solution of tert-butyl
[(4aR,6R,8aS)-8a-(5-nitro-2-fluorophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate obtained in
Preparation Example 13 (575 mg) in dichloromethane (55 ml) at
-78.degree. C. The mixture was stirred overnight with gradual
heating to room temperature. A sodium bicarbonate solution was
added to the reaction solution, and the aqueous layer was extracted
with chloroform. The organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by NH-silica gel column
chromatography to obtain the title compound (240 mg).
[0653] ESI-MS m/z 444 [M.sup.++H]
(2) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-amino-2-fluorophenyl)-6-fluoromethyl-4.4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0654] The title compound (26 mg) was obtained from tert-butyl
[(4aR,6R,8aS)-8a-(5-nitro-2-fluorophenyl)-6-fluoromethyl-4,4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (39 mg)
according to Preparation Example 13.
[0655] ESI-MS m/z 414 [M.sup.++H]
Preparation Example 16
Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,6R*,8aS*)-8a-(5-bromo-2-fluor-
ophenyl)-6-trifluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanapht-
halen-2-yl]amine
##STR00050##
[0656] (1) Synthesis of
(.+-.)-(3aR*,5R*,7aS*)-7a-(5-bromo-2-fluorophenyl)-5-trifluoromethyl-hexa-
hydropyrano[3,4-c]isoxazole
[0657] The title compound (484 mg) was obtained from
(.+-.)-(3aR*,5R*)-5-trifluoromethyl-3,3a,4,5-tetrahydro-7,1-pyrano[3,4-c]-
isoxazole obtained in Preparation Example 14 (300 mg) and
1,3-dibromo-4-fluorobenzene (855 mg) according to the method of
Preparation Example 1-(3).
[0658] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.74-1.83
(m, 1H), 2.04-2.10 (m, 1H), 3.12-3.18 (m, 1H), 3.64 (dd, J=5.2, 8.0
Hz, 1H), 3.79 (d, J=7.6 Hz, 1H), 3.94-4.05 (m, 2H), 4.15 (dd,
J=2.0, 8.0 Hz, 1H), 6.22 (s, 1H), 6.96 (dd, J=8.4, 11.6 Hz, 1H),
7.43 (ddd, J=2.8, 4.4, 8.4 Hz, 1H), 8.09 (dd, J=2.4, 6.8 Hz,
1H).
(2) Synthesis of
(.+-.)-[(2R*,4R*,5S*)-5-amino-5-(5-bromo-2-fluorophenyl)-2-trifluoromethy-
l-tetrahydropyran-4-yl]methanol
[0659] The title compound (390 mg) was obtained from
(.+-.)-(3aR*,5R*,7aS*)-7a-(5-bromo-2-fluorophenyl)-5-trifluoromethylhexah-
ydropyrano[3,4-c]isoxazole (484 mg) according to Preparation
Example 1-(4).
[0660] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.86-1.92
(m, 1H), 2.19-2.30 (m, 1H), 2.37-2.42 (m, 1H), 3.41 (dd, J=3.2,
11.6 Hz, 1H), 3.51 (d, J=12.4 Hz, 1H), 3.43 (dd, J=3.2, 12.0 Hz,
1H), 4.00-4.05 (m, 1H), 4.23 (dd, J=2.0, 11.2 Hz, 1H), 6.97 (dd,
J=8.4, 12.0 Hz, 1H), 7.45 (ddd, J=2.4, 4.4, 8.8 Hz, 1H), 7.84 (dd,
J=2.4, 6.8 Hz, 1H).
(3) Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,6R*,8aS*)-8a-(5-bromo-2-fluor-
ophenyl)-6-trifluoromethyl-4.4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanapht-
halen-2-yl]amine
[0661] Benzoyl isothiocyanate (156 .mu.l) was added to a solution
of
(.+-.)-[(2R*,4R*,5S*)-5-amino-5-(5-bromo-2-fluorophenyl)-2-trifluoromethy-
ltetrahydropyran-4-yl]methanol (390 mg) in dichloromethane (10 ml),
and the mixture was stirred at room temperature overnight. The
solvent was evaporated under reduced pressure and the residue was
purified by silica gel chromatography. The resulting intermediate
was dissolved in methanol (50 ml). Concentrated hydrochloric acid
(1.0 ml) was added and the mixture was heated under reflux for five
hours. When the reaction was completed, the reaction solution was
returned to room temperature, and the solvent was evaporated under
reduced pressure. Methanol (50 ml) and DBU (500 .mu.l) were added
to the residue, followed by heating under reflux for four hours.
When the reaction was completed, the reaction solution was returned
to room temperature, and the solvent was evaporated under reduced
pressure. The residue was purified by NH-silica gel column
chromatography. The resulting intermediate was dissolved in THF (10
ml). Di-tert-butyl dicarbonate (458 mg) and DMAP (385 mg) were
added and the mixture was stirred at room temperature overnight.
The solvent was evaporated under reduced pressure and the residue
was purified by silica gel column chromatography to obtain the
title compound (138 mg).
[0662] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.55 (s,
18H), 1.71-1.75 (m, 1H), 2.29 (ddd, J=3.2, 12.0, 24.8 Hz, 1H), 2.73
(dd, J=2.8, 12.8 Hz, 1H), 3.04-3.13 (m, 2H), 4.00-4.13 (m, 3H),
6.94 (dd, J=8.8, 12.4 Hz, 1H), 7.41 (ddd, J=2.4, 4.4, 8.8 Hz, 1H),
7.82 (dd, J=2.8, 7.2 Hz, 1H).
Preparation Example 17
Synthesis of
N,N-di(tert-butyloxycarbonyl)-[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-
-fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]am-
ine
##STR00051##
[0663] (1) Synthesis of
(3aR,5R,7aS)-5-benzyloxymethyl-7a-(5-bromo-2-fluorophenyl)hexahydropyrano-
[3,4-c]isoxazole
[0664] THF (10 ml) was added to a solution of
1,3-dibromo-4-fluorobenzene (4.31 g) in toluene (100 ml). The
mixture was cooled to -78.degree. C. and n-butyllithium (2.63 M,
6.15 ml) was added dropwise. After stirring at the same temperature
for one hour, a solution of
(3aR,5R)-5-benzyloxymethyl-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole
obtained in Preparation Example 13-(4) (2.00 g) in toluene-THF
(10:1) (20 ml) and a boron trifluoride-diethyl ether complex (2.03
ml) were added dropwise at the same time. After stirring at the
same temperature for two hours, a saturated ammonium chloride
solution was added to terminate the reaction. The aqueous layer was
extracted with ethyl acetate, and the organic layer was dried over
anhydrous magnesium sulfate. The solvent was evaporated under
reduced pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (2.74 g).
[0665] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.47-1.57
(m, 1H), 1.85 (ddd, J=1.6, 6.8, 14.0 Hz, 1H), 3.07-3.12 (m, 1H),
3.47-3.59 (m, 3H), 3.72 (d, J=7.6 Hz, 1H), 3.82-3.88 (m, 2H), 4.11
(dd, I=2.0, 13.2 Hz, 1H), 4.56 (d, J=12.0 Hz, 1H), 4.63 (d, J=12.0
Hz, 1H), 6.26 (s, 1H), 6.92 (dd, J=8.4, 10.0 Hz, 1H), 7.30-7.41 (m,
6H), 8.09 (dd, I=2.4, 6.8 Hz, 1H).
(2) Synthesis of
[(2R,4R,5S)-5-amino-2-benzyloxymethyl-5-(5-bromo-2-fluorophenyl)tetrahydr-
opyran-4-yl]methanol
[0666] Zinc powder (4.24 g) was added to a solution of
(3aR,5R,7aS)-5-benzyloxymethyl-7a-(5-bromo-2-fluorophenyl)hexahydropyrano-
[3,4-c]isoxazole (2.74 g) in acetic acid (40 ml). After stiffing at
room temperature overnight, the insoluble matter was removed by
filtration through celite. The solvent was evaporated under reduced
pressure and ice was added to the residue, followed by
neutralization with a 5 N sodium hydroxide solution. The aqueous
layer was extracted with dichloromethane, and the organic layer was
dried over anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure and the residue was purified by silica gel
column chromatography to obtain the title compound (2.22 g).
[0667] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.63-1.67
(m, 1H), 1.95-2.05 (m, 1H), 2.31-234 (m, 1H), 3.35 (dd, J=3.2, 11.6
Hz, 1H), 3.48 (d, J=11.2 Hz, 1H), 3.53-3.64 (m, 3H), 3.83-3.87 (m,
1H), 4.21 (dd, J=2.0, 11.2 Hz, 1H), 4.57-4.67 (m, 2H), 6.95 (dd,
I=9.2, 12.0 Hz, 1H), 7.24-7.37 (m, 5H), 7.41 (ddd, J=2.8, 4.4, 9.2
Hz, 1H), 7.80 (dd, J=2.4, 6.8 Hz, 1H).
(3) Synthesis of
(4aR,6R,8aS)-6-benzyloxymethyl-8a-(5-bromo-2-fluorophenyl)-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-aza-naphthalen-2-ylamine
[0668]
[(2R,4R,5S)-5-Amino-2-benzyloxymethyl-5-(5-bromo-2-fluorophenyl)tet-
rahydropyran-4-yl]methanol (2.22 g) was dissolved in
dichloromethane (30 ml), and benzoyl isothiocyanate (776 .mu.l) was
added. The mixture was stirred at room temperature for five hours,
and then the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
an intermediate. The resulting intermediate was dissolved in
methanol (50 ml), and concentrated hydrochloric acid (2 ml) was
added. The mixture was heated under reflux for six hours and then
cooled to room temperature. The solvent was evaporated under
reduced pressure. Methanol (30 ml) and DBU (2 ml) were added to the
residue, followed by heating under reflux for three hours. The
reaction solution was cooled to room temperature, and the solvent
was evaporated under reduced pressure. The residue was purified by
NH-silica gel column chromatography to obtain the title compound
(2.30 g).
[0669] .sup.1H-NMR. (400 MHz, CDCl.sub.3) .delta. (ppm): 1.50-1.54
(m, 1H), 1.74-1.77 (m, 1H), 2.58-2.60 (m, 1H), 2.90-2.99 (m, 2H),
3.46 (dd, J=4.4, 10.0 Hz, 1H), 3.62 (dd, J=6.4, 10.0 Hz, 1H), 3.80
(d, I=10.8 Hz, 1H), 3.85-3.90 (m, 1H), 4.08-4.11 (m, 1H), 4.54-4.64
(m, 2H), 6.91 (dd, J=8.4, 12.0 Hz, 1H), 7.27-7.38 (m, 6H), 7.45
(dd, I=2.4, 6.8 Hz, 1H).
(4) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0670] Concentrated hydrochloric acid (20 ml) was added to
(4aR,6R,8aS)-6-benzyloxymethyl-8a-(5-bromo-2-fluorophenyl)-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine (2.20 g), and the
mixture was heated under reflux for two hours. The reaction
solution was returned to room temperature, and ice was added to the
reaction mixture. The mixture was neutralized with 5 N sodium
hydroxide, and the generated solid was collected by a glass filter.
The solid was dried under reduced pressure and then dissolved in
THF (138 ml). Triethylamine (5.0 ml) and di-tert-butyl dicarbonate
(2.06 g) were added and the mixture was stirred at room temperature
for six hours. The solvent was evaporated under reduced pressure
and the residue was purified by silica gel column chromatography to
obtain the title compound (1.24 g).
[0671] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.56-1.59 (m, 1H), 1.85-1.94 (m, 1H), 2.55 (dd, J=2.8, 12.8
Hz, 1H), 2.93 (dd, J=4.0, 13.2 Hz, 1H), 3.00-3.10 (m, 1H),
3.65-3.66 (m, 2H), 3.77-3.80 (m, 2H), 4.09-4.13 (m, 1H), 6.97 (dd,
J=8.4, 12.0 Hz, 1H), 7.38-7.45 (m, 2H).
(5) Synthesis of tert-butyl
[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-fluoromethyl-a,5,6,8,8a-hexah-
ydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0672] [Bis(2-methoxyethyl)amino]sulfur trifluoride (155 .mu.l) was
added dropwise to a solution of tert-butyl
[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-hydroxymethyl-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (200 mg) in
dichloromethane (5.0 ml) at -78.degree. C. The mixture was stirred
overnight with gradual heating to room temperature. A sodium
bicarbonate solution was added to the reaction mixture to terminate
the reaction. The aqueous layer was extracted with ethyl acetate,
and the organic layer was dried over anhydrous magnesium sulfate.
The solvent was evaporated under reduced pressure and the residue
was purified by silica gel column chromatography to obtain the
title compound (145 mg).
[0673] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.53 (s,
9H), 1.57-1.60 (m, 1H), 1.87-1.96 (m, 1H), 2.56 (dd, J=3.2, 12.8
Hz, 1H), 2.94 (dd, J=4.0, 12.8 Hz, 1H), 3.04-3.07 (m, 1H), 3.79 (d,
J=11.6 Hz, 1H), 3.92-3.97 (m, 1H), 4.10-4.13 (m, 1H), 4.34-4.54 (m,
2H), 6.97 (dd, J=8.4, 11.6 Hz, 1H), 7.37-7.44 (m, 2H).
(6) Synthesis of
N,N-di(tert-butyloxycarbonyl)-[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-
-fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]am-
ine
[0674] Di-tert-butyl dicarbonate (185 mg) and DMAP (69.1 mg) were
added to a solution of tert-butyl
[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-fluoromethyl-4,4a,5,6,8,8a-he-
xahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (135 mg) in THF
(30 ml). The mixture was stirred at room temperature for two hours,
and then the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (121 mg).
[0675] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.55-1.56
(m, 19H), 1.95-2.05 (m, 1H), 2.69 (dd, J=2.8, 12.8 Hz, 1H),
3.05-3.12 (m, 2H), 3.92-4.00 (m, 1H), 4.01 (d, 0.1=10.8 Hz, 1H),
4.09 (dd, J=2.4, 11.6 Hz, 1H), 4.30-4.58 (m, 2H), 6.93 (dd, J=8.4,
12.0 Hz, 1H), 7.39 (ddd, J=2.4, 4.4, 8.8 Hz, 1H), 7.80 (dd, J=2.8,
7.6 Hz, 1H).
Preparation Example 18
Synthesis of
(.+-.)--N-benzoyl-N-(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(5-bromo-2-fl-
uorophenyl)-4.4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amin-
e
##STR00052##
[0676] (1) Synthesis of
(.+-.)-(3aR*,7aS*)-7a-(5-bromo-2-fluorophenyl)-hexahydropyrano[3,4-c]isoz-
azole
[0677] 1,3-Dibromo-4-fluorobenzene (837 mg) was dissolved in a
toluene-THF (10:1) mixture (15 ml). The mixture was cooled to
-78.degree. C. and n-butyllithium (2.64 M, 1.19 ml) was added
dropwise. After stirring at the same temperature for one hour, a
solution of (.+-.)-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole
obtained in Preparation Example 1-(2) (200 mg) in toluene-THF
(10:1) (5.0 ml) and a boron trifluoride-diethyl ether complex (394
pd) were added dropwise at the same time. After stirring at the
same temperature for three hours, the reaction was terminated with
an ammonium chloride solution. The aqueous layer was extracted with
ethyl acetate, and the organic layer was washed with water and
brine. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (365 mg).
[0678] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.76-1.91
(m, 2H), 3.03-3.08 (m, 1H), 3.61-3.77 (m, 4H), 4.00-4.06 (m, 2H),
6.28 (s, 1H), 6.93 (dd, J=8.8, 11.6 Hz, 1H), 7.37-7.41 (m, 1H),
8.09 (dd, J=2.4, 6.8 Hz, 1H).
(2) Synthesis of
(.+-.)-N-[(4aR*,8aS*)-8a-(5-bromo-2-fluorophenyl)-4,4a,6,8,8a-hexahydro-7-
-oxa-3-thia-1-azanaaphthalen-2-yl]benzamide
[0679] Zinc powder (759 mg) was added to a solution of
(.+-.)-(3aR*,7aS*)-7a-(5-bromo-2-fluorophenyl)hexahydropyrano[3,4-c]isoxa-
zole (350 mg) in acetic acid (6.73 ml). After stirring at room
temperature overnight, the insoluble matter was removed by
filtration through celite. The solvent was evaporated under reduced
pressure, and the resulting residue was neutralized with 5 N sodium
hydroxide in an ice bath. The aqueous layer was extracted with
ethyl acetate, and the organic layer was washed with brine. The
organic layer was dried over anhydrous magnesium sulfate, and the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain an
intermediate (300 mg).
[0680] Benzoyl isothiocyanate (1334 was added to a solution of the
resulting intermediate in dichloromethane (10 ml), and the mixture
was stirred at room temperature overnight. The solvent was
evaporated under reduced pressure. Methanol (10 ml) and
concentrated hydrochloric acid (several drops) were added to the
resulting residue, and the mixture was heated under reflux for two
hours. The reaction solution was returned to room temperature, and
the solvent was evaporated under reduced pressure. The resulting
residue was neutralized with a sodium bicarbonate solution, and the
aqueous layer was extracted with ethyl acetate. The organic layer
was washed with brine and dried over anhydrous magnesium sulfate.
The solvent was evaporated under reduced pressure and the residue
was purified by NH-silica gel column chromatography to obtain the
title compound (211 mg).
[0681] ESI-MS m/z 449 [M.sup.++H]
(3) Synthesis of
(.+-.)--N-benzoyl-N-(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(5-bromo-2-fl-
uorophenyl)-4.4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amin-
e
[0682] DMAP (86.1 mg) and di-tert-butyl dicarbonate (123 mg) were
added to a solution of
(.+-.)-N-[(4aR*,8aS*)-8a-(5-bromo-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-
-7-oxa-3-thia-1-azanaphthalen-2-yl]benzamide (211 mg) in THF (10
ml). The mixture was stirred at room temperature overnight, and
then the solvent was evaporated under reduced pressure. The residue
was purified by silica gel column chromatography to obtain the
title compound (229 mg).
[0683] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.34 (s,
9H), 1.37-1.49 (m, 1H), 2.18-2.27 (m, 1H), 2.70 (dd, J=2.8, 12.8
Hz, 1H), 2.93-2.98 (m, 1H), 3.08 (dd, J=3.6, 12.8 Hz, 1H),
3.62-3.67 (m, 1H), 3.66 (d, J=10.8 Hz, 1H), 4.06-4.08 (m, 2H), 6.94
(dd, J=8.4, 12.0 Hz, 1H), 7.38-7.47 (m, 3H), 7.52-7.56 (m, 1H),
7.75-7.78 (m, 2H), 7.93 (dd, J=2.4, 6.8 Hz, 1H).
Preparation Example 19
Synthesis of
(+1-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-aminothiophen-2-yl)--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00053## ##STR00054##
[0684] (1) Synthesis of
(.+-.)-(3aR*,7aS*)-7a-(4-bromothiophen-2-yl)-hexahydropyrano[3,4-c]isoxaz-
ole
[0685] n-Butyllithium (2.63 M, 2.99 ml) was added dropwise to a
solution of 2,4-dibromothiophene (2.00 g) in toluene-THF (10:1) (22
ml) at -78.degree. C. After stirring at the same temperature for
one hour, a solution of
(.+-.)-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole obtained in
Preparation Example 1-(2) (500 mg) in toluene-THF (10:1) (10 ml)
and a boron trifluoride-diethyl ether complex (990 .mu.l) were
added dropwise at the same time. After stirring at the same
temperature for two hours, an ammonium chloride solution was added
to terminate the reaction. The aqueous layer was extracted with
ethyl acetate, and the organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (700 mg).
[0686] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.74-1.92
(m, 2H), 2.82-2.87 (m, 1H), 3.58-4.03 (m, 6H), 6.96 (d, J=1.6H,
1H), 7.16 (d, J=1.6 Hz, 1H).
(2) Synthesis of
(.+-.)-(4aR*,8aS*)-8a-(4-bromothiophen-2-yl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-ylamine
[0687] Zinc powder (1.58 g) was added to a solution of
(.+-.)-(3aR*,7aS*)-7a-(4-bromothiophen-2-yl)hexahydropyrano[3,4-c]isoxazo-
le (700 mg) in acetic acid (20 ml). After stirring at room
temperature overnight, the insoluble matter was removed by
filtration through celite. The solvent was evaporated under reduced
pressure, and the residue was neutralized with ice and 5 N sodium
hydroxide. The aqueous layer was extracted with ethyl acetate, and
the organic layer was washed with brine. The organic layer was
dried over anhydrous magnesium sulfate, and the solvent was
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography. The resulting intermediate was
dissolved in dichloromethane (20 ml), and benzoyl isothiocyanate
(324 .mu.l) was added. The mixture was stirred at room temperature
overnight, and then the solvent was evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography. The resulting intermediate was dissolved in
methanol (20 ml), and concentrated hydrochloric acid (several
drops) was added. The mixture was heated under reflux for six hours
and then cooled to room temperature. The solvent was evaporated
under reduced pressure. The residue was dissolved in methanol (20
ml) and DBU (1.00 ml) was added, followed by heating under reflux
for eight hours. The solvent was evaporated under reduced pressure
and the residue was purified by NH-silica gel column chromatography
to obtain the title compound (770 mg).
[0688] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.45-1.48
(m, 1H), 2.14 (ddd, J=4.8, 12.4, 26.0 Hz, 1H), 2.24-2.30 (m, 1H),
2.62 (dd, J=3.2, 12.4 Hz, 1H), 3.26 (dd, J=3.6, 12.4 Hz, 1H), 3.54
(d, J=11.6 Hz, 1H), 3.57-3.64 (m, 1H), 3.91 (d, J=11.2 Hz, 1H),
4.08-4.12 (m, 1H), 6.76 (d, J=1.2 Hz, 1H), 7.12 (d, J=1.2 Hz,
1H).
(3) Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-bromothiophen-2-y-
l)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0689] DMAP (847 mg) and di-tert-butyl dicarbonate (1.51 g) were
added to a solution of
(.+-.)-(4aR*,8aS*)-8a-(4-bromothiophen-2-yl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-ylamine (770 mg) in THF (10 ml). The
mixture was stirred at room temperature for three hours, and then
the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain the title
compound (1.07 g).
[0690] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.50-1.51
(m, 1H), 1.53 (s, 18H), 2.24 (ddd, J=4.4, 12.4, 25.2 Hz, 1H),
2.33-2.38 (m, 1H), 2.68 (dd, J=3.2, 12.8 Hz, 1H), 3.33 (dd, J=3.6,
13.2 Hz, 1H), 3.56-3.63 (m, 2H), 4.04 (dd, J=4.4, 11.6 Hz, 1H),
4.11 (d, J=11.6 Hz, 1H), 6.54 (d, J=1.6 Hz, 1H), 7.16 (d, J=1.6 Hz,
1H).
(4) Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aR*)-8a-[4-(4,4,5,5-tetramet-
hyl-[1,3,2]dioxaborolan-2-yl)-thiophen-2-yl]-4,4a,5,6,8,8a-hexahydro-7-oxa-
-3-thia-1-azanaphthalen-2-yl]amine
[0691] Bis(pinacolato)diboron (2.15 g), potassium acetate (663 mg)
and a 1,1'-bis(diphenylphosphino)ferrocene
palladium-dichloromethane complex (138 mg) were added to a solution
of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-bromothiophen-2-y-
l)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
(900 mg) in DMF (46.9 ml). After replacement with nitrogen, the
mixture was stirred at 80.degree. C. for six hours. The reaction
solution was returned to room temperature and diluted with ethyl
acetate. The organic layer was washed with water and dried over
anhydrous magnesium sulfate. The solvent was evaporated under
reduced pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (790 mg).
[0692] ESI-MS m/z 581 [M.sup.++H]
(5) Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aR*)-8a-(4-azidothiophen-2-y-
l)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0693] Sodium azide (177 mg) and copper (II) acetate (99.2 mg) were
added to a solution of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aR*)-8a-[4-(4,4,5,5-tetramet-
hyl-[1,3,2]dioxaborolan-2-yl)-thiophen-2-yl]-4,4a,5,6,8,8a-hexahydro-7-oxa-
-3-thia-1-azanaphthalen-2-yl]amine (790 mg) in methanol (88 ml).
The mixture was stirred at room temperature overnight, and then the
excess of methanol was evaporated under reduced pressure. An
ammonium chloride solution was added to the residue, and the
aqueous layer was with ethyl acetate. The organic layer was dried
over anhydrous magnesium sulfate, and the solvent was evaporated
under reduced pressure. The residue was purified by NH-silica gel
column chromatography to obtain the title compound (503 mg).
[0694] ESI-MS m/z 518 [M.sup.++H]
(6) Synthesis of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-aminothiophen-2-y-
l)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0695] Zinc powder (133 mg) and ammonium formate (320 mg) were
added to a solution of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aR*)-8a-(4-azidothiophen-2-y-
l)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
(503 mg) in methanol (76.2 ml). The mixture was stirred at room
temperature overnight, and then the solvent was evaporated under
reduced pressure at room temperature or lower. Water was added to
the residue, and the aqueous layer was extracted with ethyl
acetate. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
the title compound (325 mg).
[0696] ESI-MS m/z 518 [M.sup.++Na]
(7) Synthesis of
(+)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-aminothiophen-2-yl)--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0697]
(.+-.)-N,N-Di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-aminothioph-
en-2-yl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
(32.5 mg) was purified by CHIRALCEL.TM. OJ-H (mobile phase:
hexane:ethanol=8:2, flow rate: 10 ml/min), and the fraction with a
retention time of 14.9 to 23.5 minutes was collected to obtain the
title compound. The same operation was repeated to obtain the title
compound (112 mg) from the raw material (325 mg).
[0698] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.46-1.48
(m, 1H), 1.53 (s, 18H), 2.16-2.33 (m, 2H), 2.64 (dd, J=2.8, 12.8
Hz, 1H), 3.39 (dd, J=3.6, 12.8 Hz, 1H), 3.55-3.62 (m, 1H), 3.65 (d,
J=11.2 Hz, 1H), 4.03 (dd, J=4.8, 11.6 Hz, 1H), 4.13 (d, J=2.8 Hz,
1H), 6.07 (d, J=2.0 Hz, 1H), 6.67 (d, J=2.0 Hz, 1H).
Preparation Example 20
Synthesis of
N,N-di-(tert-butyloxycarbonyl)-[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)--
6-benzyloxymethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-y-
l]amine
##STR00055##
[0700] Di-tert-butyl dicarbonate (113 mg) and DMAP (63.0 mg) were
added to a solution of
(4aR,6R,8aS)-6-benzyloxymethyl-8a-(5-bromo-2-fluorophenyl)-4,4a,5,6,8,8a--
hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine obtained by the
method of Preparation Example 17-(3) (80.0 mg) in THF (5.0 ml). The
mixture was stirred at room temperature overnight, and then the
solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography to obtain the title
compound (95.0 mg).
[0701] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.54-1.56
(m, 19H), 1.88-1.98 (m, 1H), 2.65-2.67 (m, 1H), 2.99-3.10 (m, 2H),
3.44 (dd, J=4.4, 9.6 Hz, 1H), 3.62 (dd, J=10.0, 16.8 Hz, 1H),
3.85-3.90 (m, 1H), 3.99-4.10 (m, 2H), 4.52-4.64 (m, 2H), 6.92 (dd,
J=8.4, 12.0 Hz, 1H), 7.28-7.39 (m, 6H), 7.79 (dd, J=2.4, 7.2 Hz,
1H).
Preparation Example 21
Synthesis of tert-butyl
(.+-.)-[(4aR*,8aS*)-8a-(6-amino-2,2-difluorobenzo[1,3]dioxol-4-yl)-4,4a,5-
,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
##STR00056##
[0702] (1) Synthesis of
(.+-.)-(3aR*,7aS*)-7a-(2,2-difluorobenzo[1,3]dioxol-4-yphexahydropyrano[3-
,4-c]isoxazole
[0703] THF (2.0 ml) was added to a solution of
4-bromo-2,2-difluoro-1,3-benzodioxol (1.96 g) in toluene (20 ml).
The mixture was cooled to -78.degree. C., and a solution of
(.+-.)-3,3a,4,5-tetrahydro-7H-pyrano[3,4-c]isoxazole obtained in
Preparation Example 1-(2) (500 mg) in toluene-THF (10:1) (10 ml)
and a boron trifluoride-diethyl ether complex (990 .mu.l) were
added dropwise at the same time. After stirring at the same
temperature for two hours, an ammonium chloride solution was added
to terminate the reaction. The aqueous layer was extracted with
ethyl acetate, and the organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (873 mg).
[0704] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.75-1.92
(m, 2H), 3.04-3.09 (m, 1H), 3.63-3.85 (m, 4H), 3.99 (d, J=12.8 Hz,
1H), 4.03-4.06 (m, 1H), 6.30 (s, 1H), 7.01 (dd, J=1.2, 8.4 Hz, 1H),
7.10 (t, J=8.4 Hz, 1H), 7.60 (dd, J=1.2, 8.0 Hz, 1H).
(2) Synthesis of
(.+-.)-[(3S*,4R*)-3-amino-3-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-tetrahyd-
ropyran-4-yl]methanol
[0705] Zinc powder (2.01 g) was added to a solution of
(.+-.)-(3aR*,7aS*)-7a-(2,2-difluoro-benzo[1,3]dioxol-4-yl)-hexahydropyran-
o[3,4-c]isoxazole (875 mg) in acetic acid (30 ml), and the mixture
was stirred at room temperature overnight. The insoluble matter was
removed by filtration through celite, and the solvent was
evaporated under reduced pressure. Ice was added to the residue,
followed by neutralization with a 5 N sodium hydroxide solution.
The aqueous layer was extracted with dichloromethane, and the
organic layer was dried over anhydrous magnesium sulfate. The
solvent was evaporated under reduced pressure and the residue was
purified by silica gel column chromatography to obtain the title
compound (661 mg).
[0706] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.62-1.66
(m, 1H), 2.14-2.20 (m, 1H), 2.22-2.31 (m, 1H), 3.38 (dd, J=2.4,
11.2 Hz, 2H), 3.56-3.68 (m, 2H), 4.04 (d, J=11.6 Hz, 1H), 4.17 (dd,
J=4.4, 11.2 Hz, 1H), 7.05 (dd, J=1.2, 8.0, 1H), 7.14 (t, J=8.0 Hz,
1H), 7.32 (dd, J=1.2, 8.0 Hz, 1H).
(3) Synthesis of
(.+-.)-(4aR*,8aS*)-8a-(2,2-difluorobenzo[1,3]dioxol-4-yl)-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine
[0707] Benzoyl isothiocyanate (372 .mu.l) was added to a solution
of
(.+-.)-[(3S*,4R*)-3-amino-3-(2,2-difluorobenzo[1,3]dioxol-4-yl)tetrahydro-
pyran-4-yl]methanol (661 mg) in dichloromethane (9.53 ml). The
mixture was stirred at room temperature for three hours, and then
the solvent was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography. The resulting
intermediate was dissolved in methanol (20 ml). Concentrated
hydrochloric acid (five drops) was added and the mixture was heated
under reflux for five hours. The reaction solution was cooled to
room temperature, and the solvent was evaporated under reduced
pressure. The residue was dissolved in methanol (20 ml) and DBU
(700 .mu.l) was added, followed by heating under reflux for five
hours. The reaction solution was cooled to room temperature, and
the solvent was evaporated under reduced pressure. The residue was
purified by NH-silica gel column chromatography to obtain the title
compound (350 mg).
[0708] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.48
(m, 1H), 2.08-2.19 (m, 1H), 2.64 (dd, J=2.8, 12.4 Hz, 1H),
2.74-2.80 (m, 1H), 2.98 (dd, J=4.4, 12.4 Hz, 1H), 3.69 (ddd, J=2.4,
11.6, 12.8 Hz, 1H), 3.79 (d, 11.2 Hz, 1H), 3.93 (d, J=10.8 Hz, 1H),
4.10 (dd, J=5.2, 11.2 Hz, 1H) 6.99 (dd, J=2.0, 7.2 Hz, 1H),
7.03-7.09 (m, 2H).
(4) Synthesis of tert-butyl
(.+-.)-[(4aR*,8aS*1-8a-(2,2-difluoro-6-nitrobenzo[1,3]dioxol-4-yl)-4,4a
5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0709] Fuming nitric acid (7.60 .mu.l) was added to a solution
(.+-.)-(4aR*,8aS*)-8a-(2,2-difluorobenzo[1,3]dioxol-4-yl)-4,4a,5,6,8,8a-h-
exahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine (50.0 mg) in TFA
(1.0 ml) in an ice bath. Then, concentrated sulfuric acid (0.5 ml)
was added dropwise. After stirring at the same temperature for one
hour, the reaction mixture was poured into ice to terminate the
reaction. The mixture was neutralized with 5 N hydroxide. The
aqueous layer was extracted with dichloromethane, and the organic
layer was dried over anhydrous magnesium sulfate. The solvent was
evaporated under reduced pressure to obtain an intermediate. The
resulting intermediate was dissolved in THF (10 ml). Di-tert-butyl
dicarbonate (66.8 mg) and triethylamine (64.5 .mu.l) were added and
the mixture was stirred at room temperature for one hour. Further,
di-tert-butyl dicarbonate (130 mg) and triethylamine (1.00 ml) were
added and the mixture was stirred at room temperature overnight.
The solvent was evaporated under reduced pressure and the residue
was purified by silica gel column chromatography to obtain the
title compound (62.0 mg).
[0710] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.51 (s,
9H), 1.55-1.59 (m, 1H), 2.15-2.25 (m, 1H), 2.63-2.66 (m, 1H),
2.87-2.89 (m, 2H), 3.65-3.71 (m, 1H), 3.76-3.84 (m, 2H), 4.10-4.15
(m, 1H), 7.93 (d, J=2.0 Hz, 1H), 8.05 (d, J=2.0 Hz, 1H).
[0711] ESI-MS m/z 496 [M+Na]
(5) Synthesis of tert-butyl
(.+-.)-[(4aR*,8aS*)-8a-(6-amino-2,2-difluorobenzo[1.3]dioxol-4-yl)-4,4a,6-
,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate
[0712] Iron powder (7.09 mg) and a saturated ammonium chloride
solution (1.0 ml) were added to a solution of tert-butyl
(.+-.)-[(4aR*,8aS*)-8a-(2,2-difluoro-6-nitrobenzo[1,3]dioxol-4-yl)-4,4a,5-
,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (60.0
mg) in ethanol (20 ml), and the mixture was heated under reflux for
30 minutes. The reaction solution was returned to room temperature
and the insoluble matter was removed by filtration through celite.
The solvent was evaporated under reduced pressure and the residue
was purified by silica gel column chromatography to obtain the
title compound (50.0 mg).
[0713] ESI-MS m/z 444 [M.sup.++H]
Preparation Example 22
Synthesis of 5-(2-methoxyethoxy)pyrazine-2-carboxylic acid
##STR00057##
[0714] (1) Synthesis of 2-methoxyethyl
5-(2-methoxyethoxy)-pyrazine-2-carboxylate
[0715] 60% sodium hydride (27.8 mg) was added to a solution of
2-methoxyethanol (50.2 .mu.l) in DMF (1 ml) under ice-cooling,
followed by stirring for 10 minutes. A solution of methyl
5-chloropyrazine-2-carboxylate (100 mg) in DMF (1 ml) was added to
the reaction solution at the same temperature, followed by stirring
for one hour and 50 minutes. Acetic acid (50.0 .mu.l) and water
were added to the reaction solution, followed by extraction with
ethyl acetate. The organic layer was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (19.7 mg).
[0716] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 3.24 (s,
3H), 3.45 (s, 3H), 3.73-3.81 (m, 4H), 4.53-4.61 (m, 4H), 8.34-8.38
(m, 1H), 8.86-8.90 (m, 1H).
(2) Synthesis of 5-(2-methoxyethoxy)pyrazine-2-carboxylic acid
[0717] Potassium trimethylsilanolate (14.8 mg) was added to a
solution of the compound obtained in the previous step (19.7 mg) in
tetrahydrofuran (1 ml), and the mixture was stirred at room
temperature for one hour. The reaction solution was concentrated
under reduced pressure. Water and ethyl acetate were added to the
residue, and the aqueous layer was separated. 5 M hydrochloric acid
was added to the aqueous layer, followed by extraction with
chloroform. The organic layer was concentrated under reduced
pressure to obtain the title compound (13.2 mg).
[0718] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 3.45 (s,
3H), 3.77-3.82 (m, 2H), 4.60-4.64 (m, 2H), 8.24 (d, J=1.4 Hz, 1H),
8.96 (d, J=1.4 Hz, 11-1).
Example 1
Synthesis of
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
##STR00058##
[0720] Oxalyl chloride (140 .mu.l) was added to a suspension of
5-cyanopyridine-2-carboxylic acid (50 mg) in dichloromethane (2 ml)
under ice-cooling. Tetrahydrofuran (4 ml) was further added at the
same temperature, and the solid was completely dissolved. After
confirming completion of foaming, the solvent was evaporated under
reduced pressure. Tetrahydrofuran (5 ml) was added to the residue
to obtain an acid chloride solution. The acid chloride solution
prepared above (788 .mu.l) was added to a solution of tert-butyl
(-)-[(4aR*,8aS*)-8a-(5-amino-2-fluorophenyl)-4,4a,5,6,8,8a-hexahydro-7-ox-
a-3-thia-1-azanaphthalen-2-yl]carbamate (14.5 mg) in
tetrahydrofuran (5 ml) under ice-cooling. After adding pyridine
(500 .mu.l) at the same temperature, the mixture was heated to room
temperature and stirred for two hours. After completion of the
reaction, a sodium bicarbonate solution was added to the reaction
solution. The aqueous layer was extracted with ethyl acetate, and
the organic layer was dried over anhydrous magnesium sulfate. The
solvent was evaporated under reduced pressure to obtain an amide
compound. The resulting amide compound was dissolved in
dichloromethane (4 ml), and trifluoroacetic acid (1 ml) was added.
The mixture was stirred at room temperature for three hours, and
then ice was added. The aqueous layer was neutralized with a sodium
bicarbonate solution, followed by extraction with ethyl acetate.
The organic layer was dried over anhydrous magnesium sulfate, and
the solvent was evaporated under reduced pressure. The residue was
purified by NH-silica gel column chromatography to obtain the title
compound (8.0 mg).
[0721] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.45 (ddd,
J=2.0, 4.0, 13.6 Hz, 1H), 2.14 (m, 1H), 2.65 (dd, J=2.8, 12.4 Hz,
1H), 2.94 (ddd, J=4.0, 7.2, 11.6 Hz, 1H), 3.02 (dd, J=4.0, 12.0 Hz,
1H), 3.69 (m, 1H), 3.77 (d, J=10.8 Hz, 1H), 4.06 (dd, J=2.0, 10.8
Hz, 1H), 4.10 (m, 1H), 7.09 (dd, J=8.8, 11.6 Hz, 1H), 7.39 (dd,
J=2.8, 6.8 Hz, 1H), 8.01 (ddd, J=2.8, 4.4, 9.2 Hz, 1H), 8.20 (dd,
J=1.6, 8.0 Hz, 1H), 8.42 (dd, J=0.8, 8.0 Hz, 1H), 8.89 (dd, J=0.8,
2.0 Hz, 1H), 9.82 (s, 1H).
Example 2
Synthesis of
N-[348S*,8aR*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-8-
a-yl)-4-fluorophenyl]-5-fluoromethoxypyrazine-2-carboxamide
##STR00059##
[0723] The compound obtained in Preparation Example 2 (19.0 mg),
N,N-diisopropylethylamine (41.1 .mu.L) and PyBOP (102 mg) were
added to a solution of the compound obtained in Preparation Example
1 (30.0 mg) in dichloromethane (857 .mu.L). The reaction solution
was stirred at room temperature for 16 hours and 30 minutes. Then,
the reaction mixture was purified by silica gel column
chromatography to obtain an amide compound. The resulting amide
compound was dissolved in dichloromethane (643 .mu.L), and
trifluoroacetic acid (214 .mu.L) was added. The reaction solution
was allowed to stand at room temperature for one hour, and then the
solvent was evaporated under reduced pressure. A saturated sodium
bicarbonate solution was added to the residue, followed by
extraction with ethyl acetate. The organic layer was concentrated
under reduced pressure. The residue was purified by NH-silica gel
column chromatography to obtain the title compound (15.4 mg).
[0724] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.41-1.48
(m, 1H), 2.08-2.20 (m, 1H), 2.64 (dd, J=12.2, 3.5 Hz, 1H),
2.89-2.98 (m, 1H), 3.02 (dd, J=12.2, 5.0 Hz, 1H), 3.64-3.74 (m,
1H), 3.74-3.80 (m, 1H), 4.03-4.13 (m, 2H), 6.08-6.10 (m, 1H),
6.21-6.23 (m, 1H), 7.08 (dd, J=12.0, 8.8 Hz, 1H), 7.33 (dd, J=6.8,
2.8 Hz, 1H), 7.99-8.04 (m, 1H), 8.29 (d, J=1.2 Hz, 1H), 9.08 (d,
J=1.2 Hz, 1H), 9.47 (brs, 1H).
Example 3
Synthesis of
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-difluoromethoxypyrazine-2-carboxamide
##STR00060##
[0726] The title compound (14.0 mg) was obtained from the compound
obtained in Preparation Example 1 (18.0 mg) and
5-difluoromethoxypyrazine-2-carboxylic acid (24.9 mg) according to
the method of Example 2.
[0727] .sup.1H-NMR (400 MHz, CDCl.sub.3)) .delta. (ppm): 1.46-1.49
(m, 1H), 2.08-116 (m, 2H), 2.65-2.68 (m, 1H), 2.98-3.04 (m, 2H),
3.66-3.72 (m, 1H), 3.81-3.84 (m, 1H), 4.04-4.07 (m, 1H), 7.06-7.12
(m, 1H), 7.36-7.39 (m, 1H), 7.51 (t, J=71.6 Hz, 1H), 8.02-8.04 (m,
1H), 8.34 (s, 9.06 (s, 1H), 9.50 (s, 1H)
EXAMPLES 4 TO 5
[0728] The compounds of Examples 4 to 5 were synthesized below
according to Example 2 using the compound of Preparation Example
5-(9) and the corresponding carboxylic acids, as shown in the
following Table 1.
TABLE-US-00001 TABLE 1 Example 4 ##STR00061## Compound name:
N-[3-((4aR*,8aS*)-2-amino-
4,4,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-trifluoromethoxyphenyl]-5-cyanopyridine- 2-carboxamide
ESI-MS m/z 478 [M.sup.+ + H] Example 5 ##STR00062## Compound name:
N-[3-((8S*,8aS*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-trifluoromethoxyphenyl]-5- chloropyridine-2-carboxamide
ESI-MS m/z 487 [M.sup.+ + H]
EXAMPLES 6 TO 10
[0729] The compounds of Examples 6 to 10 were synthesized below
according to Example 2 using the compound of Preparation Example
6-(12) and the corresponding carboxylic acids, as shown in the
following Table 2.
TABLE-US-00002 TABLE 2 Example 6 ##STR00063## Compound name:
N-[3-((4aR*,6S*,8aS*)-2-amino-
6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
chloropyridine-2-carboxamide ESI-MS m/z 435 [M.sup.+ + H] Example 7
##STR00064## Compound name: N-[3-((4aR*,6S*,8aS*)-2-amino-
6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5- cyanopyridine-2-carboxamide
ESI-MS m/z 426 [M.sup.+ + H] Example 8 ##STR00065## Compound name:
N-[3-((4aR*,6S*,8aS*)-2-amino-
6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
trifluoromethylpyridine-2-carboxamide ESI-MS m/z 469 [M.sup.+ + H]
Example 9 ##STR00066## Compound name:
N-[3-((4aR*,6S*,8aS*)-2-amino-
6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyrazine-2-carboxamide ESI-MS m/z 468 [M.sup.+ + H]
Example 10 ##STR00067## Compound name:
N-[3-((4aR*,6S*,8aS*)-2-amino-
6-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
fluoromethoxypyrazine-2-carboxamide ESI-MS m/z 450 [M.sup.+ +
H]
EXAMPLES 11 TO 15
[0730] The compounds of Examples 11 to 15 were synthesized below
according to Example 2 using the compound of Preparation Example
7-(12) and the corresponding carboxylic acids, as shown in the
following Table 3.
TABLE-US-00003 TABLE 3 Example 11 ##STR00068## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-amino-6-
methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2- carboxamide
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.45-1.53 (m, 1H),
1.80-1.93 (m, 1H), 2.58-2.67 (m, 1H), 2.94-3.07 (m, 2H), 3.43 (s,
3H), 3.43-3.57 (m, 2H), 3.81-3.92 (m, 2H), 4.14-4.21 (m, 1H),
7.02-7.11 (m, 1H), 7.35-7.41 (m, 1H), 7.97-8.06 (m, 1H), 8.16-8.23
(m, 1H), 8.37-8.44 (m, 1H), 8.86-8.91 (m, 1H), 9.80 (brs, 1H).
ESI-MS m/z 456 [M.sup.+ + H] Example 12 ##STR00069## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-amino-6-
methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethylpyrazine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.45-1.54 (m, 1H), 1.79-1.92 (m, 1H),
2.58-2.67 (m, 1H), 2.94-3.07 (m, 2H), 3.42 (s, 3H), 3.43-3.48 (m,
1H), 3.50-3.57 (m, 1H), 3.82-3.92 (m, 2H), 4.13-4.20 (m, 1H), 6.79
(t, J = 54.6 Hz, 1H), 7.02-7.10 (m, 1H), 7.35-7.41 (m, 1H),
7.96-8.04 (m, 1H), 8.88-8.93 (m, 1H), 9.47-9.52 (m, 1H), 9.60 (brs,
1H). ESI-MS m/z 482 [M.sup.+ + H] Example 13 ##STR00070## Compound
name: N-[3-((4aR*,6R*,8aS*)-2-amino-6-
methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-chloropyridine-2-
carboxamide ESI-MS m/z 465 [M.sup.+ + H] Example 14 ##STR00071##
Compound name: N-[3-((4aR*,6R*,8aS*)-2-amino-6-
methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
fluoromethoxypyrazine-2-carboxamide ESI-MS m/z 480 [M.sup.+ + H]
Example 15 ##STR00072## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-amino-6-
methoxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyrazine-2-carboxamide ESI-MS m/z 498 [M.sup.+ +
H]
EXAMPLES 16 TO 30
[0731] The compounds of Examples 16 to 30 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 4.
TABLE-US-00004 TABLE 4 Example 16 ##STR00073## Compound name:
N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-cyanopyridine-2-carboxamide .sup.1H-NMR(400 MHz,
CDCl.sub.3) .delta. (ppm): 2.87(dd, J = 4.0, 12.4 Hz, 1H),
2.99-3.07(m, 1H), 3.17(dd, J = 2.8, 12.8 Hz, 1H), 3.53 (ddd, J =
4.8, 10.4, 10.4 Hz, 1H), 3.74(dd, J = 2.4, 11.2 Hz, 1H), 4.08(dd, J
= 2.0, 11.2 Hz, 1H), 4.26(dd, J = 5.6, 10.4 Hz, 1H), 4.18-5.01(m,
1H), 7.11(dd, J = 8.8, 11.6 Hz, 1H), 7.42(dd, J = 2.8, 6.8 Hz, 1H),
7.97(ddd, J = 2.8, 4.0, 8.4 Hz, 1H), 8.20(dd, J = 2.4, 8.0 Hz, 1H),
8.41(dd, J = 0.8, 8.0 Hz, 1H), 8.88(dd, J = 0.8, 2.0 Hz, 1H),
9.81(s, 1H). ESI-MS m/z 430 [M.sup.+ + H] Example 17 ##STR00074##
Compound name: N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide
.sup.1H-NMR(400 MHz, CDCl.sub.3) .delta. (ppm): 2.87(dd, J = 4.0,
12.8 Hz, 1H), 2.99-3.07(m, 1H), 3.17(dd, J = 3.2, 12.8 Hz, 1H),
3.50- 3.57(m, 1H) 3.74(dd, J = 2.4, 10.8 Hz, 1H), 4.08(dd, J = 2.0,
10.8 Hz, 1H), 4.27(dd, J = 5.6, 10.4 Hz, 1H), 4.80-5.00(m, 1H),
6.80(t, J = 54.4 Hz, 1H), 7.13(dd, J = 8.8, 11.6 Hz, 1H), 7.43(dd,
J = 2.4, 6.4 Hz, 1H), 7.95-7.99(m, 1H), 8.93(s, 1H), 9.52(s, 1H),
9.62(s, 1H). ESI-MS m/z 456 [M.sup.+ + H] Example 18 ##STR00075##
Compound name: N-[3-((4aS,5S,8aS)-2-amino-5-fluoro-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-chloropyridine-2-carboxamide ESI-MS m/z 439
[M.sup.+ + H] Example 19 ##STR00076## Compound name:
N-[3-((4aS,5S,8aS)-2-amino-5-
fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
trifluoromethylpyridine-2-carboxamide ESI-MS m/z 473 [M.sup.+ + H]
Example 20 ##STR00077## Compound name:
N-[3-((4aS,5S,8aS)-2-amino-5-
fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyridine-2-carboxamide ESI-MS m/z 471 [M.sup.+ + H]
Example 21 ##STR00078## Compound name:
N-[3-((4aS,5S,8aS)-2-amino-5-
fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-2-fluorophenyl]-5-
fluoromethoxypyrazine-2-carboxamide ESI-MS m/z 454 [M.sup.+ + H]
Example 22 ##STR00079## Compound name:
N-[3-((4aS,5S,8aS)-2-amino-5-
fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyrazine-2-carboxamide ESI-MS m/z 472 [M.sup.+ + H]
Example 23 ##STR00080## Compound name:
N-[3-((4aR*,5S*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
chloropyridine-2-carboxamide ESI-MS m/z 435 [M.sup.+ + H] Example
24 ##STR00081## Compound name: N-[3-((4aR*,5S*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5- cyanopyridine-2-carboxamide
ESI-MS m/z 426 [M.sup.+ + H] Example 25 ##STR00082## Compound name:
N-[3-((4aR*,5S*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyrazine-2-carboxamide ESI-MS m/z 468[M.sup.+ + H]
Example 26 ##STR00083## Compound name:
N-[3-((4aR*,5R*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
chloropyridine-2-carboxamide ESI-MS m/z 435 [M.sup.+ + H] Example
27 ##STR00084## Compound name: N-[3-((4aR*,5R*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5- cyanopyridine-2-carboxamide
ESI-MS m/z 426 [M.sup.+ + H] Example 28 ##STR00085## Compound name:
N-[3-((4aR*,5R*,8aS*)-2-amino-
5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethoxypyrazine-2-carboxamide ESI-MS m/z 468 [M.sup.+ + H]
Example 29 ##STR00086## Compound name:
N-[3-((4aR*,5R*,8aS*)-2-amino-5-
methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethylpyrazine-2-carboxamide ESI-MS m/z 452 [M.sup.+ + H]
Example 30 ##STR00087## Compound name:
N-[3-((4aS*,5R*,8aS*)-2-amino-5-
methoxy-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine- 2-carboxamide
ESI-MS m/z 442 [M.sup.+ H]
Example 31
Synthesis of
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
##STR00088##
[0732] (1) Synthesis of tert-butyl
(.+-.)-((2R*,4aR*,8aS*)-8a-{5-[(5-cyanopyridine-2-carbonyl-amino]-2-fluor-
ophenyl}-4-methyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-y-
l)-carbamate
[0733] PyBOP (357 mg) was added to a solution of the compound
obtained in Preparation Example 11-(10) (100 mg), the compound
obtained in Preparation Example 3-(2) (56 mg) and
N,N-diisopropylethylamine (143 .mu.L) in dichloromethane (5 mL),
and the mixture was stirred at room temperature for five hours. The
reaction solution was directly charged to a silica gel and purified
by silica gel column chromatography to obtain the title compound
(100 mg).
[0734] ESI-MS; m/z 526 [M.sup.++H].
(2) Synthesis of tert-butyl
(+)-((2R*,4aR*,8aS*1-8a-{5-[(5-cyanopyridine-2-carbonyl)-amino]-2-fluorop-
henyl}-4-methyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl)-
-carbamate
[0735] The compound obtained in Example 31-(1) was purified by
CHIRALPAK.TM. IB (mobile phase: hexane:ethanol=7:3, flow rate: 10
ml/min), and the fraction with a retention time of 23.4 to 26.7
minutes was collected to obtain the title compound. The same
operation was repeated to obtain the title compound (20 mg; >99%
ee) from the raw material (100 mg).
[0736] ESI-MS; m/z 526 [M.sup.++H].
(3) Synthesis of
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
[0737] TFA (1 mL) was added to a solution of the compound obtained
in Example 31-(2) (20 mg) in chloroform (2 mL), and the mixture was
stirred at room temperature for five hours. The reaction solution
was neutralized with saturated aqueous sodium bicarbonate.
Chloroform was added to the mixture, and the organic layer was
separated. The organic layer was dried over anhydrous magnesium
sulfate. The organic layer was concentrated under reduced pressure
to obtain the title compound (14 mg).
[0738] ESI-MS; m/z 426 [M.sup.++H].
Example 32
Synthesis of
N-[3-((2R*,4aR*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
-azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxami-
de
##STR00089##
[0739] (1) Synthesis of tert-butyl
(.+-.)-((2R*,4aR*,8aS*)-8a-{5-[(5-difluoromethylpyrazine-2-carbonyl)-amin-
o]-2-fluoro-phenyl}-4-methyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-aza-na-
phthalen-2-yl)-carbamate
[0740] The title compound (132 mg) was obtained from the compound
obtained in Preparation Example 11-(10) (100 mg) and the compound
obtained in Preparation Example 12-(5) (56 mg) according to Example
31-(1).
[0741] ESI-MS; m/z 552 [M.sup.++H].
(2) Synthesis of tert-butyl
(+)-((2R*,4aR*,8aS*)-8a-{5-[(5-difluoromethylpyrazine-2-carbonyl)-amino]--
2-fluoro-phenyl}-4-methyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphth-
alen-2-yl)-carbamate
[0742] The compound obtained in Example 32-(1) was purified by
CHIRALPAK.TM. IA (mobile phase: ethanol, flow rate: 10 ml/min), and
the fraction with a retention time of 10.8 to 13.5 minutes was
collected to obtain the title compound. The same operation was
repeated to obtain the title compound (52 mg; >99% ee) from the
raw material (130 mg).
[0743] ESI-MS; m/z 552 [M.sup.++H].
(3) Synthesis of
N-[3-((2R*,4R*,8aS*)-2-amino-4-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1--
azanaphthalen-8a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamid-
e
[0744] TFA (1 mL) was added to a solution of the compound obtained
in Example 32-(2) (52 mg) in chloroform (3 mL), and the mixture was
stirred at room temperature for four hours. The reaction solution
was neutralized with saturated aqueous sodium bicarbonate.
Chloroform was added to the mixture, and the organic layer was
separated. The organic layer was dried over anhydrous magnesium
sulfate. The organic layer was concentrated under reduced pressure.
The residue was purified by NH-silica gel column chromatography to
obtain the title compound (42 mg).
[0745] ESI-MS; m/z 452 [M.sup.++H].
EXAMPLES 33 TO 34
[0746] The compounds of Examples 33 to 34 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 5.
TABLE-US-00005 TABLE 5 Example 33 ##STR00090## Compound name:
N-[3-((4aR,6R,8aS)-2-amino-6-
hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-
chloropyridine-2-carboxamide ESI-MS m/z 451 [M.sup.+ + H] Example
34 ##STR00091## Compound name: N-[3-((4aR,6R,8aS)-2-amino-6-
hydroxymethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-
cyanopyridine-2-carboxamide ESI-MS m/z 442 [M.sup.+ + H]
EXAMPLES 35 TO 43
[0747] The compounds of Examples 35 to 43 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 6.
TABLE-US-00006 TABLE 6 Example 35 ##STR00092## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-cyanopyridine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.69-1.73 (m, 1H), 2.12(ddd, J = 2.4,
12.4, 24.8 Hz, 1H), 2.67 (dd, J = 2.4, 12.4 Hz, 1H), 2.99-3.07(m,
2H), 3.95 (d, J = 11.2 Hz, 1H), 4.05-4.09(m, 1H), 4.18(d, J = 2.0,
11.2 Hz, 1H), 7.09(dd, J = 8.8, 11.6 Hz, 1H), 7.40(dd, J = 2.8, 6.4
Hz, 1H), 8.00-8.05(m, 1H), 8.21(dd, J = 2.0, 8.0 Hz, 1H), 8.42(d, J
= 8.0 Hz, 1H), 8.90(s, 1H), 9.81(s, 1H). Example 36 ##STR00093##
Compound name: N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethoxypyrazine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.69-1.73 (m, 1H), 2.13(ddd, J
= 2.4, 12.0, 24.8 Hz, 1H), 2.67 (dd, J = 2.4, 12.0 Hz, 1H),
2.98-3.07(m, 2H), 3.98 (d, J = 10.8 Hz, 1H), 4.04-4.11(m, 1H),
4.17(dd, J = 2.0, 12.8 Hz, 1H), 7.02(dd, J = 8.4, 11.6 Hz, 1H),
7.38(dd, J = 2.8, 6.8 Hz, 1H), 7.51(t, J = 71.2 Hz, 1H),
7.91-7.95(m, 1H), 8.27(d, J = 1.2 Hz, 1H), 9.01(d, J - 1.2 Hz, 1H),
9.37(s, 1H). Example 37 ##STR00094## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthlen-8a-yl)-4-
fluorophenyl]-5-fluoropyriidne-2-carboxamide ESI-MS m/z 473
[M.sup.+ + H] Example 38 ##STR00095## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-pyridine-2-carboxamide ESI-MS m/z 455 [M.sup.+ + H]
Example 39 ##STR00096## Compound name: N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-fluoromethoxypyrazine-2- carboxamide ESI-MS m/z 504
[M.sup.+ + H] Example 40 ##STR00097## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-pyrimidine-4-carboxamide ESI-MS m/z 456 [M.sup.+ + H]
Example 41 ##STR00098## Compound name: N-[3-((4aR*,6R*,8aS*-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-3,5-difluoropyridine-2- carboxamide ESI-MS m/z 491
[M.sup.+ + H] Example 42 ##STR00099## Compound name:
N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethoxypyridine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.68-1.73 (m, 1H),2.13(ddd, J
= 2.8, 12.4, 25.2 Hz, 1H), 2.66 (dd, J = 2.8, 12.4 Hz, 1H),
2.98-3.03(m, 1H), 3.06 (dd, J = 4.4, 12.4 Hz, 1H), 3.97(d, J = 10.8
Hz, 1H), 4.04-4.13(m, 1H), 4.18(dd,J = 2.0, 10.8 Hz, 1H), 6.65(t, J
= 71.6 Hz, 1H), 7.03(dd, J = 8.8, 12.0 Hz, 1H), 7.38(dd, J = 2.8,
7.2 Hz, 1H), 7.65(dd, J = 2.8, 8.8 Hz, 1H), 7.97-8.00(m, 1H),
8.28(d, J = 8.8 Hz, 1H), 8.43(d, J = 2.4 Hz, 1H), 9.75(s, 1H).
Example 43 ##STR00100## Compound name: N-[3-((4aR*,6R*,8aS*)-2-
amino-6-trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethylpyrazine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.69-1.74 (m, 1H), 2.12(ddd, J
= 2.4, 12.0, 24.8 Hz, 1H), 2.68 (dd, J = 2.8, 12.4 Hz, 1H),
2.99-3.08(m, 2H), 3.95 (d, J = 11.2 Hz, 1H), 4.05-4.11(m, 1H),
3.18(dd, J = 2.0, 10.8 Hz, 1H), 6.80(t, J = 54.4 Hz, 1H), 7.09 (dd,
J = 8.8, 12.0 Hz, 1H), 7.41(dd, J = 2.8, 7.2 Hz, 1H), 7.97-8.01(m,
1H), 8.91(d, J = 0.8 Hz, 1H), 9.51(t, J = 0.8 Hz, 1H), 9.60(s,
1H).
EXAMPLES 44 TO 48
[0748] The compounds of Examples 44 to 48 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 7.
TABLE-US-00007 TABLE 7 Example 44 ##STR00101## Compound name:
N-[3-((4aR,6R,8aS)-2-amino-6-
fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5- cyanopyridine-2-carboxamide
ESI-MS m/z 444 [M.sup.+ + H] Example 45 ##STR00102## Compound name:
N-[3-((4aR,6R,8aS)-2-amino-6-
fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
chloropyridine-2-carboxamide ESI-MS m/z 453 [M.sup.+ + H] Example
46 ##STR00103## Compound name: N-[3-((4aR,6R,8aS)-2-amino-6-
fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
trifluoromethylpyridine-2-carboxamide ESI-MS m/z 487 [M.sup.+ + H]
Example 47 ##STR00104## Compound name:
N-[3-((4aR,6R,8aS)-2-amino-6-
fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
fluoromethoxypyrazine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.49-1.54 (m, 1H), 1.83-1.92(m, 1H),
2.63(dd, J = 2.4, 12.4 Hz, 1H), 3.00-3.07(m, 2H), 3.90(d, J = 11.2
Hz, 1H), 3.93-4.00(m, 1H), 4.16(dd, J = 1.6, 11.2 Hz, 1H),
4.35-4.58(m, 2H), 6.09(dd, J = 2.0, 3.6 Hz, 1H), 6.21(dd, J = 2.0,
4.0 Hz, 1H), 7.06(dd, J = 8.8, 12.0 Hz, 1H), 7.35(dd, J = 2.4, 6.4
Hz, 1H), 7.97-8.01(m, 1H), 8.27(d, J = 0.8 Hz, 1H), 9.06(t, J = 0.8
Hz, 1H), 9.45(s, 1H). Example 48 ##STR00105## Compound name:
N-[3-((4aR,6R,8aS)-2-amino-
6-fluoromethyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-
1-azanaphthalen-8a-yl)-4-fluorophenyl]-5-
difluoromethylpyrazine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.49-1.54 (m, 1H), 1.83-1.92(m, 1H),
2.65(dd, J = 2.8, 12.4 Hz, 1H), 3.00-3.07(m, 2H), 3.89(d, J = 10.8
Hz, 1H), 3.93-4.00(m, 1H), 4.17(dd, J = 2.0, 10.8 Hz, 1H), 1H),
3.45-4.59(m, 2H), 6.76(t, J = 54.8 Hz, 1H), 7.08(dd, J = 8.8, 12.0
Hz, 1H), 7.40(dd, J = 2.8, 6.4 Hz, 1H), 7.97-8.01(m, 1H), 8.91(d, J
= 1.2 Hz, 1H), 9.51(d, J = 1.2 Hz, 1H), 9.60(s, 1H).
EXAMPLES 49 TO 58
[0749] The compounds of Examples 49 to 58 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 8.
TABLE-US-00008 TABLE 8 Example 49 ##STR00106## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-chloropyridine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.45(dd, J = 2.0, 13.6 Hz, 1H),
2.10-2.20(m, 1H), 2.63(dd, J = 2.8, 12.4 Hz, 1H), 2.92-2.96(m, 1H),
3.02(dd, J = 4.4, 12.8 Hz, 1H), 3.66-3.72(m, 1H), 3.80(d, J = 10.8
Hz, 1H), 4.04-4.15(m, 2H), 7.05(dd, J = 8.8, 11.6 Hz, 1H), 7.37(dd,
J = 2.8, 6.8 Hz, 1H), 7.87(dd, J = 2.0, 8.4 Hz, 1H), 7.97-8.01(m,
1H), 8.21(d, J = 8.4 Hz, 1H), 8.53(d, J = 2.0 Hz, 1H), 9.77 (s,
1H). Example 50 ##STR00107## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-bromopyridine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.45(d, J = 12.8 Hz, 1H), 2.10-2.19(m,
1H), 2.65(dd, J = 2.4, 12.4 Hz, 1H), 2.93-2.97(m, 1H), 3.03(dd, J =
4.0, 12.0 Hz, 1H), 3.69(t, J = 12.0 Hz, 1H), 3.79(d, J = 10.8 Hz,
1H), 4.05-4.14(m, 2H), 7.07(dd, J = 8.8, 12.0 Hz, 1H), 7.36-7.39(m,
1H), 7.98-8.05(m, 2H), 8.16(d, J = 8.0, 1H), 8.66(s, 1H), 9.79 (s,
1H). Example 51 ##STR00108## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-3,5-difluoropyridine-2-carboxamide .sup.1H-NMR (400
MHz, CDCl.sub.3) .delta. (ppm): 1.45(dt, J = 2.0, 13.6 Hz, 1H),
2.05-2.19(m, 1H), 2.64(dd, J = 3.2, 12.4 Hz, 1H), 2.91-2.97(m, 1H),
3.02(dd, J = 4.0, 12.0 Hz, 1H), 3.65-3.72(m, 1H), 3.78(d, J = 10.8
Hz, 1H), 4.03-4.15(m, 2H), 7.06(dd, J = 8.8, 12.0 Hz, 1H),
7.24-7.27(m, 1H), 7.36-7.41(m, 1H), 8.05-8.09(m, 1H), 8.33(d, J =
2.0 Hz, 1H), 9.56(s, 1H). Example 52 ##STR00109## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-3,5-dichloropyridine-2-carboxamide .sup.1H-NMR (400
MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.47(m, 1H), 2.08-2.19(m, 1H),
2.64(dd, J = 3.2, 12.4 Hz, 1H), 2.92- 2.97(m, 1H), 3.01(dd, J =
4.4, 12.4 Hz, 1H), 3.65-3.71 (m, 1H), 3.76(d, J = 11.2 Hz, 1H),
4.03-4.11(m, 2H), 7.07 (dd, J = 9.2, 12.0 Hz, 1H), 7.19(dd, J =
2.8, 6.8 Hz, 1H), 7.90(d, J = 2.0 Hz, 1H), 8.11-8.15(m, 1H),
8.46(d, J = 2.0 Hz, 1H), 9.68(s, 1H). Example 53 ##STR00110##
Compound name: N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-fluoropyridine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.43-1.47(m, 1H), 2.09-2.20(m, 1H),
2.63(dd, J = 2.8, 12.0 Hz, 1H), 2.91- 2.97(m, 1H), 3.02(dd, J =
4.0, 12.0 Hz, 1H), 3.65-3.72 (m, 1H), 3.79(d, J = 10.8 Hz, 1H),
4.04-4.12(m, 2H), 7.06 (dd, J = 8.8, 11.6 Hz, 1H), 7.35(dd, J =
2.4, 6.4 Hz, 1H), 7.59(dt, J = 2.4, 8.4 Hz, 1H), 7.99-8.03(m, 1H),
8.31(dd, J = 4.4, 8.4 Hz, 1H), 8.44(d, J = 2.8 Hz, 1H), 9.76(s,
1H). Example 54 ##STR00111## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-3,5-dibromopyridine-2-carboxamide EIS-MS m/z 545
[M.sup.+ + H] Example 55 ##STR00112## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-trifluoromethylpyridine-2-carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.47(m, 1H), 2.10-2.19(m,
1H), 2.65(dd, J = 3.2, 12.4 Hz, 1H), 2.92- 2.97(m, 1H), 3.03(dd, J
= 4.0, 12.0 Hz, 1H), 3.66-3.72 (m, 1H), 3.79(d, J = 11.2 Hz, 1H),
4.05-4.12(m, 2H), 7.08 (dd, J = 8.8, 12.0 Hz, 1H), 7.39(dd, J =
2.8, 6.4 Hz, 1H), 8.00-8.04(m, 1H), 8.16(dd, J = 1.6, 8.4 Hz, 1H),
8.42(d, J = 8.0 Hz, 1H), 8.88(t, J = 0.8 Hz, 1H), 9.89(s, 1H).
Example 56 ##STR00113## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethylpyridine-2-carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.47(m, 1H), 2.09-2.21(m,
1H), 2.64(dd, J = 2.8, 12.0 Hz, 1H), 2.92- 2.98(m, 1H), 3.02(dd, J
= 8.0, 12.4 Hz, 1H), 3.66-3.72 (m, 1H), 3.81(d, J = 10.8 Hz, 1H),
4.05-4.15(m, 2H), 6.81 (t, J = 55.6 Hz, 1H), 7.05(dd, J = 9.2, 12.0
Hz, 1H), 8.40 (dd, J = 2.8, 6.8 Hz, 1H), 7.98-8.06(m, 2H), 8.36(d,
J = 8.4 Hz, 1H), 8.73(s, 1H), 9.90(s, 1H). Example 57 ##STR00114##
Compound name: N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.44-1.48(m, 1H), 2.10-2.19(m,
1H), 2.65(dd, J = 2.8, 12.0 Hz, 1H), 2.93- 3.04(m, 2H),
3.66-3.72(m, 1H), 3.80(d, J = 11.2 Hz, 1H), 4.04-4.15(m, 2H),
6.79(t, J = 54.4 Hz, 1H), 7.08(dd, J = 8.8, 12.0 Hz, 1H), 7.40(dd,
J = 2.8, 6.4 Hz, 1H), 7.97-8.01(m, 1H), 8.90(d, J = 0.8 Hz, 1H),
9.50(s, 1H), 9.60(s, 1H). Example 58 ##STR00115## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-difluoromethoxypyridine-2-carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.47(m, 1H), 2.05-2.20(m,
1H), 2.63(dd, J = 2.8, 12.0 Hz, 1H), 2.91- 2.97(m, 1H), 3.03(dd, J
= 4.0, 12.4 Hz, 1H), 3.65-3.72 (m, 1H), 8.79(d, J = 11.2 Hz, 1H),
4.04-4.13(m, 2H), 6.65 (t, J = 72.0 Hz, 1H), 7.07(dd, J = 8.8, 12.0
Hz, 1H). 7.36 (dd, J = 3.2, 7.2 Hz, 1H), 7.66(dd, J = 3.2, 8.8 Hz,
1H), 8.00- 8.04(m, 1H), 8.31(d, J = 9.2 Hz, 1H), 8.46(d, J = 2.4
Hz, 1H), 9.80(s, 1H).
Example 59
Synthesis of
(.+-.)-(4aR*,6R*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-tri-
fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamin-
e
##STR00116##
[0751] 2-Fluoropyridine-3-boronic acid (63.9 mg),
tetrakis(triphenylphosphine)palladium (26.2 mg) and a 1 N sodium
carbonate solution (453 .mu.l) were added to a solution of
(.+-.)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,6R*,8aS*)-8a-(5-bromo-2-fluor-
ophenyl)-6-trifluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanapht-
halen-2-yl]amine (138 mg) in DMF (9.9 ml), and the mixture was
stirred in a nitrogen atmosphere at 85.degree. C. for seven hours.
The reaction solution was cooled to room temperature and then
diluted with ethyl acetate. The organic layer was washed with water
and brine. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure.
Dichloromethane (4.0 ml) and TFA (1.0 ml) were added to the
residue, and the mixture was stirred at room temperature for four
hours. When the reaction was completed, the reaction solution was
diluted with dichloromethane and ice was added, followed by
neutralization with a sodium bicarbonate solution. The aqueous
layer was extracted with chloroform, and the organic layer was
dried over anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure and the residue was purified by NH-silica
gel column chromatography. The resulting white solid was washed
with diethyl ether to obtain the title compound (14.0 mg).
[0752] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.68-1.72
(m, 1H), 2.12 (ddd, J=2.8, 12.0, 24.8 Hz, 1H), 2.68 (dd, J=2.4,
12.4 Hz, 1H), 2.99-3.08 (m, 2H), 3.96 (d, J=11.6 Hz, 1H), 4.06-4.11
(m, 1H), 4.20 (dd, J=2.0, 11.2 Hz, 1H), 7.15 (dd, J=8.8, 12.4 Hz,
1H), 7.25-7.30 (m, 1H), 7.50-7.54 (m, 2H), 7.83 (ddd, J=1.6, 7.2,
9.2 Hz, 1H), 8.19-8.21 (m, 1H).
Example 60
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-fluoromethyl--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine
##STR00117##
[0754] 2-Fluoropyridine-3-boronic acid (51.1 mg),
tetrakis(triphenylphosphine)palladium (19.1 mg) and a 1 N sodium
carbonate solution (363 .mu.l) were added to a solution of
N,N-di(tert-butyloxycarbonyl)-[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-
-fluoromethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]am-
ine (95 mg) in DMF (6.79 ml). After replacement with nitrogen, the
mixture was stirred at 85.degree. C. for two hours. After cooling
to room temperature, the mixture was diluted with water. The
aqueous layer was extracted with ethyl acetate, and the organic
layer was washed with water, The organic layer was dried over
anhydrous magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography. The resulting intermediate was dissolved in
dichloromethane (4.0 ml). TFA (1.0 ml) was added and the mixture
was stirred at room temperature for three hours. Ice was added to
the reaction mixture, followed by neutralization with a sodium
bicarbonate solution. The aqueous layer was extracted with
chloroform, and the organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (59.0 mg).
[0755] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.48-1.53
(m, 1H), 1.82-1.92 (m, 1H), 2.63-2.66 (m, 1H), 2.98-3.07 (m, 2H),
3.89 (d, J=10.8 Hz, 1H), 3.93-4.01 (m, 1H), 4.17-4.20 (m, 1H),
4.35-4.58 (m, 2H), 7.14 (dd, J=8.0, 12.0 Hz, 1H), 7.25-7.22 (m,
1H), 7.48-7.55 (m, 2H), 7.78-7.83 (m, 1H), 8.16-8.18 (m, 1H).
Example 61
Synthesis of
(.+-.)-(4aR*,8aS*)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-4,4a,5,6,-
8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine
##STR00118##
[0757] 2-Fluoropyridine-3-boronic acid (25.6 mg),
tetrakis(triphenylphosphine)palladium (10.5 mg) and a 1 N sodium
carbonate solution (182 .mu.l) were added to a solution of
(.+-.)--N-benzoyl-N-(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(5-bromo-2-fl-
uorophenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amin-
e (50 mg) in DMF (5.0 ml). After replacement with nitrogen, the
mixture was stirred at 90.degree. C. for six hours. The reaction
solution was cooled to room temperature and diluted with water. The
aqueous layer was extracted with ethyl acetate. The organic layer
was washed with water and brine and dried over anhydrous magnesium
sulfate. The solvent was evaporated under reduced pressure and the
residue was purified by NH-silica gel column chromatography to
obtain the title compound (12.7 mg).
[0758] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.43-1.47
(m, 1H), 2.08-2.20 (m, 1H), 2.66 (dd, J=2.8, 12.0 Hz, 1H),
2.90-2.96 (m, 1H), 3.01 (dd, J=4.0, 12.4 Hz, 1H), 3.69 (dt, J=2.8,
12.4 Hz, 1H), 3.79 (d, J=11.2 Hz, 1H), 4.07-4.13 (m, 2H), 4.60
(brs, 2H), 7.14 (dd, J=8.4, 12.0 Hz, 1H), 7.25-7.28 (m, 1H),
7.48-7.55 (m, 2H), 7.81-7.86 (m, 1H), 8.18-8.20 (m, 1H).
EXAMPLES 62 TO 63
[0759] The compounds of Examples 62 to 63 were synthesized
according to Example 61 using the corresponding boron acids, as
shown in the following Table 9.
TABLE-US-00009 TABLE 9 Example 62 ##STR00119## Compound name:
(.+-.)-(4aR*,8aS*)-8a-(2-fluoro-5-
pyrimidin-5-ylphenyl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-
thia-1-azanaphthalen-2-ylamine ESI-MS m/z 345 [M.sup.+ + H] Example
63 ##STR00120## Compound name:
(.+-.)-(4aR*,8aS*)-8a-[5-(5-chloropyridin-
3-yl)-2-fluorophenyl]-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-
1-azanaphthalen-2-ylamine ESI-MS m/z 378 [M.sup.+ + H]
Example 64
Synthesis of
N-[5-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)thiophen-3-yl]-5-cyanopyridine-2-carboxamide
##STR00121##
[0761] 5-Cyanopyridine-2-carboxylic acid (19.0 mg),
diisopropylethylamine (50.7 .mu.l) and PyBOP (83.5 mg) were
sequentially added to a solution of
(+)-N,N-di(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-aminothiophen-2-yl)--
4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine (50
mg) in dichloromethane (5.0 ml) in an ice bath. The mixture was
returned to room temperature and stirred overnight. The solvent was
evaporated under reduced pressure and the residue was purified by
NH-silica gel column chromatography. The resulting intermediate was
dissolved in dichloromethane (4.0 ml) and TFA (1.0 ml) was added.
After stirring at room temperature for four hours, ice was added to
terminate the reaction. The mixture was neutralized with a sodium
bicarbonate solution, and the aqueous layer was neutralized with
ethyl acetate. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by NH-silica gel column chromatography to
obtain the title compound (33.9 mg).
[0762] ESI-MS m/z 400 [M.sup.++H]
Example 65
Synthesis of
(.+-.)-(4aR*,8aR*1-8a-[4-(2-fluoropyridin-3-yl)-thiophen-2-yl]-4,4a,5,6,8-
,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine
##STR00122##
[0764] 2-Fluoropyridine-3-boronic acid (26.9 mg),
tetrakis(triphenylphosphine)palladium (11.0 mg) and a 1 N sodium
carbonate solution (191 .mu.l) were sequentially added to a
solution of
(.+-.)-N,N-di-(tert-butyloxycarbonyl)-[(4aR*,8aS*)-8a-(4-bromothiophen-2--
yl)-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
obtained in Preparation Example 19-(3) (51.0 mg) in DMF (2.0 ml).
After replacement with nitrogen, the mixture was stirred at
80.degree. C. for five hours. The reaction solution was returned to
room temperature and diluted with water. The aqueous layer was
extracted with ethyl acetate, and the organic layer was washed with
water. The organic layer was dried over anhydrous magnesium
sulfate, and the solvent was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography to obtain
an intermediate. The resulting intermediate was dissolved in
dichloromethane (5.0 ml). TFA (2.0 ml) was added and the mixture
was stirred at room temperature for three hours. Ice was added to
the mixture, followed by neutralization with a sodium bicarbonate
solution. The aqueous layer was extracted with ethyl acetate, and
the organic layer was dried over anhydrous magnesium sulfate. The
solvent was evaporated under reduced pressure and the residue was
purified by NH-silica gel column chromatography to obtain the title
compound (22.0 mg).
[0765] ESI-MS m/z 350 [M.sup.++H]
Example 66
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-benzyloxymeth-
yl-4,4a,5,
6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-ylamine
##STR00123##
[0767] 2-Fluoropyridine-3-boronic acid (44.0 mg),
tetrakis(triphenylphosphine)palladium (18.0 mg) and a 1 N sodium
carbonate solution (312 .mu.l) were added to a solution of
N,N-di-(tert-butyloxycarbonyl)-[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)--
6-benzyloxymethyl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-y-
l]amine (95 mg) in DMF (6.79 ml). After replacement with nitrogen,
the mixture was stirred at 85.degree. C. for seven hours. After
cooling to room temperature, the mixture was diluted with water.
The aqueous layer was extracted with ethyl acetate, and the organic
layer was washed with water. The organic layer was dried over
anhydrous magnesium sulfate, and the solvent was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography. The resulting intermediate was dissolved in
dichloromethane (4.0 ml). TFA (1.0 ml) was added and the mixture
was stirred at room temperature for three hours. Ice was added to
the reaction mixture, followed by neutralization with a sodium
bicarbonate solution. The aqueous layer was extracted with
chloroform, and the organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography to obtain the title compound (23.0 mg).
[0768] ESI-MS m/z 482 [M.sup.++H]
Example 67
Synthesis of
(.+-.)-N-[74(4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanap-
hthalen-8a-yl)-2,2-difluorobenzo[1,3]dioxol-5-yl]-5-cyanopyridine-2-carbox-
amide
##STR00124##
[0770] 5-Cyanopyridine-2-carboxylic acid (4.0 mg),
diisopropylethylamine (11.5 .mu.l) and PyBOP (17.6 mg) were added
to a solution of tert-butyl
(.+-.)-[(4aR*,8aS*)-8a-(6-amino-2,2-difluorobenzo[1,3]dioxol-4-yl)-4,4a,5-
,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]carbamate (10
mg) in dichloromethane (2.0 ml) in an ice bath. The mixture was
heated to room temperature and stirred for four hours. The solvent
was evaporated under reduced pressure and the residue was purified
by NH-pTLC to obtain an intermediate. The resulting intermediate
was dissolved in dichloromethane (3.0 ml) and TFA (1.0 ml) was
added. After stirring at room temperature for four hours, the
reaction solution was diluted with water and neutralized with a
sodium bicarbonate solution. The aqueous layer was extracted with
dichloromethane, and the organic layer was dried over anhydrous
magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by NH-pTLC to obtain the
title compound.
[0771] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.51-1.53
(m, 1H), 2.15 (ddd, J=5.2, 13.2, 26.0 Hz, 1H), 2.71 (dd, J=2.8,
12.4 Hz, 1H), 2.86-2.90 (m, 1H), 3.07 (dd, J=4.4, 12.4 Hz, 1H),
3.68-3.73 (m, 1H), 3.85-3.91 (m, 2H), 4.11-4.15 (m, 1H), 7.03 (d,
J=2.0 Hz, 1H), 8.07 (d, J=2.0 Hz, 1H), 8.21 (dd, J=2.0, 8.0 Hz,
1H), 8.41 (dd, J=0.8, 8.0 Hz, 1H), 8.92 (dd, J=0.8, 2.0 Hz, 1H),
9.94 (brs, 1H).
EXAMPLES 68 TO 73
[0772] The compounds of Examples 68 to 73 were synthesized
according to Example 2 using the corresponding carboxylic acids and
the corresponding aniline intermediates in Preparation Examples, as
shown in the following Table 10.
TABLE-US-00010 TABLE 10 Example 68 ##STR00125## Compound name:
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-5-(2-methoxyethoxy)-pyrazine-2- carboxamide
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.40-1.50(m, 1H),
2.01-2.21(m, 1H), 2.59-2.68(m, 1H), 2.88-2.98(m, 1H), 2.98-3.06(m,
1H), 3.46(s, 3H), 3.63-3.73(m, 1H), 3.73- 3.84(m, 3H), 4.01-4.12(m,
2H), 4.55-4.65(m, 2H), 7.02- 7.11(m, 1H), 7.29-7.35(m, 1H),
7.98-8.06(m, 1H), 8.19- 8.24(m ,1H), 8.96-9.01(m, 1H), 9.46(brs,
1H). ESI-MS m/z 462 [M.sup.+ + H] Example 69 ##STR00126## Compound
name: N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-
tetrahydro-7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-
fluorophenyl]-2-methylthiazole-4-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 1.39-1.50(m, 1H), 2.06-2.21(m, 1H),
2.59-2.67(m, 1H), 2.76(s, 3H), 2.89- 2.97(m, 1H), 2.98-3.07(m, 1H),
3.62-3.73(m, 1H), 3.73- 3.81(m, 1H), 4.01-4.13(m, 2H), 7.02-7.10(m,
1H), 7.28- 7.34(m, 1H), 7.93-7.99(m, 1H), 8.04(s, 1H), 9.17(brs,
1H). ESI-MS m/z 407 [M.sup.+ + H) Example 70 ##STR00127## Compound
name: N-[3-((4aR*,5R*,8aS*) Compound name:
N-[3-((4aR*,5R*,8aS*)-2-amino-5-
methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-2,5-dimethylfuran-3-carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. (ppm): 0.94(d, J = 6.8 Hz, 3H),
2.21-2.27(m, 1H), 2.28(s, 3H), 2.58(s, 3H), 2.61- 2.68(m, 1H),
2.93-2.96(m, 2H), 3.25-3.36(m, 1H), 3.85- 3.92(m, 1H), 3.95-4.07(m,
2H), 6.21(brs, 1H), 7.03-7.11 (m, 2H), 7.58-7.63(m, 1H). ESI-MS m/z
418 [M.sup.+ + H] Example 71 ##STR00128## Compound name:
N-[3-((4aR*,5R*,8aS*)-2-amino-5-
methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-4-methyl-[1,2,3]thiadiazole-5- carboxamide
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 0.91(d, J = 6.4
Hz, 3H), 2.07-2.20(m, 1H), 2.44-2.52(m, 1H), 2.78-2.86(m, 1H),
2.86-2.93(m, 1H), 2.96(s, 3H), 3.22-3.31(m, 1H), 3.66-3.74(m, 1H),
3.84-3.91(m, 1H), 4.02-4.08(m, 1H), 7.05-7.12(m, 1H), 7.14-7.19(m,
1H), 7.91(brs, 1H). ESI-MS m/z 422 [M.sup.+ + H] Example 72
##STR00129## Compound name: N-[3-((4aR*,5R*8aS*)-2-ami-
no-5-methyl-4,4a,5,6-tetrahydro-7-oxa-3-thia-
1-azanaphthalen-8a-yl)-4-fluorophenyl]-3-pipe-
ridin-2-ylpropionamide .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
(ppm): 0.92(d, J = 6.8 Hz, 3H), 1.56-1.86(m, 6H), 2.10-2.23(m, 1H),
2.42-2.73(m, 9H), 2.84-2.96(m, 2H), 3.24-3.36(m, 1H), 3.83-4.01(m,
2H), 4.06-4.13(m, 1H), 6.96- 7.12(m, 2H), 7.90-8.01(m, 1H),
11.5(brs, 1H). ESI-MS m/z 435 [M.sup.+ + H] Example 73 ##STR00130##
Compund name: N-[3-((4aR*,5R*,8aS*)-
2-amino-5-methyl-4,4a,5,6-tetrahydro-
7-oxa-3-thia-1-azanaphthalen-8a-yl)-4-fluoro-
phenyl]-2-methyloxazol-4-carboxa mide .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. (ppm): 0.91(d, J = 6.8 Hz, 3H), 2.11-2.27(m,
1H), 2.42-2.50(m, 1H), 2.50- 2.57(m, 3H), 2.80-2.94(m, 2H),
3.23-3.34(m, 1H), 3.72-3.81(m, 1H), 3.89-3.97(m, 1H), 4.05-4.12 (m,
1H), 6.99-7.08(m, 1H), 725-7.32(m, 1H), 7.89- 7.96(m, 1H),
8.14-8.19(m, 1H), 8.65(brs, 1H). ESI-MS m/z 405 [M.sup.+ + H]
Example 74
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2H-pyrazol-3-yl)phenyl]-6-methoxymethyl-4,4a-
,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00131##
[0773] (1) Synthesis of di-tert-butyl
[(4aR,6R,8aS)-8a-(5-bromo-2-fluorophenyl)-6-methoxymethyl-4,4a,5,6,8,8a-h-
exahydropyrano[3,4-d][1,3]thiazin-2-yl]imidodicarbonate
[0774] The title compound was synthesized from the compound
obtained in Preparation Example 7-(4) according to Preparation
Example 16 (1)-(3).
[0775] ESI-MS; m/z 611 [M.sup.++Na].
(2) Synthesis of di-tert-butyl
[(4a,6R,8aS)-8a-(5-acetyl-2-fluorophenyl)-6-methoxymethyl-4,4a,5,6,8,8a-h-
exahydropyrano[3,4-d][1,3]thiazin-2-yl]imidodicarbonate
[0776] The compound obtained in Example 74-(1) (2.73 g) was
dissolved in 1,4-dioxane (40 mL). 1-Ethoxyvinyltri-n-butyltin (2.42
mL), cesium fluoride (1.55 g) and
bis(tri-t-butylphosphine)palladium (118 mg) were sequentially added
to the solution, and the mixture was stirred in a nitrogen
atmosphere at 100.degree. C. After 1.5 hours, the reaction solution
was left to cool. The reaction mixture was filtered through celite
and washed with ethyl acetate. The filtrate was concentrated under
reduced pressure. Ethyl acetate and 1 N KHSO4 were added to the
residue, and the organic layer was separated. The organic layer was
sequentially washed with 1 N KHSO4, a saturated sodium bicarbonate
solution and brine. The organic layer was dried over anhydrous
magnesium sulfate. The drying agent was removed by filtration and
the filtrate was concentrated under reduced pressure. The residue
was subjected to silica gel chromatography to obtain di-tert-butyl
{(4aR,6R,8aS)-8a-[5-(1-ethoxyvinyl)-2-fluorophenyl]-6-methoxymethyl-4,4a,-
5,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-yl}imidodicarbonate
(1.91 g). 1.5 g of 1.91 g of the resulting compound was dissolved
in THF (10 mL). Then, 2 N hydrochloric acid (3.5 mL) was added and
the mixture was stirred at room temperature. After one hour, ethyl
acetate was added to the reaction solution, and the mixture was
sequentially washed with a saturated sodium bicarbonate solution
and brine. The organic layer was dried over anhydrous magnesium
sulfate. The drying agent was removed by filtration and the
filtrate was concentrated under reduced pressure. The residue was
subjected to silica gel chromatography to obtain the title compound
(1.2 g).
[0777] ESI-MS; m/z 575 [M.sup.++Na].
(3) Synthesis of t-butyl
{(4aR,6R,8aS)-8a-[2-fluoro-5(2H-pyrazol-3-yl)phenyl]-6-methoxymethyl-4,4a-
,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl}carbamate
[0778] The compound obtained in Example 74-(2) (207 mg) was
dissolved in N,N-dimethylformamide dimethyl acetal (2.3 mL), and
then the solution was stirred in a nitrogen atmosphere at
110.degree. C. After about 14 hours, the reaction solution was left
to cool and then concentrated under reduced pressure. Ethanol (3
mL) was added to the residue and then hydrazine hydrate (78 .mu.L)
was added, followed by stirring at room temperature. After about
three days, the reaction solution was concentrated under reduced
pressure. Ethyl acetate and a saturated sodium bicarbonate solution
were added to the residue, and the organic layer was separated. The
organic layer was dried over anhydrous magnesium sulfate. The
drying agent was removed by filtration and the filtrate was
concentrated under reduced pressure. The residue was subjected to
silica gel chromatography to obtain the title compound (38 mg).
[0779] ESI-MS; m/z 477 [M.sup.++1].
(4) Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2H-pyrazol-3-yl)phenyl]-6-methoxymethyl-4,4a-
,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0780] The compound obtained in Example 74-(3) (38 mg) was
dissolved in dichloromethane (2 mL), and then trifluoroacetic acid
(0.4 mL) was added, followed by stirring at room temperature. After
three hours, the reaction solution was concentrated under reduced
pressure. Chloroform and a saturated sodium bicarbonate solution
were added to the residue, and the organic layer was separated. The
organic layer was dried over anhydrous magnesium sulfate. The
drying agent was removed by filtration and the filtrate was
concentrated under reduced pressure. The residue was subjected to
column chromatography to obtain the title compound (18 mg).
[0781] ESI-MS; m/z 377 [M.sup.++1].
Example 75
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2H-pyrazol-3-yl)phenyl]-6-methoxymethyl-4,4a-
,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00132##
[0783] The title compound was synthesized according to Example 74
using N,N-dimethylacetamide dimethylacetal in place of
N,N-dimethylformamide dimethyl acetal,
[0784] ESI-MS; m/z 391 [M.sup.++1].
Example 76
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-methoxymethyl-
-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00133##
[0785] (1) Synthesis of di-tert-butyl
[(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-methoxymethy-
l-4,4a,5,6,8,8a-hexahydropyrano[3,4d][1,3]thiazine-2-yl]imidodicarbonate
[0786] The compound obtained in Example 74-(1) (1.33 g) was
dissolved in THF (28 mL). 2-Fluoropyridine-3-boronic acid (955 mg),
potassium fluoride (558 mg), Pd2 DBA3 (200 mg) and
Pd(t-Bu.sub.3P).sub.2 (220 mg) were added to the solution, and the
mixture was stirred in a nitrogen atmosphere at room temperature
overnight. The reaction solution was diluted with ethyl acetate and
filtered through NH silica gel. The filtrate was further washed
with a mixture of ethyl acetate:heptane=4:1. The filtrate was
concentrated under reduced pressure to obtain a residue. The
residue was subjected to silica gel chromatography to obtain the
title compound (547 mg).
[0787] ESI-MS; m/z 628 [M.sup.++Na].
(2) Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-fluoropyridin-3-yl)phenyl]-6-methoxymethyl-
-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0788] The compound obtained in Example 76-(1) (67 mg) was
dissolved in dichloromethane (2 mL), and then TFA (0.5 mL) was
added. After two hours, the reaction solution was concentrated
under reduced pressure. Chloroform, a 1 N sodium hydroxide solution
and a saturated sodium bicarbonate solution were added to the
residue, and the organic layer was separated. The organic layer was
dried over anhydrous magnesium sulfate. The drying agent was
removed by filtration and the filtrate was concentrated. The
residue was subjected to silica gel chromatography to obtain the
title compound (30 mg).
[0789] ESI-MS; m/z 406 [M.sup.++1].
Example 77
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(3-fluoropyridin-4-yl)phenyl]-6-methoxymethyl-
-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00134##
[0791] The title compound was synthesized according to Example
76.
[0792] ESI-MS; m/z 406 [M.sup.++1].
Example 78
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-(2-methoxypyridin-3-yl)phenyl]-6-methoxymethy-
l-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00135##
[0793] (1) Synthesis oft-butyl
{(4aR,6R,8aS)-8-[2-fluoro-5-(2-methoxypyridin-3-yl)phenyl]-6-methoxymethy-
l-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl}carbamate
[0794] Methanol (1 mL) and a 28% sodium methoxide-methanol solution
(1 mL) were added to the compound synthesized in Example 76-(1)
(164 mg), followed by stirring at 50.degree. C. After three hours
and 30 minutes, the reaction solution was left to cool. Ethyl
acetate and a saturated ammonium chloride solution were added to
the reaction solution, and the organic layer was separated. The
organic layer was washed with brine. The organic layer was dried
over anhydrous magnesium sulfate. The drying agent was removed by
filtration and the filtrate was concentrated under reduced
pressure. The residue was subjected to silica gel chromatography to
obtain the title compound (114 mg).
[0795] ESI-MS; m/z 540 [M.sup.++Na].
(2) Synthesis of
((4aR,6R,8aS)-8a-[2-fluoro-5-(2-methoxypyridin-3-yl)phenyl]-6-methoxymeth-
yl-4,4a,5,6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl)amine
[0796] The compound obtained in Example 78-(1) (114 mg) was
dissolved in dichloromethane (3 mL), and then TFA (1 mL) was added,
followed by stirring at room temperature. After three hours, the
reaction solution was concentrated under reduced pressure.
Chloroform and a saturated sodium bicarbonate solution were added
to the residue, and the organic layer was separated. The organic
layer was dried over anhydrous magnesium sulfate. The drying agent
was removed by filtration and the filtrate was concentrated under
reduced pressure. The residue was subjected to column
chromatography to obtain the title compound (61 mg).
[0797] ESI-MS; m/z 418 [M.sup.++1].
Example 79
Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-pyridazin-3-ylphenyl]-6-methoxymethyl-4,4a,5,-
6,8,8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
##STR00136##
[0798] (1) Synthesis of di-tert-butyl
[(4aR,6R,8aS)-8a-(2-fluoro-5-pyridazin-3-ylphenyl)-6-methoxymethyl-4,4a,5-
,6,8,8a-hexahydropyrano[3,4-d][1,3]thiazin-2-yl]imidodicarbonate
[0799] The compound synthesized in Example 76-(1) (229 mg) was
dissolved in 1,4-dioxane (4 mL). 3-(Tributylstannyl)pyridazine (215
mg), cesium fluoride (130 mg) and
bis(tri-t-butylphosphine)palladium (10 mg) were sequentially added
to the solution, and the mixture was stirred in a nitrogen
atmosphere at 100.degree. C. After two hours, the reaction solution
was left to cool. The reaction mixture was filtered through celite
and washed with ethyl acetate. The filtrate was concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography to obtain the title compound (116 mg).
[0800] ESI-MS; m/z 611 [M.sup.++Na].
(2) Synthesis of
(4aR,6R,8aS)-8a-[2-fluoro-5-pyridazin-3-ylphenyl]-6-methoxymethyl-4,4a,5,-
6,8.8a-hexahydro-7-oxa-3-thia-1-azanaphthalen-2-yl]amine
[0801] The compound obtained in Example 79-(1) (116 mg) was
dissolved in dichloromethane (3 mL), and then TFA (1 mL) was added,
followed by stirring at room temperature. After three hours, the
reaction solution was concentrated under reduced pressure.
Chloroform and a saturated sodium bicarbonate solution were added
to the residue, and the organic layer was separated. The organic
layer was dried over anhydrous magnesium sulfate. The drying agent
was removed by filtration and the filtrate was concentrated under
reduced pressure. The residue was subjected to column
chromatography to obtain the title compound (48 mg).
[0802] ESI-MS; m/z 389 [M.sup.++1].
Example 80
[0803] The following compound as shown in the following Table 11
was synthesized according to Example 2 using the corresponding
carboxylic acids.
TABLE-US-00011 TABLE 11 Example 80 ##STR00137## Compound name:
N-[3- ((4aR*,6R*,8aS*)-2-amino-6-
trifluoromethyl-4,4a,5,6-tetrahydro-7-
oxa-3-thia-1-aza-naphthalen-8a-yl)-4- fluorophenyl]-5-
difluoromethylpyridine-2-carboxamide ESI-MS 505 [M.sup.+ + H]
Example 81
Synthesis of
N-[3-((4aR*,8aS*1-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-ethoxypyrazine-2-carboxamide
##STR00138##
[0804] (1) Synthesis of 5-ethoxypyrazine-2-carboxylic acid
[0805] A 5 N sodium hydroxide solution (2 mL) was added to a
solution of methyl 5-chloropyrazine-2-carboxylate (150 mg) in
ethanol (4 mL), and the mixture was stirred at room temperature for
five hours. Ethyl acetate and water were added to the reaction
solution, and the aqueous layer was separated. The aqueous layer
was made acidic with concentrated hydrochloric acid. Brine and
ethyl acetate were added to the mixture, and the organic layer was
separated. The organic layer was dried over anhydrous magnesium
sulfate. The organic layer was concentrated to obtain the title
compound (135 mg).
[0806] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.46 (t,
J=7.2 Hz, 3H), 4.51 (q, J=7.2 Hz, 2H), 8.17 (s, 1H), 8.96 (s,
1H).
(2) Synthesis of
N-[3-((4aR*,8aS*)-2-amino-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthale-
n-8a-yl)-4-fluorophenyl]-5-ethoxypyrazine-2-carboxamide
[0807] The title compound (30 mg) was obtained from the compound
obtained in Preparation Example 1-(9) (30 mg) and the compound
obtained in Example 81-(1) (16.9 mg) according to Example (2).
[0808] ESI-MS; m/z 432 [M.sup.++H]
[0809] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. (ppm): 1.40-1.46
(m, 1H), 1.45 (t, J=7.2 Hz, 3H), 2.07-2.18 (m, 1H), 2.64 (dd,
J=2.8, 8.0 Hz, 1H), 2.94 (ddd, J=4.0, 7.6, 11.6 Hz, 1H), 3.02 (dd,
0.1=4.0, 12.0 Hz, 1H), 3.65-3.71 (m, 1H), 3.78 (d, J=10.8 Hz, 1H),
4.04-4.11 (m, 2H), 4.49 (q, J=7.2 Hz, 2H), 7.06 (dd, J=8.8, 12.0
Hz, 1H), 7.32 (dd, J=2.8, 7.2 Hz, 1H), 7.99-8.03 (m, 1H), 8.11 (s,
1H), 8.98 (s, 1H), 9.47 (s, 1H).
EXAMPLES 82 TO 87
[0810] The compounds of Examples 82 to 87 were synthesized
according to Example 3 using the corresponding carboxylic acids, as
shown in the following Table 12.
TABLE-US-00012 TABLE 12 Example 82 ##STR00139## Compound name:
N-[3-((8S*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-5-methoxypyrazine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3): .delta. (ppm): 1.44-1.47 (m, 1H),
2.08-2.18(m, 1H), 2.64(dd, J = 2.4, 12.0 Hz, 1H), 2.89-2.98(m, 1H),
3.03(dd, J = 4.0, 12.0 Hz, 1H), 3.65-3.72(m, 1H), 3.79(d, J = 10.8
Hz, 1H), 4.02-4.12(m, 5H), 7.07(dd, J = 8.8, 12.0 Hz, 1H), 7.32(dd,
J = 2.8, 6.8 Hz, 1H), 8.02(ddd, J = 2.8, 4.0, 8.8 Hz, 1H), 8.15(d,
J = 1.2 Hz, 1H), 9.01 (d, J = 1.6 Hz, 1H), 9.48(bs, 1H) ESI-MS m/z
418 [M.sup.+ + H] Example 83 ##STR00140## Compund name:
N-[3-((8s*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-5-methoxypyridine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3): 1.42-1.47(m, 1H), 2.08-2.20(m, 1H), 2.63(dd,
J = 2.8, 12.4 Hz, 1H), 2.91-2.97(m, 1H), 3.03(dd, J = 4.0, 12.4 Hz,
1H), 3.65-3.72(m, 1H), 3.78(d, J = 10.8 Hz, 1H), 3.94 (s, 3H),
4.05-4.11(m, 2H), 7.06(dd, J = 8.8, 12.0 Hz, 1H) 7.33(dd, J = 2.8,
8.8 Hz, 2H), 8.04(ddd, J = 2.8, 4.0, 8.8 Hz, 1H), 8.23(d, J = 8.8
Hz, 1H), 8.27(d, J = 2.8 Hz, 1H) 9.80(bs 1H) ESI-MS m/z 417
[M.sup.+ + H] Example 84 ##STR00141## Compound name:
N-[3-((8S*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-5-fluoromethoxypyridine-2- carboxamide
.sup.1H-NMR (400 MHz, CDCl.sub.3): 1.44-1.48(m, 1H), 2.09-2.19(m,
1H), 2.65(dd, J = 3.2, 12.4 Hz, 1H), 2.95-2.99(m, 1H), 3.04(d, J =
4.0, 12.0 Hz, 1H), 3.65-3.72(m, 1H), 3.80(d, J = 11.2 Hz, 1H),
4.04- 4.13(m, 2H), 5.81(d, J = 50.0 Hz, 2H), 7.08(dd, J = 8.8, 12.0
Hz, 1H) 7.35(dd, J = 2.8, 6.8 Hz, 1H), 7.57(ddd, J = 0.8, 2.8, 8.4
Hz, 1H), 8.05(ddd, J = 2.8, 4.4, 8.8 Hz, 1H), 8.28(dd, J = 0.4, 8.4
Hz, 1H), 8.42(d, J = 2.8 Hz, 1H), 9.82(bs, 1H) ESI-MS m/z 435
[M.sup.+ + H] Example 85 ##STR00142## Compound name:
N-[3-((8S*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-3-chloro-5-
trifluoromethylpyridine-2-carboxamide .sup.1H-NMR (400 MHz,
CDCl.sub.3): 1.45-1.48(m, 1H), 2.07-2.18(m, 1H), 2.66(dd, J = 2.8,
12.4 Hz, 1H), 2.95-3.05(m, 2H), 3.65-3.72(m, 1H), 3.78(d, J = 11.2
Hz, 1H), 4.03-4.12(m, 2H), 7.07-7.12(m, 1H), 7.21(dd, J = 2.4, 6.8
Hz, 1H), 8.13-8.18(m, 2H), 8.79(dd, J = 0.8, 4.0 Hz, 1H), 9.75(bs,
1H) ESI-MS m/z 489 [M.sup.+ + H] Example 86 ##STR00143## Compound
name: N-[3-((8S*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-5-methylpyridine-2- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3): 1.44-1.47(m, 1H), 2.12-2.15(m, 1H), 2.65(dd,
J = 2.8, 12.4 Hz, 1H), 2.70(s, 3H), 2.93-2.97(m, 1H), 3.03(dd, J =
4.0, 12.4 Hz, 1H), 3.66-3.72(m, 1H), 3.78(d, J = 11.2 Hz, 1H),
4.05-4.12(m, 2H), 7.08(dd, J = 8.8, 12.0 Hz, 1H) 7.36(dd, 2.8, 6.8
Hz, 1H), 8.01.-8.05 (m, 1H) 8.44(s, 1H), 9.36(d, J = 0.8 Hz, 1H),
9.61 (bs, 1H) ESI-MS m/z 402 [M.sup.+ + H] Example 87 ##STR00144##
Compound name: N-[3-((8S*,8aR*)-2-amino-
4,4a,5,6-tetrahydro-7-oxa-3-thia-1-azanaphthalen-
8a-yl)-4-fluorophenyl]-2-methyloxazole-4- carboxamide .sup.1H-NMR
(400 MHz, CDCl.sub.3): 1.45-1.48(m, 1H), 2.11-2.14(m, 1H), 2.53(s,
3H), 2.63-2.67(m, 1H), 2.95-3.05(m, 2H), 3.65-3.71(m, 1H), 3.81(d,
J = 11.6 Hz, 1H), 4.03-4.06(m, 1H), 4.08-4.12(m, 1H), 7.03-7.09(m,
1H), 7.30-7.32(m ,1H), 7.93- 7.97(m, 1H), 8.17(s, 1H), 8.71(bs, 1H)
ESI-MS m/z 391 [M.sup.+ + H]
Example 88
[0811] The compound of Example 88 was synthesized according to
Example 2 using the corresponding carboxylic acid and the
corresponding aniline intermediate in Preparation Examples, as
shown in the following Table 13.
TABLE-US-00013 TABLE 13 Example 88 ##STR00145## Compound name:
N-[3-((8S,8aS)-2-amino-5-
fluoro-4,4a,5,6-tetrahydro-7-oxa-3-thia-1-
azanaphthalen-8a-yl)-4-fluorophenyl]-5-
methoxypyrazine-2-carboxamide .sup.1H-NMR (400 MHz, CDCl.sub.3):
2.87-2.91(m, 1H), 3.01-3.06(m, 1H), 3.16(dd, J = 2.8, 12.4 Hz, 1H),
3.53(dt, J = 4.8, 10.4 Hz, 1H), 3.75 (dd, J = 2.0, 10.8 Hz, 1H),
4.07-4.10(m, 4H), 4.26(dd, J = 1.6, 10.8 Hz, 1H), 4.84-4.98(m, 1H),
7.10(dd, J = 8.8, 12.0 Hz, 1H), 7.36(dd, J = 2.4, 6.8 Hz, 1H),
7.97-8.01(m, 1H), 8.15(d, J = 1.2 Hz, 1H), 9.01(d, J = 1.2 Hz, 1H),
9.48 (bs, 1H) ESI-MS m/z 436 [M.sup.+ + H]
Test Example 1
[0812] Quantification of A.beta. Peptide in Culture of Neurons from
Rat Fetus Brain
(1) Rat Primary Neuronal Culture
[0813] Primary neuronal cultures were prepared from the cerebral
cortex of embryonic day 18 Wistar rats (Charles River Japan,
Yokohama, Japan). Specifically, the embryos were aseptically
removed from pregnant rats under ether anesthesia. The brain was
isolated from the embryo and immersed in an ice-cold L-15 medium
(such as Invitrogen Corp. Cat #11415-064, Carlsbad, Calif., USA, or
SIGMA L1518). The cerebral cortex was collected from the isolated
brain under a stereoscopic microscope. The cerebral cortex
fragments collected were enzymatically treated in an enzyme
solution containing 0.25% trypsin (Invitrogen Corp. Cat #15050-065,
Carlsbad, Calif., USA) and 0.01% DNase (Sigma D5025, St. Louis,
Mo., USA) at 37.degree. C. for 30 minutes to disperse the cells.
Here, the enzymatic reaction was stopped by adding inactivated
horse serum to the solution. The enzymatically treated solution was
centrifuged at 1,500 rpm for five minutes to remove the
supernatant. 5 to 10 ml of a medium was added to the resulting cell
mass. Neurobasal medium (Invitrogen Corp. Cat #21103-049, Carlsbad,
Calif., USA) supplemented with 2% B27 supplement (Invitrogen Corp.
Cat #17504-044, Carlsbad, Calif., USA), 25 .mu.M 2-mercaptoethanol
(2-ME, WAKO Cat #139-06861, Osaka, Japan), 0.5 mM L-glutamine
(Invitrogen Corp. Cat #25030-081, Carlsbad, Calif., USA), and
Antibiotics-Antimycotics (Invitrogen Corp. Cat #15240-062,
Carlsbad, Calif., USA) was used as the medium
(Neurobasal/B27/2-ME). However, the above Neurobasal medium not
supplemented with 2-ME (Neurobasal/B27) was used for the assay. The
cells were redispersed by mild pipetting of the cell mass to which
the medium was added. The cell dispersion was filtered through a
40-.mu.m nylon mesh (Cell Strainer, Cat #35-2340, Becton Dickinson
Labware, Franklin Lakes, N.J., USA) to remove the remaining cell
mass, and thus a neuronal cell suspension was obtained. The
neuronal cell suspension was diluted with the medium and then
plated in a volume of 100 .mu.l/well at an initial cell density of
5.times.10.sup.5 cells/cm.sup.2 in a 96-well polystyrene culture
plate pre-coated with poly-L or D-lysine (Falcon Cat #35-3075,
Becton Dickinson Labware, Franklin Lakes, N.J., USA coated with
poly-L-lysine using the method shown below, or BIOCOAT.TM. cell
environments Poly-D-lysine cell ware 96-well plate, Cat #35-6461,
Becton Dickinson Labware, Franklin Lakes, N.J., USA). Poly-L-lysine
coating was carried out as follows. 100 .mu.g/ml of a poly-L-lysine
(SIGMA P2636, St. Louis, Mo., USA) solution was aseptically
prepared with a 0.15 M borate buffer (pH 8.5). 100 .mu.g/well of
the solution was added to the 96-well polystyrene culture plate and
incubated at room temperature for one or more hours or at 4.degree.
C. overnight or longer. Thereafter, the coated 96-well polystyrene
culture plate was washed with sterile water four or more times, and
then dried or rinsed with, for example, sterile PBS or medium, and
used for cell plating. The plated cells were cultured in the
culture plate at 37.degree. C. in 5% CO.sub.2-95% air for one day.
Then, the total amount of the medium was replaced with a fresh
Neurobasal/B27/2-ME medium, and then the cells were cultured for
further three days.
(2) Addition of Compound
[0814] The drug was added to the culture plate on Day 4 of culture
as follows. The total amount of the medium was removed from the
wells, and 180 .mu.l/well of Neurobasal medium not containing 2-ME
and containing 2% B-27 (Neurobasal/B27) was added thereto. A
solution of the test compound in dimethyl sulfoxide (hereinafter
abbreviated as DMSO) was diluted with Neurobasal/B27 to a
concentration 10-fold higher than the final concentration. 20
.mu.l/well of the dilution was added to and sufficiently mixed with
the medium. The final DMSO concentration was 1% or less. Only DMSO
was added to the control group.
(3) Sampling
[0815] The cells were cultured for three days after addition of the
compound, and the total amount of the medium was collected. The
resulting medium was used as an ELISA sample. The sample was not
diluted for ELISA measurement of A.beta.x-42 and diluted to 5-fold
with a diluent supplied with an ELISA kit for ELISA measurement of
A.beta.x-40.
(4) Evaluation of Cell Survival
[0816] Cell survival was evaluated by an MTT assay according to the
following procedure. After collecting the medium, 100 .mu.l/well of
a pre-warmed medium was added to the wells. Further, 8 .mu.l/well
of a solution of 8 mg/ml of MTT (SIGMA M2128, St. Louis, Mo., USA)
in D-PBS(-) (Dulbecco's phosphate buffered Saline, SIGMA D8537, St.
Louis, Mo., USA) was added to the wells. The 96-well polystyrene
culture plate was incubated in an incubator at 37.degree. C. in 5%
CO.sub.2-95% air for 20 minutes. 100 .mu.l/well of an MTT lysis
buffer was added thereto, and MTT formazan crystals were
sufficiently dissolved in the buffer in the incubator at 37.degree.
C. in 5% CO.sub.2-95% air. Then, the absorbance at 550 nm in each
well was measured. The MTT lysis buffer was prepared as follows.
100 g of SDS (sodium dodecyl sulfate (sodium lauryl sulfate), WAKO
191-07145, Osaka, Japan) was dissolved in a mixed solution of 250
mL of N,N-dimethylformamide (WAKO 045-02916, Osaka, Japan) with 250
mL of distilled water. 350 .mu.l each of concentrated hydrochloric
acid and acetic acid were further added to the solution to allow
the solution to have a final pH of about 4.7.
[0817] Upon measurement, wells having no cells plated and
containing only the medium and MTT solution were set as background
(bkg). The measured values were respectively applied to the
following formula including subtracting bkg values from them. Thus,
the proportion against the control group (group not treated with
the drug, CTRL) (% of CTRL) was calculated to compare and evaluate
cell survival activities.
[0818] % of
CTRL=(A550_sample-A550_bkg)/(A550_CTRL-A550_bkg).times.100
(A550_sample: absorbance at 550 nm of sample well, A550_bkg:
absorbance at 550 nm of background well, A550_CTRL: absorbance at
550 nm of control group well)
(5) A.beta. ELISA
[0819] Human/Rat .beta. Amyloid (42) ELISA Kit Wako (#290-62601)
and Human/Rat .beta. Amyloid (40) ELISA Kit Wako (#294-62501) from
Wako Pure Chemical Industries, Ltd. were used for A.beta. ELISA.
A.beta. ELISA was carried out according to the protocols
recommended by the manufacturers (methods described in the attached
documents). However, the A.beta. calibration curve was created
using beta-amyloid peptide 1-42, rat and beta-amyloid peptide 1-40,
rat (Calbiochem, #171596 [A.beta..sub.42], #171593
[A.beta..sub.40]). The results are shown in Table 14 in term of
IC50 value (.mu. M) to decrease the A.beta.42 concentration in the
medium.
TABLE-US-00014 TABLE 14 A.beta.42 production Test reducing effect
compound IC50 (.mu.M) 1 0.0017 2 0.002 3 0.001 4 0.011 5 0.058 6
0.0012 7 0.0007 8 0.0016 9 0.0006 10 0.001 11 0.0007 12 0.0011 13
0.001 14 0.0008 15 0.0004 16 0.0011 17 0.004 18 0.007 19 0.002 20
0.009 21 0.01 22 0.004 23 0.012 24 0.009 25 0.014 26 0.003 27 0.008
28 0.0014 29 0.003 30 0.006 31 0.0019 32 0.003 33 0.0011 34 0.002
35 0.0021 36 0.0005 37 0.002 38 0.003 39 0.001 40 0.002 41 0.002 42
0.0009 43 0.0017 44 0.0007 45 0.002 46 0.001 47 0.004 48 0.002 49
0.002 50 0.002 51 0.006 52 0.002 53 0.0056 54 0.002 55 0.0014 56
0.003 57 0.002 58 0.004 59 0.087 60 0.032 61 0.319 64 0.014 65 0.37
66 0.263
[0820] As is clear from the results of Table 14, the compound of
the present invention was proved to have an A.beta.42 production
reducing effect.
INDUSTRIAL APPLICABILITY
[0821] The compound of the general formula (I) or pharmaceutically
acceptable salt thereof, or solvate thereof according to the
present invention has an A.beta.42 production reducing effect.
Thus, the present invention can particularly provide a therapeutic
or prophylactic agent for a neurodegenerative disease caused by
A.beta. such as Alzheimer-type dementia or Down's syndrome.
* * * * *